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 9 
CA2+ HOMEOSTASIS 
 
The maintenance of the body Ca2+ balance is of crucial importance for many vital 
physiological functions including neuronal excitability, muscle contraction, and bone 
formation. In the body of a healthy adult, about 99% of total body Ca2+ content is part 
of the mineral bone component, whereas 1% is in the extracellular fluid (1). The 
extracellular Ca2+ concentration is tightly controlled by the concerted action of 
intestinal Ca2+ absorption, exchange of Ca2+ from bone and renal Ca2+ reabsorption (2, 
3). Both in kidney and intestine, Ca2+ can (re)enter the extracellular fluid by passive 
paracellular as well as active transcellular Ca2+ transport (4, 5). Active Ca2+ 
(re)absorption is the primary target for regulation by calciotropic hormones, including 
the active form of vitamin D (1,25-dihydroxyvitamin D3 (1,25(OH)2D3)) and 
parathyroid hormone (PTH), enabling the organism to regulate Ca2+ (re)absorption and 
respond to the bodys demand (Fig. 1) (5, 6). 
 
TRANSCELLULAR CA2+ TRANSPORT 
 
At the cellular level, active Ca2+ (re)absorption is generally envisaged as a three-step 
process (Fig. 1), consisting of passive entry of Ca2+ across the luminal or apical 
membrane, cytosolic diffusion of Ca2+ bound to 1,25(OH)2D3-sensitive Ca2+-binding 
proteins (calbindin-D28K and/or calbindin-D9K) and active extrusion of Ca2+ across the 
opposite basolateral membrane by the Na+/Ca2+-exchanger (NCX1) and/or plasma 
membrane Ca2+-ATPase (PMCA1b) (7, 8).  
The calbindins belong to a group of intracellular proteins that bind Ca2+ and undergo 
conformational changes upon binding (9). Calbindin-D28K is present in kidney, small 
intestine (only birds), pancreas, placenta, bone, and brain, whereas calbindin-D9K is 
expressed in highest concentrations in small intestine as well as in kidney (only mouse) 
(9). These Ca2+-binding proteins play an important role in transcellular Ca2+ transport, 
in which they facilitate the cytosolic diffusion of Ca2+ from the apical influx to the 
basolateral efflux sites and act as a cytosolic Ca2+ buffer to maintain low intracellular 
Ca2+ levels (4, 10). 
The efflux of Ca2+ occurs by the Ca2+ extrusion transporters, NCX1 and PMCA1b, 
against a considerable electrochemical gradient (4, 11). In kidney, the expression of 
NCX1 and PMCA1b is highest in the distal part of the nephron, where they are 
predominantly localized along the basolateral membrane (12-14). Furthermore, 
PMCA1b is abundantly expressed in the small intestine, where NCX1 is expressed at a 
low level (13, 15). In accordance with these findings, Bindels and co-workers (12, 16) 
demonstrated that NCX1 is the primary extrusion mechanism in kidney, whereas 
PMCA1b has a more prominent function in the intestine (17).  
Chapter 1 
 10 
Apical Ca2+ influx is the initial rate-limiting step of the whole process of transcellular 
Ca2+ transport and is, therefore, an efficient target for regulation. However, the 
molecular nature of the apical entry mechanism has remained obscure for a long time. 
 
FIGURE 1. Mechanism of active epithelial Ca2+ transport. Active transcellular Ca2+ transport is generally 
regarded as the site for fine-tuning Ca2+ (re)absorption and regulated by calciotropic hormones. The active 
form of vitamin D, 1,25(OH)2D3, stimulates the individual steps of transcellular Ca2+ transport by increasing 
the expression levels of the luminal Ca2+ channels, calbindins, and the extrusion systems. Active and 
transcellular Ca2+ transport is carried out as a 3-step process. Following entry of Ca2+ through the 
(hetero)tetrameric epithelial Ca2+ channels, TRPV5 and TRPV6, Ca2+ bound to calbindin diffuses to the 
basolateral membrane. At the basolateral membrane, Ca2+ is extruded via an ATP-dependent Ca2+-ATPase 
(PMCA1b) and a Na+/Ca2+-exchanger (NCX1). In this way, there is net Ca2+ (re)absorption from the luminal 
space to the extracellular compartment.  
 
IDENTIFICATION OF TRPV5 AND TRPV6 
 
A major breakthrough in completing the molecular details of transcellular Ca2+ 
transport was the identification of the epithelial Ca2+ channel from rabbit kidney, 
initially named ECaC1 (18). Subsequently, a second, highly homologous epithelial 
Ca2+ channel was identified from rat duodenum, and named Ca2+ transporter 1 (CaT1) 
or ECaC2 (19). These two channels are encoded by two distinct genes, juxtaposed on 
human chromosome 7q35. The genes comprise 15 exons, encoding proteins of about 
730 amino acids, sharing 75% homology (20-24). Southern blot analysis, using the 
conserved pore area as probe, demonstrated that the epithelial Ca2+ channel subfamily 
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is restricted to these two members (25). However, they display high sequence 
homology with members of the transient receptor potential (TRP) superfamily, which 
encompasses a diversity of non-voltage operated cation channels (26-28). The TRP 
superfamily can be divided by sequence homology into various subfamilies. ECaC1 
and ECaC2 share the highest homology with the vanilloid receptor subfamily (TRPV) 
and have, therefore, been renamed into TRPV5 and TRPV6, respectively (28). 
 
 
FIGURE 2. Predicted structural organization of TRPV5 and TRPV6. (A) The epithelial Ca2+ channels are 730 
amino acids long with a predicted molecular mass of 83 kDa. TRPV5 and TRPV6 contain a core domain 
consisting of 6 transmembrane (TM) segments. In addition, large cytosolic N- and C-terminal tails are 
present. Between TM-segment 5 and 6 there is a short hydrophobic stretch predicted to be the pore-forming 
region of these channels. (B) Potential regulatory sites are indicated in the N- and C-tail of TRPV5 and 
TRPV6, including ankyrin repeats (A), PDZ motifs and conserved PKC phosphorylation sites. 
 
The structure of TRPV5 and TRPV6 shows typical topology features shared by all 
members of the TRP family, including six transmembrane regions, a short hydrophobic 
stretch between transmembrane segment 5 and 6, which is predicted to form the Ca2+ 
pore, and large intracellular N- and C-terminal domains (Fig. 2A) (7). These 
intracellular regions contain several conserved putative regulatory sites that might be 
involved in regulation of channel activity and trafficking. For instance, several 
potential phosphorylation sites for PKC, PKA, and cGMP-dependent protein kinase 
have been identified in TRPV5 and TRPV6. However, these predicted phosphorylation 
sites are not conserved within the complete TRPV5/6 subfamily, except for three 
B
A
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putative PKC phosphorylation sites (Fig. 2B) (25). In addition, the N-terminal domain 
of both TRPV5 and TRPV6 contains three ankyrin repeats (Fig. 2B). This structural 
element is present in several proteins and plays a role in protein-protein interactions. In 
general, ankyrins link transporters and cell adhesion molecules to the spectrin-based 
cytoskeletal elements in specialized membrane domains (29). Furthermore, the N- and 
C-terminal tails of TRPV5 and TRPV6 each contain an internal PDZ motif (Fig. 2B), 
which can function as part of a molecular scaffold via interaction with PDZ domain 
containing proteins. Via this interaction, transporters, ion channels, and receptors are 
coupled to intracellular signaling molecules, which regulate their activity, and position 
them to specialized regions in a cell (30). However, the contribution of these putative 
regulatory sites to modulation of TRPV5 and TRPV6 remains to be established. 
 
MOLECULAR FEATURES OF TRPV5 AND TRPV6 
 
TRPV5 and TRPV6 are constitutively active at low intracellular Ca2+ concentrations, 
unlike many other TRP channels that are activated by binding of ligands (28, 31). 
Electrophysiological studies using human embryonic kidney cells (HEK293), 
heterologously expressing TRPV5 or TRPV6, show that both channels are permeable 
for divalent cations with a high selectivity for Ca2+. In the absence of divalent cations, 
TRPV5 and TRPV6 permeate monovalent cations (25, 32, 33). The characteristic pore 
region of TRPV5 and TRPV6 is unique for its high Ca2+ selectivity, in which a single 
aspartic residue at position number 542 (D542) or 541 (D541), respectively, is crucial 
for Ca2+ permeation (34, 35). The current-voltage relationship of TRPV5 and TRPV6 
shows inward rectification and they exhibit a Ca2+-dependent feedback mechanism 
regulating channel activity (31, 36). This Ca2+-dependent inactivation is different 
between TRPV5 and TRPV6. The inactivation of TRPV6 is characterized by a slow 
decline after an initial fast inactivation phase, whereas TRPV5 only shows the slow 
inactivation phase (36, 37). The intracellular loop between transmembrane domain 2 
and 3 was identified as a crucial domain in the fast inactivation of TRPV6 (37). 
Furthermore, Nilius et al. indicated that two domains in the TRPV5 C-terminal region 
are important for the Ca2+-dependent inactivation process (38). In addition to this 
difference in Ca2+-dependent inactivation, the relative Ba2+ permeation compared with 
Ca2+ also varies between the two channels and is higher for TRPV5 than for TRPV6 
(37). Moreover, the pharmacological blocker ruthenium red is 100-fold more potent in 
blocking TRPV5 (IC50 ~110 nM) than TRPV6 (IC50 ~9 µM) (25). Furthermore, the 
activity of TRPV5 is regulated by extracellular pH. Acidification of the medium 
inhibits the uptake of Ca2+ and reduces the currents through TRPV5 (18, 39), which 
has been demonstrated to depend on the glutamate at position 522. This residue is, 
therefore, suggested to be the pH sensor of TRPV5 (40). A recent study by Sternfeld 
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et al. showed that the TRPV6 induced Ca2+ entry can be modulated by tyrosine 
phosphorylation and dephosphorylation (41). 
 
 
 
FIGURE 3.  
Model for the pore region of TRVP5 and 
TRPV6. Depicted is the top view of the 
tetrameric organization of the TRPV5/6 
pore, based on the structure of KcsA (47). 
The pore-forming regions of 4 monomeric 
TRPV5/6 subunits join to form a single 
pore, thereby connecting the aspartic 
residues (D542 or D541) into a negatively 
charged ring, operating as a selectivity filter 
for Ca2+. At the narrowest point, formed by 
the acidic side chain of D541, the pore has a 
diameter of 5.4 Å. This model is adapted 
from reference 46. 
 
 
 
Cross-linking studies, coimmunoprecipitations, and molecular mass determination of 
TRPV5/6 complexes using sucrose gradient sedimentation showed that TRPV5 and 
TRPV6 form tetrameric channel complexes, where 4 subunits surround a single pore 
(42). Niemeyer and co-workers showed that a specific N-terminal domain 
encompassing the third ankyrin repeat is required for the assembly of TRPV6 subunits 
within a functional tetramer (43). It was proposed that this repeat initiates a molecular 
zippering process that proceeds past the fifth ankyrin repeat and creates an intracellular 
anchor that is necessary for functional subunit assembly. In addition, the N-tail and to a 
lesser extent the C-tail are critical for channel assembly of TRPV5 and the assembly 
domain in the N-tail of TRPV5 overlapped with the first ankyrin repeat (44). 
Interestingly, a structural model of the outer pore of TRPV5 and TRPV6 was recently 
provided by Dodier et al. (45) and Voets et al. (46), respectively. Using cysteine 
scanning mutagenesis, these authors indicated that the main structural features of 
TRPV5 and TRPV6 are a pore helix followed by a non-helical loop that forms the 
selectivity filter, similar to KcsA K+ channels (47). The aspartic residue D542/D541 is 
part of the selectivity filter for Ca2+ and, in TRPV6, this residue lines the narrowest 
part of the pore with an estimated diameter of 5.4 Å (Fig. 3) (46). Furthermore, 
Hoenderop and co-workers demonstrated that, in addition to the homotetrameric 
architecture, TRPV5 and TRPV6 can form heterotetrameric channel complexes (42). 
5.4Å
D541
D541
D541
D541
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The interaction between TRPV5 and TRPV6 was recently confirmed by Schaefer and 
co-workers (48). Fluorescence resonance energy transfer (FRET) analysis showed an 
efficient heteromultimerization between TRPV5 and TRPV6, whereas all other TRPV 
channel subunits preferentially assemble into homomeric complexes (48). Moreover, 
the functional properties of these tetramers, including Ca2+-dependent inactivation, 
cation selectivity and pharmacological blockade, are dependent on the subunit ratio of 
TRPV5 and TRPV6 (42). 
 
EXPRESSION OF TRPV5 AND TRPV6 IN CA2+ TRANSPORTING EPITHELIA 
 
The tissue distribution of TRPV5 and TRPV6 has been studied extensively by 
Northern blot, RT-PCR analysis and immunohistochemistry. Both channels are 
expressed in organs, in which exchange of Ca2+ occurs across epithelia and are 
involved in the maintenance of body Ca2+ balance, including the kidney, 
gastrointestinal tract and bone. 
 
Kidney 
The kidney plays an essential role in the maintenance of the Ca2+ balance by regulating 
the Ca2+ excretion of the body. On a daily basis, ~8 g of Ca2+ is filtered at the glomeruli 
of which less than 2% is excreted into the urine (49). As a consequence, filtered Ca2+ is 
extensively absorbed as it passes through the individual nephron segments (Fig. 4). 
 
Proximal tubule 
In the proximal tubule (PT), consisting of the proximal straight tubule (PST) and the 
proximal convoluted tubule (PCT), approximately 65% of the filtered Ca2+ is 
reabsorbed (11). This reabsorption occurs passively via the paracellular pathway and is 
a consequence of Na+-coupled transport, which establishes an osmotic driving force for 
fluid transport and consequent solvent drag of Ca2+ (4).  
 
Limb of Henle 
The descending and ascending thin limbs of Henles loop (DTL and ATL, 
respectively) exhibit a low Ca2+ permeability (11). Ca2+ reabsorption continues in the 
thick ascending limb (TAL), where about 20% of the filtered Ca2+ is reabsorbed via the 
paracellular pathway (4). The driving force for this passive transport is the lumen-
positive transepithelial potential difference generated by the furosemide-sensitive Cl- 
reabsorption (11). Interestingly, a new protein, named paracellin 1 (PCLN-1), 
expressed in human TAL tight junctions, possibly plays a critical role in the control of 
passive Ca2+, and also Mg2+, reabsorption, since mutations of PCLN-1 are present in 
patients with hypomagnesemia hypercalciuria syndrome (HHS) (50). Some studies 
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suggest the involvement of an additional active Ca2+ transport mechanism, but this 
issue remains controversial (4, 11). 
 
 
FIGURE 4.  
Schematic representation of an individual 
nephron segment. After filtration at the 
glomerulus (G), Ca2+ passes through the 
individual nephron segment. Passive Ca2+ 
reabsorption occurs predominantly in the 
proximal tubule and thick ascending limb 
(TAL), whereas active Ca2+ reabsoption takes 
place in the distal convoluted tubule (DCT), 
connecting tubule (CNT), and cortical 
collecting duct (CCD). PCT, proximal 
convoluted tubule; PST, proximal straight 
tubule; DTL, descending thin limb of Henle´s 
loop; ATL, ascending thin limb of Henle´s 
loop; cTAL, cortical TAL; mTAL, medullary 
TAL; OMCD, outer medullary collecting 
duct; IMCD, inner medullary collecting duct. 
 
 
Distal convoluted tubule and connecting tubule 
The fine-tuning of Ca2+ excretion in the kidney occurs in the distal part of the nephron 
and amounts to 15% of the filtered load of Ca2+. This section consists of the distal 
convoluted tubule (DCT) and connecting tubule (CNT). In these segments, Ca2+ 
reabsorption occurs against the existing electrochemical gradient and is thus defined as 
an active transcellular pathway (4, 11). The CNT contains, in contrast to DCT, in 
addition to principal cells also intercalated cells. The relative contribution of the DCT 
and CNT to active Ca2+ reabsorption appears to differ between various species. In most 
mammalian species, however, the DCT is considered to be the main site of 
transcellular Ca2+ transport. Several studies demonstrated in the mouse co-expression 
of the Ca2+ transport proteins, including TRPV5, TRPV6, calbindins, NCX1, and 
PMCA1b, in the late distal part of the DCT (DCT2) and the CNT, with the highest 
immunochemical abundance in DCT2, and a gradual decrease along CNT (Fig. 5A) 
(13, 14, 51). A minority of cells along CNT lacked immunopositive staining for 
TRPV5 and the other Ca2+-transporting proteins and these negative cells were 
identified as intercalated cells (13, 14). Moreover, in DCT2, TRPV5 is mainly 
expressed along the apical domain, whereas the CNT displays a more cytoplasmic 
TRPV5 staining (14). Taken together, these findings strongly suggest that, in the 
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mouse, the major sites of transcellular Ca2+ transport are DCT2 and, probably to a 
lesser extent, CNT.  
 
 
FIGURE 5. Localization of TRPV5 and TRPV6 in kidney. (A) Immunopositive staining for TRPV5 that is 
predominantly found along the apical membrane of the late distal part of distal convoluted tubule (DCT2) in 
the mouse. G, glomerulus; PT, proximal tubule. (B) Schematic overview of the expression of the Ca2+ 
transport proteins in the kidney. NCC, NaCl-cotransporter; AQP2, aquaporin-2.  
 
Collecting duct 
The collecting duct (CD) is the last segment of the nephron and can be divided into at 
least three regions, based primarily on their localization in the kidney. These include 
the cortical CD (CCD), the outer medullary CD (OMCD), and the inner medullary CD 
(IMCD). The CD consists of principal cells that are responsible for salt and water 
reabsorption and intercalated cells that play an important role in the regulation of acid-
base homeostasis (52). The contribution of CD to overall Ca2+ reabsorption is relatively 
small and it was suggested that ~3% of the filtered Ca2+ is absorbed by the CCD (4, 
11). Because Ca2+ is transported against its electrochemical gradient, the mechanism is 
thought to be active. Consistent with the notion that transcellular Ca2+ transport is 
small in the CCD, the expression of TRPV5, PMCA1b, and NCX1 abruptly 
disappeared at the transition to the CCD (Fig. 5B) (14). 
Interestingly, TRPV6 expression was also detected in OMCD and IMCD and displayed 
a distinct apical localization (51). However, the absence of supportive Ca2+ transport 
proteins, as confirmed by the lack of immunopositive staining for calbindins, 
questioned the involvement of these cells in transcellular Ca2+ reabsorption. In 
addition, intercalated cells also express TRPV6 (51). The consistent apical localization 
would imply that TRPV6 has a functional role as apical Ca2+ entry channel. The 
TRPV6-mediated Ca2+ influx could affect transport processes in these cells, for 
DCT1 DCT2 CNT CCD OMCD IMCD
NCC
AQP2
NCX1
PMCA1b
Calbindin-D28K
TRPV5
TRPV6
DCT2
DCT2
PT
PT
G
A B
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instance as part of a hormonal signaling cascade, thereby affecting other transport 
routes including Na+ excretion, vasopressin-mediated water-permeability and urinary 
acidification (53-55). 
 
Intestine 
Intestinal Ca2+ absorption is a crucial control system in the maintenance of the bodys 
Ca2+ balance, because it facilitates the entry of dietary Ca2+ into the extracellular 
compartment. Two distinct mechanisms, including passive (paracellular) and active 
(transcellular) transport, are involved in Ca2+ absorption and their relative magnitude of 
importance is set by the dietary Ca2+ content. The fraction of Ca2+ actively absorbed is 
higher with low dietary Ca2+ intakes (8). Active transcellular Ca2+ absorption is located 
primarily in the duodenum, whereas paracellular Ca2+ absorption occurs throughout the 
entire length of the intestine (56).  
Subsequent studies using isoform-specific probes, quantitative PCR analysis, and 
immunohistochemical analysis demonstrated the presence of TRPV6 in the gut. The 
highest expression of TRPV6 was found in duodenum, where it co-localizes with 
calbindin-D9K and PMCA1b, consistent with a role in active Ca2+ absorption (19, 22, 
25, 57). In addition, expression of TRPV5 was demonstrated in the intestine (13, 25). 
However, in duodenum the TRPV5 mRNA levels are much lower than that of TRPV6 
or even below detection levels, whereas in kidney the levels of TRPV5 are much 
higher than for TRPV6 (58-60). In order of decreasing expression, TRPV6 mRNA 
expression is present in duodenum, cecum >> colon >> ileum. Likewise, TRPV5 was 
expressed in kidney >>> duodenum, cecum, whereas ileum and colon were negative 
(51). In general, TRPV5 seems to be the major isoform in kidney, whereas TRPV6 acts 
as the major transcellular mediator of Ca2+ uptake from the intestinal lumen. 
 
Bone 
It is generally understood that, in addition to its obvious structural role, bone functions 
as a mineral reserve, to be called upon in times of Ca2+ shortage, and to be replenished 
in times of Ca2+ surplus. Bone constantly undergoes remodeling, a delicate balance 
between bone formation and bone resorption. Bone formation requires the recruitment, 
proliferation and differentiation of osteoblasts resulting in extracellular matrix 
production and mineralization (61). Bone resorption results from the action of 
multinucleated osteoclasts, thereby dissolving and removing bone mass, including 
organic matrix and mineral content (62). The movement of Ca2+ into the mineralization 
matrix or from bone to the extracellular fluid is not well understood at the molecular 
level (63). Several reports have described calbindin-D9K and calbindin-D28K expression 
in rat and human osteoblast-like cells. (64, 65). Furthermore, it has been suggested that 
calbindin-D28K may play a direct role in the mineralization process (65). In addition, 
Chapter 1 
 18 
Ca2+ efflux mechanisms, including NCX1 and PMCA1b, have been found in both 
osteoclasts and osteoblasts. Although their precise role on these bone cells is not 
known, it is possible that they participate in bone resorption or bone formation (66).  
Interestingly, TRPV5 and TRPV6 mRNA have been detected in bone cells isolated 
from mouse femurs (51). To date, information on expression and localization of these 
proteins in bone cells is limited, and their functions in matrix mineralization or 
resorption are unclear. 
 
Others 
Expression of TRPV5 and TRPV6 has also been demonstrated in tissues that are not 
primarily involved in general Ca2+ homeostasis or in transcellular Ca2+ transport. 
Studies using Northern blot, RT-PCR analysis and immunohistochemistry have 
demonstrated the presence of these Ca2+ channels in placenta, stomach, pancreas, 
prostate, mammary, sweat and salivary glands (13, 18-20, 22-25, 57, 67-69). Although 
the exact function of TRPV5 and/or TRPV6 in these organs remains to be elucidated, 
several possibilities have been suggested. For instance, the pattern of TRPV5 and 
TRPV6 expression in placenta correlates with the active Ca2+ transport across the 
placenta from the maternal to the fetal circulation in late gestation (18, 19, 70, 71). In 
addition, a role for TRPV5 and TRPV6 has been suggested in insulin secretion by the 
pancreatic β-cells and in the mucus-secreting cells of the stomach, respectively (25, 57, 
67).  Moreover, TRPV6 has been shown to correlate with prostate cancer progression 
and, therefore, represents a prognostic marker and a promising target for new 
therapeutic strategies to treat advanced prostate cancer (72, 73). 
The relative mRNA level of TRPV5 and TRPV6 in tissues co-expressing these 
channels is different. Variations in TRPV5 and TRPV6 mRNA expression patterns 
found in several studies could have resulted from differences between species or the 
employed detection methods. Ultimately, it will be important to analyze the expression 
differences quantitatively at the protein level. Moreover, differences in the localization 
of TRPV5 and TRPV6 may reflect diverse physiological functions in these tissues and 
future studies should address the physiological role of these channels in more detail. 
 
REGULATION OF ACTIVE CA2+ TRANSPORT 
 
Since Ca2+ homeostasis is of pivotal importance, transcellular Ca2+ transport in 
particular is a highly coordinated and regulated process, which can be fine-tuned to the 
bodys specific requirements. Various calciotropic hormones are known to be involved 
in the regulation of transcellular Ca2+ transport. The classic representatives of this 
group are 1,25(OH)2D3, PTH and calcitonin. 
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Vitamin D 
It is commonly accepted that vitamin D is one of the main hormones controlling Ca2+ 
balance (74). Vitamin D3 can be obtained from the diet or synthesized in the skin from 
its precursor 7-dehydrocholesterol in the presence of sunlight (75). Vitamin D3 is 
physiological inactive and will undergo an activation process. In the liver it is 
converted to 25-hydroxyvitamin D3 (25(OH)D3). The second and more important step 
in vitamin D bioactivation is the conversion into the biologically active 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) by the 1α-hydroxylase (1αOHase) enzyme in the 
mitochondria of the renal PT (76, 77). Whether these PT cells produce 1,25(OH)2D3 
depends on the Ca2+ status of the body. The activity of 1αOHase is positively regulated 
by low serum Ca2+ and phosphate levels and PTH, whereas 1,25(OH)2D3 regulates its 
own production via a negative feedback loop (78).   
Most of the biological actions of 1,25(OH)2D3 are mediated by a nuclear high-affinity 
receptor that acts as a ligand-activated transcription factor (79). The vitamin D receptor 
(VDR) has been cloned from several species and belongs to the superfamily of steroid 
hormone receptors. Upon binding of 1,25(OH)2D3, the VDR is activated and 
translocated to the nucleus. Here, heterodimerization occurs with retinoid X receptor 
(RXR). The RXR-VDR complex then binds to vitamin D-responsive elements (VDRE) 
upstream of the vitamin D target genes, where upon transcription proceeds through the 
interaction with coactivators and the transcription machinery (78, 79).The VDR has 
been found in the classic vitamin D target organs, namely the intestine, kidney, bone 
and the parathyroid glands.  
The most critical role of 1,25(OH)2D3 in mineral homeostasis is to enhance the 
efficiency of the small intestine to absorb dietary Ca2+ as demonstrated conclusively by 
studies in VDR knockout mice (80). In addition, in vivo and in vitro studies 
demonstrated that 1,25(OH)2D3 increases renal Ca2+ reabsorption (11, 81). Best 
described is the regulation of the calbindins in intestine and kidney (5, 9). Furthermore, 
vitamin D is essential for the development and maintenance of a mineralized skeleton. 
1,25(OH)2D3 stimulates bone formation by inducing the synthesis of bone matrix 
proteins and mineral apposition (65, 78). In addition, 1,25(OH)2D3 induces bone 
resorption through enhancement of osteoclastogenesis and osteoclastic activity (78, 
82).  
 
Parathyroid hormone 
PTH is a major regulator of Ca2+ metabolism. The parathyroid glands play a key role in 
maintaining the extracellular Ca2+ concentration through their capacity to sense even 
minute changes in the level of blood Ca2+ from its normal level. The Ca2+-sensing 
receptor (CaSR) is the mechanism through which the parathyroid chief cells sense 
variations in the Ca2+ concentration and release PTH (83). In addition, whereas PTH 
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stimulates the production of 1,25(OH)2D3 by activating the renal 1αOHase, 
1,25(OH)2D3 in turn suppresses the synthesis and secretion of PTH and controls 
parathyroid cell growth (84, 85).  
PTH is an 84-amino acid polypeptide hormone and interacts with a membrane-bound 
G protein-coupled receptor, which is shared by the PTH-related protein (PTHrP) (86). 
Signaling through the PTH/PTHrP receptor involves the activation of two major 
transduction systems, one through the stimulation of adenylyl cyclase with cAMP 
production and another involving phospholipase C (PLC), leading to activation of 
protein kinase A or C (PKA or PKC), respectively (86, 87). 
PTH/PTHrP receptor mRNA has been localized in rat kidney to glomerular podocytes, 
PCT, PST, cTAL, and DCT, but the receptor was not detected in the thin limb of 
Henles loop or in the CD (88, 89). Several studies, using immunodissected cell lines 
from rabbit DCT and CNT and mouse DCT, have demonstrated that PTH increases 
transepithelial Ca2+ transport via a dual signaling mechanism involving PKA- and 
PKC-dependent processes (11, 81, 90, 91). Furthermore, PTH stimulates the activity of 
1αOHase and, thereby, increases the 1,25(OH)2D3-dependent absorption of Ca2+ from 
the intestine.  However, early work also suggested direct actions of PTH on duodenal 
cells (92, 93). These findings were confirmed by Picotto et al. (94) who demonstrated 
that PTH significantly stimulates enterocyte Ca2+ influx. Moreover, 
immunohistochemical analysis of rat duodenal sections showed localization of the 
PTH/PTHrP receptor in epithelial cells along the villus with intense staining of brush-
border and basolateral membranes and cytoplasm (95, 96). Additionally, PTH activates 
osteoclasts through the mediation of nearby osteoblasts, induces the formation of more 
osteoclasts and reduces osteoclast apoptosis, resulting in bone resorption with the 
subsequent release of Ca2+ into the circulation (62, 97, 98).  
 
Calcitonin 
Calcitonin is a 32-amino acid peptide hormone produced by the C-cells of the thyroid 
gland. Secretion of calcitonin could involve the regulation by CaSRs, which are present 
in thyroid C-cells (99). Calcitonin receptors have been cloned from various species and 
belong to the G protein-linked receptor superfamily. The signaling pathways activated 
by this receptor are similar to those stimulated by PTH/PTHrP receptors, acting 
through both adenylyl cyclase and PLC (100, 101).  
Calcitonin is known for its ability to regulate bone resorption. It inhibits the bone 
resorbing activity of osteoclasts, thereby decreasing the Ca2+ efflux from bone (102-
104). Interestingly, renal 1αOHase gene expression is upregulated by calcitonin and, 
consequently, results in elevated 1,25(OH)2D3 levels and enhanced intestinal and renal 
Ca2+ (re)absorption. Furthermore, calcitonin appears to act similarly to PTH in 
reducing Ca2+ excretion by promoting its tubular reabsorption (105, 106). However, the 
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molecular mechanism is not known yet. It was postulated that calcitonin hyperpolarizes 
the plasma membrane and thereby increases the driving force for Ca2+ entry through 
Ca2+ channels (11, 107). 
 
Ca2+-sensing receptor 
Evidence that Ca2+ itself can act as an extracellular first messenger in the regulation of 
Ca2+ homeostasis came from the molecular identification of the CaSR (83). The CaSR 
is a G protein-coupled, cell surface receptor and capable of activating PLC, resulting in 
the formation of inositol 1,4,5-triphosphate-mediated increase of [Ca2+]I and inhibition 
of adenylyl cyclase (108). This receptor represents the molecular mechanism by which 
parathyroid cells detect changes in blood ionized Ca2+ concentration, modulate PTH 
secretion accordingly, and thus maintain serum Ca2+ levels within a narrow 
physiological range (83). In addition, the CaSR is expressed on a number of other cells 
involved in systemic Ca2+ homeostasis, like the thyroid C-cells, kidney, intestine, and 
bone.  
The CaSR is expressed at numerous sites along the nephron and its cellular localization 
and apparent function(s) appear to depend upon the region of the nephron in which the 
CaSR is expressed (109, 110). In the PT, the CaSR is expressed along the apical 
membrane and there is evidence that its function could be to antagonize or limit the 
effects of PTH as stimulator of 1,25(OH)2D3 production and phosphate excretion 
(111). Expression of the CaSR is most abundant in the basolateral membranes of the 
TAL. Activation of the CaSR in this segment inhibits passive Ca2+ transport and 
directly suppresses PTH-induced transcellular Ca2+ transport (112, 113). 
Immunohistochemical investigation of the rat kidney revealed expression of the CaSR 
in DCT cells, including at the basolateral and apical membranes. A study by 
Blankenship et al. reported that basolateral activation of the CaSR directly inhibits Ca2+ 
reabsorption, possibly via the inhibition of PMCA (114). Furthermore, it has been 
demonstrated that a high luminal Ca2+ concentration activates the CaSR in the apical 
membrane of the IMCD. As a consequence, the vasopressin-elicited water permeability 
is blunted by a PKC-mediated aquaporin-2 retrieval mechanism to reduce water 
reabsorption and prevent a further rise in urinary Ca2+ concentration (115). In addition, 
expression of the CaSR was demonstrated throughout the small intestine and colon 
(116, 117). The levels of CaSR activation could influence solute and water transport 
but also modulates cell proliferation and differentiation (108, 118). In skeletal tissue, 
signaling through the CaSR may affect the proliferation and/or cellular function of 
osteoblasts and osteoclasts (119, 120). It has been suggested that the CaSR inhibits 
bone resorption and osteoclastogenesis (121), however, controversy persists about 
CaSR in bone and its function in bone cell metabolism. 
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The CaSR forms a unique molecular target for drugs that can directly alter the activity 
of the receptor, thereby manipulating the extracellular Ca2+ balance. In the last decade 
synthetic compounds, referred to as calcimimetic compounds, have been developed 
(122, 123). Calcimimetics, like NPS R-467, are small organic compounds that, upon 
binding to the CaSR, enhance the sensitivity of the CaSR for Ca2+ in an allosteric 
fashion, thereby inhibiting PTH secretion by the parathyroid glands. Indeed, several 
calcimimetic compounds have been described that selectively target the parathyroid 
gland CaSRs and suppress serum levels of PTH and Ca2+ (123-125). However, the 
involvement of intestinal and renal Ca2+ (re)absorption in the calcimimetic-induced 
hypocalcemia is not clear. 
 
Other factors 
In addition to the classic calciotropic hormones, others hormones and compounds have 
been demonstrated to be involved in Ca2+ homeostasis. For instance, estrogen has 
significant effects on the regulation of Ca2+ and bone metabolism. The deleterious 
effects of estrogen deficiency after menopause result in a negative Ca2+ balance 
associated with postmenopausal osteoporosis (126, 127). In addition, it has been 
demonstrated that estrogen deficiency is associated with increased renal Ca2+ loss and 
intestinal Ca2+ malabsorption, which can be corrected by estrogen replacement therapy 
(128-131). 
The glycoprotein stanniocalcin is a promising candicate as novel calciotropic hormone. 
The hormone was originally identified in bony fish, where it exerts its 
antihypercalcemic effect by regulating Ca2+ and phosphate transporters in the gills, 
intestine, and kidney (132). The human and mouse homologues of stanniocalcin have 
also been characterized and demonstrated to be present in multiple organs, including 
Ca2+ transporting epithelia like intestine, colon, kidney, and placenta (133-135). The 
main function of stanniocalcin, similar to that of calcitonin, appears to be the 
prevention of hypercalcemia and it acts locally in kidney and gut to modulate Ca2+ and 
phosphate excretion. Stanniocalcin overexpression in mice results in high serum 
phosphate, dwarfism, and increased metabolic rate (136, 137). 
Thyroid hormone status also influences Ca2+ metabolism. Hypercalcemia is frequently 
observed with thyrotoxicosis, and long-term hyperthyroid state is associated with Ca2+ 
malabsorption and increased bone resorption (138, 139). Recent studies have 
demonstrated that in kidney and intestine both Ca2+ uptake and efflux were 
significantly increased in hyperthyroid rats and decreased in hypothyroid animals (140, 
141).  
Diuretics such as furosemide and thiazides are frequently used in the clinical practice, 
in particular as antihypertension therapy, and are known to alter Ca2+ metabolism. 
Administered alone or in a combination of diuretics over a long period of time, these 
General Introduction 
 23 
diuretics disturb Ca2+ reabsorption, resulting in hyper- or hypocalciuria, thereby 
leading to alterations in structure and stability of bone (142-145) . 
Immunosuppressants are widely prescribed drugs in various disorders and for organ 
transplant recipients. The immunosuppressive actions of tacrolimus (FK506) and 
dexamethasone are accomplished by distinct mechanisms, however, both are known to 
induce significant side effects on mineral homeostasis (146-148). These drugs are 
associated with an increased bone turnover, a negative Ca2+ balance, and 
hypercalciuria, which could ultimately result in osteoporosis (149, 150).  
 
CA2+-RELATED DISEASES 
 
Malfunction of the Ca2+ transport system or disturbances in the hormonal control 
mechanisms are frequently the cause of Ca2+ imbalance. For instance, the importance 
of 1,25(OH)2D3 in Ca2+ homeostasis is reflected by mutations in the genes coding for 
1αOHase and the VDR. Mutations in the 1αOHase gene are the cause of an autosomal 
recessive disease known as vitamin D-deficiency rickets type I (VDDR-I), which is 
characterized by low or undetectable levels of 1,25(OH)2D3 resulting in hypocalcemia, 
rickets, osteomalacia, and growth retardation (151). In addition, patients with defects in 
the gene encoding the VDR have hereditary hypocalcemic vitamin D-deficiency rickets 
type II (VDDR-II), and display a similar phenotype except for the elevated serum 
1,25(OH)2D3 levels (152).  
Furthermore, several disorders with disturbed Ca2+ homeostasis are characterized by 
hypo- or hyperparathyriodism. Primary hyperparathyroidism is a common endocrine 
disorder characterized by elevated PTH levels (153). Others involve inactivating 
mutations in the CaSR gene, resulting in familial hypocalciuric hypercalcemia or 
neonatal severe hyperparathyroidism (154), whereas activating mutations result in 
hypocalcaemia with hypercalciuria (155). Moreover, hypercalciuria is highly correlated 
with the occurrence of nephrolithiasis, i.e. kidney stones.  
Aging also has important negative effects on Ca2+ balance. The capacity of 
1,25(OH)2D3 to stimulate Ca2+ absorption reduces with age, resulting in intestinal 
malabsorption (156). Furthermore, there are age-related changes in renal Ca2+ handling 
(157). Moreover, aging is associated with hyperparathyroidism and ultimately results 
in senile osteoporosis (158). In addition, in women after menopause, Ca2+ balance is 
disturbed due to decreased estrogen levels and associated with renal Ca2+ loss, 
intestinal Ca2+ malabsorption and postmenopausal osteoporosis (127).  
Disorders by malfunction of ion transporters can lead to Gitelmans or Bartters 
syndrome. Gitelmans syndrome is an inherited form of hypokalemic alkalosis and is 
accompanied by hypocalciuria. This disorder results primarily from the loss of function 
of the thiazide-sensitive NaCl-cotransporter (NCC) present in the renal DCT (159). 
Bartters syndrome is caused by mutations in genes encoding for proteins involved in 
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the process of NaCl reabsorption in the TAL, including the Na+-K+-2Cl--cotransporter 
(NKCC2), the ATP-regulated K+ channels (ROMK), or chloride channels. This 
disorder is characterized by hypokalemic alkalosis with hypercalciuria (160). Similar 
effects on Ca2+ reabsorption are observed with treatment of diuretics (161). 
 
CHARACTERIZATION OF EPITHELIAL CA2+ CHANNEL KNOCKOUT MICE 
 
TRPV5 knockout mice 
In order to investigate the physiological function of TRPV5 in maintaining Ca2+ 
balance TRPV5 knockout mice were generated (162). Mice lacking TRPV5 (TRPV5-/-) 
displayed a significant calciuresis compared with their wild-type littermates 
(TRPV5+/+) while remaining normocalcemic. However, serum 1,25(OH)2D3 levels 
were significantly elevated in TRPV5-/- mice compared with TRPV5+/+ mice. In 
addition to the increased renal Ca2+ excretion, polyuria and an acidic urine were 
consistently observed in TRPV5-/- mice. Increasing the amount of urine and 
acidification of the urine reduces the potential risk of renal stone formation (163, 164). 
Micropuncture studies indicated that the renal Ca2+ transport defect was localized 
primarily to the DCT/CNT. Ablation of TRPV5 in the distal convolution was 
accompanied by a concomitant decrease in calbindin-D28K and NCX1 mRNA levels. In 
contrast to the excessive renal Ca2+ wasting, intestinal Ca2+ absorption as well as 
TRPV6 and calbindin-D9K expression were increased, which could function as a 
compensatory mechanism to maintain normal serum Ca2+ concentrations. Furthermore, 
the TRPV5-/- mice exhibited significant disturbances in bone structure, including 
reduced trabecular and cortical bone thickness compared with TRPV5+/+ mice (162). 
Together, ablation of the TRPV5 gene seriously disturbed renal Ca2+ handling, 
resulting in compensatory intestinal hyperabsorption and bone abnormalities.  
 
TRPV6 knockout mice 
Hediger and co-workers (165) addressed the functional role of TRPV6 in Ca2+ 
absorption by inactivation of the mouse TRPV6 gene. Preliminary results from in vivo 
oral gavage studies with 45Ca2+ revealed that these TRPV6 null (TRPV6-/-) mice have 
deficient intestinal Ca2+ absorption. In addition, TRPV6-/- mice displayed a defect in 
renal reabsorption, resulting in urinary Ca2+ wasting, and a reduced bone mineral 
density, even in the presence of high amounts of Ca2+ in their diet. 
 
Together, these findings suggest an essential role for both TRPV5 and TRPV6 in Ca2+ 
homeostasis. Moreover, the deficiencies in Ca2+ handling present in these knockout 
mice have been reported frequently in patients with idiopathic hypercalciuria, although 
the molecular basis for this disorder remains unknown. 
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SCOPE OF THIS THESIS 
 
Ca2+ homeostasis is of utmost importance for the normal development and function of 
the body. The extracellular Ca2+ concentration is determined by the concerted action of 
the kidney, intestine, and bone and regulated by calciotropic hormones. TRPV5 and 
TRPV6 convey the rate-limiting step in active Ca2+ transport and are, therefore, pivotal 
to control the Ca2+ transport rate. A delicate regulation of the expression and activity of 
TRPV5 and TRPV6 is thus of great significance to the extracellular Ca2+ balance. 
Therefore, the aim of this thesis was to investigate the hormonal regulation of Ca2+ 
transport proteins, in particular TRPV5 and TRPV6, and provide insight into the 
physiological role of these Ca2+ channels and the molecular nature of Ca2+ 
homeostasis.  
In chapter 2, the effect of estrogen on the expression of renal Ca2+ transport proteins, 
including TRPV5, was investigated. To this end, an ovariectomized rat model was used 
to study the effect of estrogen deficiency with subsequent estrogen replacement 
therapy. In addition, the involvement of 1,25(OH)2D3 in the effect of estrogen was 
examined in 1αOHase knockout mice, as a vitamin D-deficient animal model. In 
chapter 3, the importance of 1,25(OH)2D3 in Ca2+ homeostasis and renal Ca2+ 
reabsorption was studied using the 1αOHase knockout mice. In addition, these 
knockout mice represented a unique animal model to explore the involvement of the 
Ca2+ transport proteins in the pathophysiology of VDDR-I. These mice were rescued 
by 1,25(OH)2D3 supplementation or high dietary Ca2+ content and the renal expression 
of the Ca2+ transport proteins, including TRPV5, was examined. Moreover, in chapter 
4, the effects of estrogen, 1,25(OH)2D3 and dietary Ca2+ on the expression of TRPV6 
(and TRPV5) were investigated in the intestine. Furthermore, the effect of PTH on the 
expression of proteins involved in renal transcellular Ca2+ reabsorption was examined 
in chapter 5 using parathyroidectomized rats, which were subsequently treated with 
PTH. In addition, the effect of a new pharmacological treatment for 
hyperparathyroidism, the calcimimetic compound NPS R-467, on the renal expression 
of TRPV5 and TRPV6 was investigated. Moreover, the molecular mechanism 
responsible for the coordinated regulation of the renal transcellular Ca2+ transport 
proteins by PTH was studied using a primary renal cell culture. Chapter 6 describes the 
effect of aging on the expression of renal and intestinal Ca2+ transport proteins, 
including TRPV5 and TRPV6. A comparison was made between the age-related 
changes in control and TRPV5 knockout mice. Finally, a general discussion and 
summary on these subjects is presented in chapter 7. 
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ABSTRACT 
 
Estrogen deficiency results in a negative Ca2+ balance and bone loss in postmenopausal 
women. In addition to bone, the intestine and kidney are potential sites for estrogen 
action and are involved in Ca2+ handling and regulation. The epithelial Ca2+ channel 
ECaC1 (or TRPV5) is the entry channel involved in active Ca2+ transport. Ca2+ entry is 
followed by cytosolic diffusion, facilitated by calbindin-D28K and/or calbindin-D9k, and 
active extrusion across the basolateral membrane by the Na+/Ca2+-exchanger (NCX1) 
and plasma membrane Ca2+-ATPase (PMCA1b). In this transcellular Ca2+ transport, 
ECaC1 probably represents the final regulatory target for hormonal control. The aim of 
this study was to determine whether 17β-estradiol (17β-E2) is involved in Ca2+ 
reabsorption via regulation of the expression of ECaC1. The ovariectomized rat model 
was used to investigate the regulation of ECaC1, at mRNA and protein levels, by 17β-
E2 replacement therapy. Using real-time quantitative PCR and immunohistochemical 
analyses, this study demonstrated that 17β-E2 treatment at pharmacologic doses 
increased renal mRNA levels of ECaC1, calbindin-D28K, NCX1, and PMCA1b and 
increased the protein abundance of ECaC1. Furthermore, the involvement of 1,25-
dihydroxyvitamin D3 in the effects of 17β-E2 was examined in 25-hydroxyvitamin D3-
1α-hydroxylase knockout mice. Renal mRNA expression of calbindin-D9K, calbindin-
D28K, NCX1, and PMCA1b was not significantly altered after 17β-E2 treatment. In 
contrast, ECaC1 mRNA and protein levels were both significantly upregulated. 
Moreover, 17β-E2 treatment partially restored serum Ca2+ levels from 1.63 ± 0.06 to 
2.03 ± 0.12 mM. In conclusion, this study suggests that 17β-E2 is positively involved in 
renal Ca2+ reabsorption via the upregulation of ECaC1, an effect independent of 1,25-
dihydroxyvitamin D3.    
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INTRODUCTION 
 
Ca2+ homeostasis plays a key role in mammalian development and function and is 
maintained by the function of the small intestine, skeleton, and kidney. The classic 
hormones involved in Ca2+ homeostasis include 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), parathyroid hormone, and calcitonin (1, 2). Estrogen is usually not 
considered a calciotropic hormone, but the idea that estrogen plays a role in Ca2+ 
homeostasis has been widely accepted (3). This involvement is clearly illustrated by 
the fact that estrogen deficiency results in a negative Ca2+ balance and bone loss among 
postmenopausal women (4). In addition to bone, two potential sites of estrogen action 
are the intestine and kidney, which are involved in Ca2+ handling and regulation.  
There is increasing evidence that estrogen plays a physiologic role in the regulation of 
renal Ca2+ reabsorption. In vivo studies demonstrated that estrogen deficiency was 
associated with increased renal Ca2+ loss, which could be corrected with estrogen 
replacement therapy (5, 6). Furthermore, there is evidence that estrogen receptors (ER) 
are also present in the kidney (7, 8). ER localization studies have suggested both 
proximal and distal tubules as possible sites of action (9, 10). However, the underlying 
mechanism by which estrogen might affect renal Ca2+ handling is still poorly 
understood. In addition, there is considerable disagreement regarding possible direct 
effects of estrogen on Ca2+ reabsorption versus indirect effects produced via actions on 
vitamin D metabolism.   
The epithelial Ca2+ channel ECaC1 (or TRPV5), which is observed in renal distal 
convoluted tubule and connecting tubule cells, is the entry channel involved in 
transcellular Ca2+ transport (11). Ca2+ entry via ECaC1 is followed by cytosolic 
diffusion, facilitated by Ca2+-binding proteins (calbindin-D28K and/or calbindin-D9k), 
and active extrusion of Ca2+ across the basolateral membrane by a high-affinity plasma 
membrane Ca2+-ATPase (PMCA1b) and a Na+/Ca2+-exchanger (NCX1). In this active 
process, ECaC1 probably forms the final regulatory target for hormonal control (12, 
13). Therefore, ECaC1 could be a target for estrogen in the regulation of Ca2+ 
reabsorption. 
The aim of this study was to determine whether estrogen acts on the distal part of the 
renal tubule by increasing the expression of ECaC1, which could result in increased 
Ca2+ reabsorption. We used the ovariectomized (OVX) rat model of estrogen 
deficiency to investigate changes in ECaC1, at the mRNA and protein levels, with 
estrogen replacement therapy. The involvement of the important calciotropic hormone 
1,25(OH)2D3 in estrogen effects was examined in 25-hydroxyvitamin D3-1α-
hydroxylase (1αOHase) knockout mice, as a vitamin D-deficient model (14). This 
study indicates that estrogen upregulates ECaC1 expression in the kidney, thereby 
regulating Ca2+ reabsorption, and that estrogen exerts this effect independent of 
1,25(OH)2D3. 
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MATERIALS AND METHODS 
 
Animals 
Experiment 1. Twenty-five mature, virgin, female Wistar rats (Hsd/Cpd:Wu, bred 
specific pathogen-free by Harlan, CPB, Zeist, The Netherlands), weighing 225 to 250 
g, were housed individually in Macrolon cages in a light- and temperature-controlled 
room (14-h light/10-h near-dark, at 21 to 23°C). The rats received 16 g of standard 
pelleted food daily, and water was available ad libitum. On day 1 of the experiment, 
the rats were weighed and divided into five groups. After anesthesia induction, bilateral 
OVX or a sham operation was performed. Thereafter, rats received 17β-estradiol (17β-
E2) (Sigma, St. Louis, MO, USA) or vehicle (gelatin and mannitol) added to the 
pelleted food, each day. Sham-operated animals served as control animals. OVX 
animals were given either the vehicle alone, 2x 32 µg 17β-E2/day, 2x 125 µg 17β-
E2/day, or 2x 500 µg 17β-E2/day. Treatment was started immediately after OVX and 
lasted for 7 days. On the last day, the rats were euthanized. Blood was collected from 
the abdominal aorta, the uterus was excised and weighed, and the kidneys were 
dissected and immediately frozen in liquid nitrogen.  
Experiment 2. Homozygous, 9-wk-old, male 1αOHase knockout mice (14) were 
housed individually in a light- and temperature-controlled room. Both deionized water 
and standard pelleted food were available ad libitum throughout the experiment. The 
mice were randomized into the following two groups (with each group consisting of 
four mice): homozygous mice and homozygous mice given infusions of 17β-E2. 
Osmotic minipumps (model 1007D; Alzet, DURECT Corp., Cupertino, CA) were used 
for rate-controlled delivery of 17β-E2; these pumps release their contents at a rate of 
0.5 µl/h for 7 days. The pumps were filled with the desired solution and implanted 
subcutaneously in the backs of the mice. The infusion dose for the 17β-E2-treated mice 
was 10 µg/day, and control mice received vehicle solution alone (15% ethanol/50% 
DMSO/35% water, vol/vol). After 7 days, mice were euthanized, blood was collected 
via orbita puncture, and kidneys were dissected and immediately frozen in liquid 
nitrogen. The animal ethics board of the University of Nijmegen and Shriners Hospital 
for children (Montreal, Quebec, Canada) approved all animal experimental procedures. 
 
Analytical procedures 
Serum Ca2+ concentrations were analyzed by using a colorimetric assay kit, as 
described previously (15). Serum 17β-E2 levels were measured by using an extraction 
procedure with diethyl ether, followed by RIA (DPC, Los Angeles, CA) (16). 
 
Chapter 2 
 40 
RNA isolation, reverse transcription, and quantitative PCR 
Total RNA from kidney cortex was isolated by using TriZol reagent (Life 
Technologies, Breda, The Netherlands), according to the protocol described by the 
manufacturer. RNA was treated with DNAse, to prevent genomic DNA contamination, 
and was finally resuspended in diethylpyrocarbonate-treated water filtered with a 
MilliQ system (Millipore, Bedford, MA). Total RNA (2 µg) was subjected to reverse 
transcription using Moloney murine leukemia virus reverse transcriptase (Life 
Technologies), as described previously (17). Expression levels of renal ECaC1, 
calbindin-D28K, calbindin-D9K, NCX1, and PMCA1b mRNA were quantified by real-
time quantitative PCR, using an ABI Prism 7700 sequence detection system (PE 
Biosystems, Rotkreuz, Switzerland). The expression level of hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) was used as an internal control to normalize 
differences in RNA extractions, the degree of RNA degradation, and reverse 
transcription efficiencies. Primers and probes targeting the genes of interest were 
designed by using Primer Express software (Applied Biosystems, Foster City, CA) and 
are listed in Table 1. The 3-ends of the probes were labeled with the quencher dye 6-
carboxytetramethylrhodamine (TAMRA). The 5-ends of all probes were labeled with 
the reporter dye 6-carboxyfluorescein (FAM) (Biolegio, Malden, The Netherlands).  
 
TABLE 1. Sequences of primers and Taqman probes for real-time quantitative PCRa 
 
a PCR primers and fluorescent probes (5FAM3TAMRA) were designed by using the computer program 
Primer Express (Applied Biosystems) and were purchased from Biolegio. HPRT, hypoxanthine-guanine 
phosphoribosyl transferase; ECaC1, epithelial Ca2+ channel 1; PMCA1b, plasma membrane Ca2+-ATPase; 
NCX1, Na+/Ca2+-exchanger; R, rat; M, mouse. 
 
Immunohistochemical analyses 
Seven-micron sections of frozen kidney tissue were cut with a cryotome and collected 
on SuperFrost/Plus-coated (Menzel-Glazer, Germany) glass slides. For ECaC1 
5-ACCTTGACTGATATTGTTTTGACTATTTCATCATTCTGGA-35-TTTCTCATACTCCTCGTCATCGATT-35-TCCCTACAAAACTATTGAAGGCACA-3
NCX1
5-CAGCTGAAAGGCTTCCCGCCAAA-35-CAGCCATTGCTCTATTGAAAGTTC-35-CGCCATCTTCTGCACCATT-3
PMCA1b
Calbindin-D9K
5-ACCAGTGCAGGAAAATTTCCTTCTTAAATTCCA-35-TGAACTCTTTCCCACACATTTTGAT-35-AACTGACAGAGATGGCCAGGTTA-3
Calbindin-D28K 
5-TGTTTCTCAGATAGCTGCTCTTGTACTTCCTCTTTGT-35-GTTTGGAGAACCACAGAGCCTCTA-35-CGTTGGTTCTTACGGGTTGAAC-3
ECaC1
5-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-35-TTACCAGTGTCAATTATATCTTCAACAATC-35-TTATCAGACTGAAGAGCTACTGTAATGATC-3
HPRT
ProbeReverse primerForward primerGene
R
M
5-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-35-TTACCAGTGTCAATTATATCTTCAACAATC-35-TATCAGACTGAAGAGCTACTGTAATGACC-3
R
M
5-TGCTTCTCAGATAGTTGTTCTTGTACTTCCTCCTTGT-35-TTGCAGAACCACAGAGCCTCTA-35-CTTACGGGTTGAACACCACCA-3
R
M
5-ACCAGTGCAGGAAAATTTCCTTCTTAAATTCCA-35-TGAACTCTTTCCCACACATTTTGAT-35-GGAAGCTGGAGCTGACAGAGAT-3
M 5-CAAAAATATGCAGCCAAGGAAGGCGA-35-CTCCATCGCCATTCTTATCCA-35-CCTGCAGAAATGAAGAGCATTTT-3
R
M
5-CAGCTGAAAGGCTTCCCGCCAAA-35-CAGCCATTGTTCTATTGAAAGTTC-35-CGCCATCTTCTGCACAATT-3
R
M
5-ACCTTGACTGATATTGTTTTGACTATTTCATCATTCTGGA-35-TTTCTCATACTCCTCGTCATCGATT-35-TCCCTACAAAACCATTGAAGGCACA-3
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staining, sections were incubated in boiled citrate buffer (0.01 M sodium citrate, 0.01 
M citric acid, pH 6), cooled for 30 min, and washed three times with TN buffer (0.15 
M NaCl, 0.1 M Tris-HCl, pH 7.5). For immunoperoxidase staining, sections were 
incubated for 30 min at room temperature in TN buffer containing 0.3% (vol/vol) H2O2 
and washed three times with TN buffer. Sections were then incubated for 30 min in 
TNB buffer (TN buffer containing 0.5%, wt/vol, blocking reagent; NEN Life Science 
Products, Perkin Elmer, Boston, MA). Subsequently, sections were incubated for 16 h 
at 4°C in TNB buffer containing affinity-purified guinea pig anti-ECaC1 antiserum 
(1:200) (11). Sections were washed three times with TNT buffer (TN buffer containing 
0.05%, vol/vol, Tween 20) and then incubated for 1 h at room temperature with biotin-
labeled, affinity-purified, goat anti-guinea pig IgG (1:2000; Sigma Chemicals Co., St. 
Louis, MO). After washing with TNT buffer, sections were incubated with 
streptavidin-horseradish peroxidase (1:100; NEN Life Science Products) for 30 min at 
room temperature. Sections were washed three times with TNT buffer and incubated 
for 7 min with fluorescein tyramide in amplification diluent (1:50; NEN Life Science 
Products). Sections were then washed, dehydrated in 50 to 100% (vol/vol) methanol, 
and mounted in Mowiol (Hoechst, Frankfurt, Germany) containing 2.5% (wt/vol) 
NaN3. Photographs were taken with a Bio-Rad MRC 1000 confocal laser scanning 
microscope. The anti-ECaC1 antibody used in this study has been extensively 
characterized but is, unfortunately, not able to be used for immunoblotting (17). For 
semiquantitative assessment of ECaC1 protein expression, the relative amounts of 
immunopositive tubules in 10 to 15 randomly selected microscopic fields were 
determined for each animal, using a Zeiss Axioskop microscope (Zeiss, Thornwood, 
NY) equipped for epifluorescence illumination. 
 
Statistical analyses 
Values are expressed as mean ± SE. Differences between groups were tested by one-
way ANOVA and were further evaluated by using Fishers multiple-comparison 
procedure (18). Differences in means with P < 0.05 were considered statistically 
significant. All analyses were performed by using the Statview statistical package 
(Power PC version 4.51; Statview, Berkely, CA) on a Macintosh computer. 
 
RESULTS 
 
Effects of OVX and 17β-E2 treatment on rats  
Age-matched, untreated, OVX rats weighed significantly more than rats in the sham-
operated group (Table 2). In contrast, 17β-E2 treatment induced significant reductions 
in weight, with the greatest decrease being observed for the OVX/high-dose 17β-E2-
treated rats (Table 2). OVX resulted in the expected atrophy of the uterus, which was 
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prevented by 17β-E2 therapy in OVX/high-dose 17β-E2-treated rats (Table 2). Serum 
17β-E2 levels were reduced in untreated OVX rats, confirming OVX, whereas 
supplementation with the highest 17β-E2 dose resulted in significantly higher serum 
17β-E2 levels (Table 2). 17β-E2 treatment reduced serum Ca2+ levels, resulting in 
slightly but significantly lower serum Ca2+ level in the OVX/high-dose 17β-E2-treated 
group.  
 
TABLE 2.  Effects of OVX and 17β-E2 supplementation in ratsa  
 
a OVX, ovariectomized; 17β-E2, 17β-estradiol; +E2L, supplemented with 2x 32 µg 17β-E2/day; +E2M, 
supplemented with 2x 125 µg 17β-E2/day; +E2H, supplemented with 2x 500 µg 17β-E2/day. Data are 
presented as mean ± SE. b P<0.05 versus sham. c P<0.05 versus OVX. d P<0.05 versus all groups. e P<0.05 
versus OVX, OVX plus low-dose 17β-E2, and OVX plus medium-dose 17β-E2. f P<0.0001 versus all groups. 
 
Effect of 17β-E2 on ECaC1 expression in rat kidneys  
To investigate the effect of 17β-E2 on ECaC1 mRNA expression, real-time quantitative 
PCR was performed with total RNA isolated from kidney cortex (Fig. 1A). The data 
demonstrated that 17β-E2 supplementation, using the highest dosage, for estrogen-
depleted rats resulted in a 2.5-fold increase in ECaC1 mRNA expression, compared 
with OVX rats. The expression levels of other Ca2+ transport proteins involved in 
transcellular Ca2+ transport, namely calbindin-D28K, NCX1 and PMCA1b, were also 
determined. More than twofold upregulation of calbindin-D28K mRNA expression was 
observed in OVX/high-dose 17β-E2-treated rats, compared with OVX rats (Fig. 1B). In 
addition, significant increases in the expression of both NCX1 (5.5-fold) and PMCA1b 
(1.5-fold) mRNA in OVX/medium-dose 17β-E2-treated rats, compared with OVX rats, 
were demonstrated (Fig. 1C, D). Next, the abundance of ECaC1 protein in kidneys was 
examined. Figure 2A presents representative immunofluorescence labeling of distal 
tubules in sections of kidney cortex from OVX and OVX/high-dose 17β-E2-treated 
rats. More ECaC1 protein was detected in tissue from the supplemented rats, as 
0.51 ± 0.07 0.23 ± 0.04b
Ca2+ (mM)
203 ± 4 215 ± 3b
Body weight (g)
207 ± 4 205 ± 4
Sham OVX
Beginning
Final
Organ weight (g)
Uterus
Serum level
17β-E2 (pg/ml)
2.38 ± 0.02 2.40 ± 0.03
11 ± 6 5 ± 3
OVX + E2L OVX + E2M OVX + E2H
N = 5 N = 5 N = 5 N = 5 N = 5
0.21 ± 0.01 0.39 ± 0.04
207 ± 4 202 ± 4c
207 ± 3 209 ± 4
2.39 ± 0.02 2.36 ± 0.04
5 ± 1 12 ± 2
0.66 ± 0.13e
189 ± 4d
204 ± 2
2.31 ± 0.02c
64 ± 6f
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indicated by the increased staining in the kidney cortex. In these immunopositive 
tubules, ECaC1 was localized to the apical membrane of distal tubular segments. For 
semiquantitative assessment of ECaC1 protein expression, the relative amounts of 
immunopositive tubules in 10 to 15 randomly selected microscopic fields were counted 
for each kidney cortex section. Figure 2B presents the average values for each 
experimental group. The levels of ECaC1 expression in OVX/medium-dose 17β-E2-
treated and OVX/high-dose 17β-E2-treated rats were significantly higher than those in 
OVX rats.  
 
 
FIGURE 1.  
Effects of ovariectomy (OVX) 
and 17β-estradiol (17β-E2) 
supplementation on the mRNA 
expression levels of ECaC1 
and other Ca2+ transport 
proteins in rat kidneys. mRNA 
expression levels were 
measured by using real-time 
quantitative PCR, as described 
in Materials and Methods. The 
expression levels of ECaC1 
(A), calbindin-D28K (B), 
plasma membrane Ca2+-
ATPase (PMCA1b) (C), and 
Na+/Ca2+-exchanger (NCX1) 
(D) for the different 
experimental groups are 
presented relative to levels in 
sham-operated rats. +E2L, 
supplemented with 2x 32 µg 
17β-E2/day; +E2M, supplemented with 2x 125 µg 17β-E2/day; +E2H, supplemented with 2x 500 µg 17β-
E2/day. Data are presented as mean ± SE (n=5). * P<0.01 versus all groups. # P<0.05 versus OVX and OVX 
plus low dose 17β-E2;  P<0.05 versus all groups. 
 
17β-E2-induced increases in serum Ca2+ levels in 1,25(OH)2D3-deficient mice 
One of the characteristics of the homozygous 1αOHase knockout is growth retardation, 
as illustrated by their low body weights (Table 3), compared with wild-type animals 
(>20 g) (14, 19). After 17β-E2 treatment, no significant change in body weight was 
observed. The 1αOHase knockout mice exhibited severe hypocalcemia, with serum 
Ca2+ levels of 1.63 ± 0.06 mM. Surprisingly, after treatment with 17β-E2, serum Ca2+ 
levels significantly increased to 2.03 ± 0.12 mM. Measurement of serum 17β-E2 levels 
confirmed the increase in 17β-E2 levels after treatment (Table 3). 
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FIGURE 2. Effects of OVX and 17β-E2 supplementation on the protein expression levels of ECaC1 in rat 
kidneys. (A) Immunoperoxidase staining for ECaC1 in kidney cortex sections from OVX rats (left) and 
OVX/high-dose 17β-E2-treated rats (right). (B) Protein expression levels, calculated by counting the relative 
amounts of positive tubules in 10 to 15 views in each immunostained section. +E2L; supplemented with 2x 
32 µg 17β-E2 /day; +E2M, supplemented with 2x 125 µg 17β-E2/day; +E2H, supplemented with 2x 500 µg 
17β-E2/day. Data are presented as mean ± SE (n=4). * P<0.001 versus all groups. # P<0.01 versus OVX and 
OVX plus low-dose 17β-E2. 
 
TABLE 3.  Effects of 17β-E2 in 1αOHase knockout micea 
 
a 1αOHase, 25-hydroxyvitamin D3-1α-hydroxylase; control, 1αOHase knockout mice; 17β-E2, 1αOHase 
knockout mice supplemented with 10 µg 17β-E2/day; ND, not detectable. Data are presented as mean ± SE.  
b P<0.05 versus all (before and after). 
 
1,25(OH)2D3-independent effect of 17β-E2 on ECaC1 expression 
To investigate the involvement of 1,25(OH)2D3 on the stimulatory effect of 17β-E2 
supplementation on the expression of ECaC1 and other renal Ca2+ transport proteins, 
control and 17β-E2-treated 1αOHase knockout mice were used. A 2.5-fold increase in 
ECaC1 transcript levels in the kidney cortex of 17β-E2-treated mice, compared with 
control mice, was observed (Fig. 3A). However, in contrast to the upregulation of 
ECaC1, no significant changes in the expression of calbindin-D28K, calbindin-D9K, 
NCX1, or PMCA1b were observed after treatment (Fig. 3B-E). Immunohistochemical 
analyses confirmed the increase in ECaC1 expression, after 17β-E2 treatment, at the 
A B
0
4
8
12
16
20
EC
aC
1 
ex
pr
es
si
on
(%
 p
os
.tu
bu
le
s)
*
#
Sham OVX OVX
+E2L
OVX
+E2M
OVX
+E2H
EC
aC
1 
ex
pr
es
si
on
(%
 p
os
.tu
bu
le
s)
Ca2+ (mM), before
15 ± 2 14 ± 1
Body weight (g)
15 ± 2 16 ± 1
Control 17β-E2
Beginning
Final
Serum level
17β-E2 (pg/ml)
1.54 ± 0.06 1.63 ± 0.06
ND 67 ± 12
N = 4 N = 4
Ca2+ (mMl), end 1.69 ± 0.10 2.03 ± 0.12b
Estrogen regulates renal ECaC1 expression 
 45 
Control -/- 17β-E2 -/-
*
A
0
100
200
300
R
N
A
 e
xp
re
ss
io
n 
(%
)
B
0
40
80
120
160
R
N
A
 e
xp
re
ss
io
n 
(%
)
Control -/- 17β-E2 -/-
C
0
40
80
120
160
R
N
A
 e
xp
re
ss
io
n 
(%
)
Control -/- 17β-E2 -/-
0
40
80
120
160
R
N
A
 e
xp
re
ss
io
n 
(%
)
D
Control -/- 17β-E2 -/-
E
0
40
80
120
160
R
N
A
 e
xp
re
ss
io
n 
(%
)
Control -/- 17β-E2 -/-
R
N
A
 e
xp
re
ss
io
n 
(%
)
R
N
A
 e
xp
re
ss
io
n 
(%
)
R
N
A
 e
xp
re
ss
io
n 
(%
)
R
N
A
 e
xp
re
ss
io
n 
(%
)
R
N
A
 e
xp
re
ss
io
n 
(%
)
protein level, as indicated by the increased staining in the kidney cortex of 17β-E2-
treated mice, compared with control mice (Fig. 4A). Semiquantitative assessment of 
the relative amounts of immunopositive tubules demonstrated a significant increase in 
the expression of ECaC1 protein after 17β-E2 treatment (Fig. 4B).  
 
 
 
FIGURE 3.  
Effects of 17β-E2 on the 
mRNA expression levels 
of ECaC1 and other Ca2+ 
transport proteins in 
kidneys from 1αOHase 
knockout mice. The 
mRNA expression levels 
of ECaC1 (A), calbindin-
D28K (B), calbindin-D9K 
(C), PMCA1b (D), and 
NCX1 (E) were measured 
for the different experimental groups by using 
real-time quantitative PCR. Control-/-, 1αOHase 
knockout mice; 17β-E2-/-, 1αOHase knockout 
mice supplemented with 10 µg 17β-E2/day. Data 
are presented as mean ± SE (n = 4). * P<0.001 
versus 1αOHase knockout mice. 
 
 
 
 
 
 
FIGURE 4. Effects of 17β-E2 on the protein expression levels of ECaC1 in the kidneys of 1αOHase knockout 
mice. (A) Immunoperoxidase staining for ECaC1 in kidney cortex sections from control (left) and 17β-E2-
supplemented (right) 1αOHase knockout mice. (B) Protein expression levels, calculated by counting the 
relative amounts of positive tubules in 10 to 15 views in each immunostained section. Control-/-, 1αOHase 
knockout mice mice; 17β-E2-/-, 1αOHase knockout mice supplemented with 10 µg 17β-E2/day. Data are 
presented as mean ±  SE (n=4). * P<0.001versus 1αOHase knockout mice. 
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DISCUSSION 
 
The main conclusion from this study is that estrogen upregulates the expression of 
ECaC1 in the kidney, in a 1,25(OH)2D3-independent manner. By upregulating ECaC1 
expression, as the rate-limiting step in transcellular transport, estrogen could be 
positively involved in Ca2+ reabsorption. Estrogen deficiencies after menopause result 
in bone loss, which is associated with increases in serum and urinary Ca2+ (4). It has 
been generally reported that the increases in serum and urinary Ca2+ levels are 
secondary to increases in bone resorption. However, some studies have demonstrated 
that the increases in urinary Ca2+ levels after menopause are not attributable to 
increases in the filtered load, suggesting that estrogen also has an effect on renal Ca2+ 
handling (5, 6). This study identified ECaC1 as a molecular target for the action of 
estrogen in the kidney.  
Estrogen replacement therapy for the OVX rats, at pharmacologic doses, resulted in 
significant upregulation of ECaC1 mRNA and protein expression. ECaC1 protein was 
observed exclusively at the apical side of distal tubular cells, in agreement with 
previous studies (17, 20). The increased mRNA level after 17β-E2 treatment could be 
attributable to enhanced transcriptional activity or mRNA stabilization. In addition to 
increases in mRNA abundance, translational regulation of ECaC1 might occur, 
ultimately resulting in increased channel activity at the apical cell surface. In general, 
estrogen activates the ER, which subsequently regulates gene transcription by binding 
to the classic estrogen response elements (ERE). ERs have been observed in the 
kidney, especially in the proximal tubules, where 17β-E2 is retained in the nuclei (10). 
However, Davidoff et al. reported, using autoradiography, that ERs are also localized 
(albeit to a lesser extent) in the distal tubules, the site of ECaC1 expression (9). 
Interestingly, Weber et al. recently described an ERE in the promoter sequence of the 
mouse ECaC2 gene; the response element was not present in the mouse ECaC1 gene 
(21). Alternatively, transcriptional activation by the estrogen-liganded ER can be 
mediated via activator protein 1 (AP-1) binding sites or GC-rich stimulatory protein 
(Sp1) binding sites (22, 23). Importantly, the human ECaC1 promoter contains several 
of these AP-1 and Sp1 sites (20, 24). Several of these AP-1 and Sp1 binding sites can 
be observed in the 5-upstream region of the translational initiation site in the mouse 
ECaC1 gene and could be involved in the positive effect of 17β-E2 treatment on 
ECaC1 mRNA expression. Future studies using ER knockout mice should indicate 
whether the observed effects on ECaC1 expression are mediated via ER or an unknown 
mechanism. Furthermore, detailed promoter analysis is necessary to identify the 
regulatory sites involved in this estrogen-mediated regulation of ECaC1. 
Because the activity of ECaC1 is tightly controlled by the cytosolic Ca2+ 
concentrations, a sufficient cytosolic Ca2+-buffering capacity is essential (25, 26). This 
study demonstrates that, in rat kidney, ECaC1 and calbindin-D28K are synchronically 
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upregulated, suggesting that this requirement is fulfilled. There is evidence that an 
estrogen-responsive promoter exists in the 5-upstream region of the mouse calbindin-
D28K gene (27). Criddle et al. demonstrated that estrogen treatment increased renal 
calbindin-D28K mRNA levels in OVX rats, several hours after administration (28). In 
addition, tremendous upregulation of NCX1 and a slight but significant increase in the 
levels of PMCA1b (both of which are members of the basolateral extrusion system) 
were observed. In agreement with this finding, it has been suggested that Ca2+ 
extrusion across the basolateral membrane is mediated primarily by NCX1 (13, 29). 
Taken together, these findings suggest a positive effect of 17β-E2 on renal tubular 
reabsorption of Ca2+. However, 17β-E2 treatment resulted in decreased serum Ca2+ 
levels. This effect of estrogen therapy on serum Ca2+ levels was previously observed 
among human subjects (30). This apparent discrepancy can be explained on the basis 
of the increased Ca2+ requirements for estrogen-deficient animals. Correction of 
estrogen deficiencies results in decreased bone resorption and increased formation, 
causing slight decreases in serum Ca2+ concentrations (3). 
The relationship between estrogen actions in the kidney and vitamin D metabolism is 
still unclear. 1,25(OH)2D3 is a major regulator of Ca2+ homeostasis, and the kidney is 
the principal site of its synthesis (31). In the literature, conflicting data have been 
presented regarding direct versus indirect effects of 17β-E2 on Ca2+ reabsorption. Some 
studies demonstrated that estrogen treatment increased 1,25(OH)2D3 levels among 
postmenopausal women (32). One study demonstrated that 17β-E2 was retained in cell 
nuclei of proximal tubules, where the synthesis of 1,25(OH)2D3 takes place (10). With 
the use of cultured opossum kidney cells, a suppressive effect of 17β-E2 on 1αOHase 
activity was demonstrated (33). Among postmenopausal women, however, estrogen 
replacement therapy resulted in unchanged or increased renal 1αOHase activity (30, 
34). In previous studies, it was demonstrated that Ca2+ reabsorption was stimulated by 
1,25(OH)2D3 (35, 36). Furthermore, 1,25(OH)2D3 enhances the renal expression of 
ECaC1 and Ca2+ transport proteins (calbindins, NCX1, and PMCA1b) as demonstrated 
in previous studies (20, 29, 36, 37). In contrast, some studies suggested a direct effect 
of 17β-E2 on Ca2+ reabsorption, independent of vitamin D (3, 28).   
1αOHase knockout mice represent an ideal animal model for studies of the effects of 
17β-E2 on transcellular Ca2+ transport independent of 1,25(OH)2D3. As demonstrated 
in this study and reported by the two laboratories that engineered the 1αOHase 
knockout mice, these animals exhibit severe hypocalcemia (14, 19). Treatment with 
17β-E2, at pharmacologic doses, results in significant increases in serum Ca2+ levels (to 
subnormal concentrations) and increases in the expression of ECaC1. These findings 
suggest a positive effect of 17β-E2 on serum Ca2+ levels, which might be attributable to 
increased renal Ca2+ reabsorption through ECaC1, independently of 1,25(OH)2D3. 
Therefore, 17β-E2 could be directly involved in Ca2+ reabsorption via upregulation of 
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ECaC1 gene expression in the absence of circulating 1,25(OH)2D3. In contrast, the 
expression of the other transport proteins remained unchanged, indicating 
1,25(OH)2D3-dependence for the regulation of calbindins, NCX1, and PMCA1b. An 
explanation for this discrepancy could be that, in addition to 17β-E2, 1,25(OH)2D3 is 
needed for optimal stimulation of Ca2+ transport, eventually leading to normalized Ca2+ 
levels. Another explanation could be that, in addition to upregulated expression of 
ECaC1, sufficient calbindins and extrusion proteins are present to facilitate active 
transport, leading to normalization of serum Ca2+ levels. This is in accord with 
previous studies that suggested that ECaC1 represents the rate-limiting step in active 
Ca2+ transport (12, 13). Also, the intestine must be considered to contribute to the 
increase in serum Ca2+ levels. It was previously demonstrated that estrogen has a 
positive effect on intestinal Ca2+ absorption, and it has been suggested that this effect is 
independent of 1,25(OH)2D3 (16, 38, 39). ECaC1 and its homolog ECaC2 are present 
in the duodenum, as are other transport proteins necessary for active Ca2+ transport (11, 
17) 
In addition to direct effects on bone, estrogen deficiencies might directly influence 
renal and intestinal Ca2+ handling, resulting in a continuing negative Ca2+ balance. 
Furthermore, interactions with other calciotropic hormones in these tissues must be 
considered. Because of the high prevalence of osteoporosis, intensive investigations 
have been performed to clarify the underlying pathophysiologic mechanisms. This 
study provides evidence that 17β-E2 is positively involved in renal Ca2+ reabsorption 
via the upregulation of ECaC1, an effect independent of 1,25(OH)2D3. Future detailed 
studies of the cellular mechanism of estrogen actions in bone, kidney, and intestine 
should lead to novel insights regarding the treatment of estrogen-associated disorders.  
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ABSTRACT 
 
Pseudovitamin D-deficiency rickets (PDDR) is an autosomal disease characterized by 
hyperparathyroidism, rickets, and undetectable levels of 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3). Mice in which the 25-hydroxyvitamin D3-1α-hydroxylase (1αOHase) 
gene was inactivated presented the same clinical phenotype as patients with PDDR and 
were used to study renal expression of the epithelial Ca2+ channel (ECaC1), the 
calbindins, Na+/Ca2+-exchanger (NCX1), and Ca2+-ATPase (PMCA1b). Serum Ca2+ 
(1.20 ± 0.05 mM) and mRNA/protein expression of ECaC1 (41 ± 3%), calbindin-D28K 
(31 ± 2%), calbindin-D9K (58 ± 7%), NCX1 (10 ± 2%), PMCA1b (96 ± 4%) were 
decreased in 1αOHase-/- mice compared with 1αOHase+/- littermates. Feeding these 
mice a Ca2+-enriched diet normalized serum Ca2+ levels and expression of Ca2+ 
proteins except for calbindin-D9K expression. 1,25(OH)2D3 repletion resulted in 
increased expression of Ca2+ transport proteins and normalization of serum Ca2+ levels. 
Localization of Ca2+ transport proteins was clearly polarized in which ECaC1 was 
localized along the apical membrane, calbindin-D28K in the cytoplasm, and calbindin-
D9K along the apical and basolateral membranes, resulting in a comprehensive 
mechanism facilitating renal transcellular Ca2+ transport. This study demonstrated that 
high dietary Ca2+ intake is an important regulator of the renal Ca2+ transport proteins in 
1,25(OH)2D3-deficient status and thus contributes to the normalization of blood Ca2+ 
levels. 
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INTRODUCTION 
 
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is an important hormone in Ca2+ 
homeostasis and bone mineralization (1). The genomic effects underlying part of the 
regulatory processes are mediated by the interaction of 1,25(OH)2D3 with the nuclear 
vitamin D receptor (VDR) in a ligand concentration-dependent manner (2). 
1,25(OH)2D3 is synthesized from an inactive metabolite by the renal cytochrome P450 
enzyme 25-hydroxyvitamin D3-1α-hydroxylase (CYP27B1, hereafter referred to as 
1αOHase). The importance of this enzyme is reflected by severe disorders resulting 
from mutations in the gene coding for 1αOHase, including pseudovitamin D-deficiency 
rickets (PDDR), also known as vitamin D-deficiency rickets type I (VDDR-I) (3). 
PDDR is an autosomal recessive disease characterized by growth retardation, failure to 
thrive, hypocalcemia, osteomalacia, and rickets. Recently, the genetic association of 
1αOHase with PDDR has been confirmed by deletion of the 1αOHase gene in mice (4, 
5).  
1,25(OH)2D3 is synthesized primarily in the kidney by conversion of 25-hydroxy-
vitamin D3 in the mitochondria of the proximal tubules (6). The kidney is also an 
important target organ for 1,25(OH)2D3 and responsible for the regulation of the 
extracellular Ca2+ concentration by controlling Ca2+ excretion from the body. In normal 
adult animals, a major portion (>95%) of filtered Ca2+ in the kidney is reabsorbed, and 
only a small fraction (2%) equal to the amount of Ca2+ absorbed in the intestine is 
excreted in urine to maintain Ca2+ balance. Immunohistochemical studies demonstrated 
that the VDR is predominantly localized to the distal tubule, which is the site for 
1,25(OH)2D3-controlled active Ca2+ reabsorption (7). Ca2+ reabsorption in these 
segments consists of passive entry of Ca2+ across the apical membrane through the 
epithelial Ca2+ channel (ECaC1), cytosolic diffusion of Ca2+ bound to calbindin 
(calbindin-D28K and calbindin-D9K), and active extrusion of Ca2+ across the opposite 
basolateral membrane by the Na+/Ca2+-exchanger (NCX1) and the plasma membrane 
Ca2+-ATPase (PMCA1b) (8, 9). 
The recent identification of the apical Ca2+ channel allows the development of a 
comprehensive study of hormonal-dependent active Ca2+ transport in the kidney, where 
the individual contribution of the participating proteins can be underscored (10). 
Primary or secondary involvement of these Ca2+ transport proteins can be expected in 
several pathological situations. For example, conditions associated with a disturbed 
serum Ca2+ concentration, such as in PDDR, are certainly of interest due to the 
conspicuous presence of these Ca2+ transport proteins in the kidney; therefore, 
knowledge of regulation of these proteins provides new insight into Ca2+ metabolism 
under (patho)physiological circumstances. 
The aim of the present study was to investigate the regulation of Ca2+ transport proteins 
in the kidney and their role in maintaining Ca2+ balance. The recently generated 
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1αOHase knockout mice were used, which develop a severe hypocalcemia and 
represent a unique model system for PDDR. Furthermore, these mice allow to 
dissociate 1,25(OH)2D3-dependent from 1,25(OH)2D3-independent processes. 
1αOHase knockout mice were rescued by 1,25(OH)2D3 repletions or high dietary Ca2+ 
intake and the renal expression of ECaC1, calbindin-D28K, calbindin-D9K, NCX1, and 
PMCA1b was subsequently measured at mRNA and protein level by real-time PCR 
and immunoblotting and immunohistochemistry. 
 
MATERIALS AND METHODS 
 
Animals  
25-Hydroxyvitamin D3-1α-hydroxylase knockout mice were recently generated by 
targeted ablation of exon 8 encoding the heme binding domain of the enzyme (4). 
1αOHase knockout mice were genotyped by Southern blot analysis at 3 wk of age 
directly after the weaning period as described (4). Initial characterization of the 
1αOHase knockout mice demonstrated there are no significant differences between 
wild-type (1αOHase+/+) and heterozygous 1αOHase knockout mice (1αOHase+/-) (4). 
The heterozygous mice therefore were used as control animals. 1αOHase+/- and 
homozygous 1αOHase (1αOHase-/-) knockout mice were fed from wk 3 to 8 either a 
normal diet (1.1% calcium, 0.8% phosphorus, 0% lactose), a Ca2+-enriched diet (2% 
calcium, 1.25% phosphorus, 20% lactose; Harlan Tekled, Madison, WI), or a normal 
diet in combination with i.p. injected 1,25(OH)2D3 repletions of 500 pg/g body weight 
daily in wk 3-4 and 100 pg/g daily in wk 5-8. Animals (n=6 in each group) were killed 
at 8 wk of age, and blood and kidney samples were taken. The animal ethics board of 
the University of Nijmegen (Nijmegen) and Shriners Hospital for Children (Montreal) 
approved all animal experimental procedures. 
 
RNA isolation and quantitative RT-PCR  
Mice were exsanguinated under anesthesia. Kidney tissue was homogenized in Trizol 
(Gibco, BRL, Grans Island, NY) and total RNA was isolated as specified by the 
manufacturer. RNA (2 µg) was reverse transcribed using Moloney murine leukemia 
virus reverse transcriptase (RT, Gibco, BRL). Quantitative RT-PCR reactions were 
performed using an ABI-prism 7700 sequence detector (Gene-Amp PCR system 9600, 
PE Biosystems, Foster City, CA). Sequences of PCR primers and fluorescent probes 
for ECaC1, calbindin-D9K, calbindin-D28K, Ca2+-ATPase (PMCA1b), Na+/Ca2+-
exchanger (NCX1), and hypoxanthine-guanine phosphoribosyl transferase (HPRT) are 
depicted in Table 1 (11). The amplicons were verified by sequencing. The relative 
expression levels of the target genes were calculated as a ratio to the HPRT gene. 
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TABLE 1. Primers and probes for quantitative reverse transcription real-time PCRa 
 
a PCR primers and fluorescent probes (5'FAM-3'TAMRA) for mouse ECaC1, calbindin-D9K, calbindin-D28K, 
PMCA1b, NCX1, and HPRT. Primers and probes were designed using the computer program Primer 
Express (Perkin Elmer) and primers and probes were purchased from Biolegio (Malden, Netherlands). 
 
Immunoblotting  
Kidney tissue was removed, immediately frozen in liquid nitrogen, and homogenized 
in phosphate-buffered saline (PBS). All samples (20 µg of protein) were separated on 
12% and 16% (w/v) SDS-PAGE gels and blotted to PVDF-nitrocellulose membranes 
(Immobilon-P, Millipore Corporation, Bedford, MA). Blots were incubated for 16 h 
with calbindin-D28K antibody (Sigma, 1:10,000), calbindin-D9K antibody (Swant, 
Switzerland, 1:10,000), or Na+/K+-ATPase antibody (kindly provided by Dr. Moller; 
1:20,000; ref 12). Subsequently, immunoreactive protein was detected using the 
enhanced chemiluminescence method as described previously (13).  
 
Immunofluorescence confocal microscopy  
Kidney tissue was cut into pieces, placed in 1% (w/v) periodate-lysine-
paraformaldehyde fixative for 2 h at room temperature and incubated overnight at 4°C 
in PBS containing 15% (w/v) sucrose as described previously (14). Subsequently, 
kidney samples were frozen in liquid nitrogen and 7 µm frozen sections were cut for 
different staining procedures. The kidney sections were stained with affinity-purified 
guinea pig anti-ECaC antiserum (1:1000) as described previously (14). Sections triple 
stained for ECaC1 and calbindins were incubated simultaneously for 16 h at 4°C with 
affinity-purified antiserum against ECaC1, calbindin-D9K (1:500), calbindin-D28K 
(1:500). To visualize ECaC1, calbindin-D28K, and calbindin-D9K, sections were stained 
with affinity-purified goat anti-guinea pig-biotin as described (15), goat anti-rabbit 
Alexa 594-conjugated anti IgG (1:300), and goat anti-mouse Cy5-conjugated anti-IgG 
(1:50), respectively (Molecular Probes, Eugene, OR). All negative controls, including 
sections incubated with preimmune serum, antiserum preabsorbed for 1 h with 10 
µg/ml ECaC-GST fusion protein, or conjugated antibodies alone, were devoid of any 
staining. Sections were dehydrated in methanol and subsequently mounted in Mowiol 
5-ACCTTGACTGATATTGTTTTGACTATTTCATCATTCTGGA-35-TTTCTCATACTCCTCGTCATCGATT-35-TCCCTACAAAACTATTGAAGGCACA-3NCX1
5-CAGCTGAAAGGCTTCCCGCCAAA-35-CAGCCATTGCTCTATTGAAAGTTC-35-CGCCATCTTCTGCACCATT-3PMCA1b
Calbindin-D9K
5-ACCAGTGCAGGAAAATTTCCTTCTTAAATTCCA-35-TGAACTCTTTCCCACACATTTTGAT-35-AACTGACAGAGATGGCCAGGTTA-3Calbindin-D28K 
5-TGTTTCTCAGATAGCTGCTCTTGTACTTCCTCTTTGT-35-GTTTGGAGAACCACAGAGCCTCTA-35-CGTTGGTTCTTACGGGTTGAAC-3ECaC1
5-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-35-TTACCAGTGTCAATTATATCTTCAACAATC-35-TTATCAGACTGAAGAGCTACTGTAATGATC-3HPRT
ProbeReverse primerForward primerGene
5-CAAAAATATGCAGCCAAGGAAGGCGA-35-CTCCATCGCCATTCTTATCCA-35-CCTGCAGAAATGAAGAGCATTTT-3
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(Hoechst, Frankfurt, Germany) and visualized by confocal laser scanning microscopy 
(MRC-1000; Bio-Rad, Richmond, CA) using a Nikon Diaphot microscope (Tokyo, 
Japan). The ECaC1 antibody used in this study has been extensively characterized but 
is, so far not reacting on immunoblots (15). To semiquantify ECaC1 protein expression 
immunopositive tubules in 10 random microscopic fields were counted for each 
condition as described (15). 
 
Biochemical assays  
Serum 1,25(OH)2D3 levels were measured using a specific RIA (ImmunoDiognostic 
Systems Ltd., Boldon, UK). Total calcium was measured using a Monarch automated 
analyzer (4).  
 
Statistical analysis 
The data are expressed as mean ± SE. Overall statistical significance was determined 
by analysis of variance. In the case of significance (P < 0.05), individual groups were 
compared by contrast analysis according to Scheffé. 
 
RESULTS 
 
Inactivation of both alleles of the 1αOHase gene (1αOHase-/-) resulted in severe 
hypocalcemia with serum Ca2+ concentrations as low as 1.2 mM, in contrast to the 
heterozygous littermates, which exhibit normal serum Ca2+ concentrations (Table 2). 
Supplementation of hypocalcemic 1αOHase-/- mice with 1,25(OH)2D3 or a high dietary 
Ca2+ intake normalized the serum Ca2+ concentration.  
 
TABLE 2.   The effect of normal diet, Ca2+-enriched diet and 1,25(OH)2D3-supplemented diet 
on serum Ca2+ concentration in 1αOHase knockout micea 
 
a Values are presented as mean ± SE (n=6). * P<0.001, significant from 1αOHase+/- mice on a normal Ca2+ 
diet; # P<0.001, significant from 1αOHase-/- mice on a normal Ca2+ diet. 
 
1,25(OH)2D3-supplemented diet 2.59 ± 0.06 2.59 ± 0.07#
Ca2+-enriched diet 2.34 ± 0.04 2.33 ± 0.10#
Normal diet 2.19 ± 0.01 1.20 ± 0.05*
Serum Ca2+ concentration (mM)
1αOHase+/- 1αOHase-/-
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FIGURE 1.  
Gene expression patterns in 
kidney of 1αOHase-/- (filled 
bars) and 1αOHase+/- (open 
bars) mice on normal diet, Ca2+-
enriched diet, and the 
1,25(OH)2D3-supplemented diet. 
Renal expression of ECaC1 (A), 
calbindin-D28K (B), calbindin-
D9K (C), NCX1 (D), and 
PMCA1b (E) assessed by real-time PCR analysis is calculated as a ratio to the HPRT RNA level and 
expressed relative to levels of 1αOHase+/- mice on a normal diet. Values are presented as mean ± SE (n=6). * 
P<0.05, significant from 1αOHase+/- mice on a normal diet. # P<0.05, significant from 1αOHase-/- mice on a 
normal diet. 
 
To determine the molecular mechanism responsible for the severe hypocalcemia in 
1αOHase-/- mice, renal expression of ECaC1, calbindin-D28K, calbindin-D9K, NCX1, 
and PMCA1b in 1αOHase-/- and 1αOHase+/- knockout mice was examined. Using 
quantitative real-time PCR, a twofold decrease in ECaC1 mRNA levels was observed 
in kidneys of 1αOHase-/- compared with 1αOHase+/- mice (Fig. 1A). Down-regulation 
of ECaC1 was accompanied by a decrease in calbindin-D28K (3-fold) and calbindin-D9K 
(2-fold) mRNA (Fig. 1B, C). The high dietary Ca2+ diet restored the low ECaC1 and 
calbindin-D28K mRNA levels in the 1αOHase-/- mice. In contrast, the expression was 
decreased in the heterozygous littermates by the high Ca2+ diet (Fig. 1A, B). Calbindin-
D9K mRNA was decreased in kidney of 1αOHase-/- mice whereas this transcript was 
not up-regulated by high dietary Ca2+ intake (Fig. 1C). Subsequently, regulation of the 
basolateral extrusion transporters was studied. The most important Ca2+ extrusion 
mechanism in the distal part of the nephron is NCX1, and this exchanger was severely 
down-regulated in kidneys from 1αOHase-/- mice. Again, similar to ECaC1 and 
calbindin-D28K, this transcript was up-regulated by dietary Ca2+ intake whereas Ca2+ 
supplementation had no effect on the expression of the exchanger in 1αOHase+/- (Fig. 
1D). mRNA encoding PMCA1b is not significantly reduced in kidneys of 1αOHase-/- 
mice (Fig. 1E). High dietary Ca2+ intake, however, resulted in a significant increase in 
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expression. Supplementation of the 1αOHase-/- mice with 1,25(OH)2D3 significantly 
increased mRNA expression levels of all the Ca2+ transport molecules measured 
including ECaC1, calbindin-D28K, calbindin-D9K, NCX1, and PMCA1b (Fig. 1). 
 
 
FIGURE 2. 
(A) Immunofluorescence localization of ECaC1 
in kidney (depicted in white) of 1αOHase+/- and 
1αOHase-/- mice on normal diet, Ca2+-enriched 
diet and the 1,25(OH)2D3-supplemented diet. (B) 
Semi-quantitative results were obtained by 
counting randomly 10 microscopic fields for 
ECaC1 immunopositive distal tubular segments in kidney cortex of 1αOHase+/- (open bars) and 1αOHase-/- 
(filled bars) mice. Values are presented as mean ± SE (n=6). * P<0.05, significant from 1αOHase+/- mice on a 
normal diet. # P<0.05, significant from 1αOHase-/- mice on a normal diet. Bar is 25 µm. 
 
 
Expression of Ca2+ transport proteins was studied at the protein level. First, the 
abundance of ECaC1 protein was examined. ECaC1 immunopositive tubules in 10 
random microscopic fields of kidney cortex were counted semiquantitatively for each 
animal (15). Figure 2 depicts the average values obtained for four 1αOHase knockout 
mice. Inactivating the 1,25(OH)2D3 gene in 1αOHase-/- mice had a major effect on 
ECaC1 protein expression as indicated by the low number of immunopositive distal 
tubules in the kidney cortex. Normalization of the 1,25(OH)2D3 levels or high dietary 
Ca2+ intake restored ECaC1 expression to levels comparable to those observed in 
1αOHase+/- mice (Fig. 2). In agreement with the reduced ECaC1 mRNA expression, 
this Ca2+-enriched diet lowered protein expression in 1αOHase+/- mice. Immunoblotting 
showed a significant down-regulation of calbindin-D28K and calbindin-D9K protein 
abundance in the 1αOHase-/- mice (Fig. 3). The decrease in calbindin-D28K protein was 
recovered by high dietary Ca2+ intake, whereas calbindin-D9K expression was not 
Chapter 3 
 60 
altered. Calbindin protein expression levels were completely restored in 1αOHase-/- 
mice after repletion with 1,25(OH)2D3. The corresponding Na+/K+-ATPase bands did 
not vary significantly in density, which precludes unequal loading as an explanation for 
the differences (Fig. 3). 
 
 
 
FIGURE 3. Effects of normal diet, Ca2+-enriched diet and 1,25(OH)2D3-supplemented diet on calbindin-D28K 
and calbindin-D9K expression in kidney of 1αOHase-/- and 1αOHase+/- mice. Immunoblots were run with 20 
µg of protein per lane of whole-kidney homogenates and probed with anti-calbindin-D28K or anti-calbindin-
D9K. Immunoblots were probed with an antibody against Na+/K+-ATPase (12) to exclude the possibility that 
the difference in calbindin expression was due to unequal loading. 
 
Figure 4 shows representative triple immunofluorescence labeling of distal tubules in 
mice kidney cortex sections stained for ECaC1 (green), calbindin-D28K (blue), and 
calbindin-D9K (red). Superimposed images showed co-localization of these Ca2+ 
transport proteins in 1αOHase-/- and 1αOHase+/- mice, both on a normal diet. 
Moreover, kidneys of 1,25(OH)2D3-repleted mice clearly indicate an increased number 
of ECaC1 and calbindins immunopositive distal tubules; identical to the normal diet, a 
remarkable overlap was apparent. High dietary Ca2+ intake by 1αOHase-/- mice 
increased the amount of immunopositive tubules expressing ECaC1 and calbindin-
D28K; the expression of calbindin-D9K was not significantly altered and distal tubules 
were now observed that express exclusively calbindin-D28K, a phenomenon that was 
never seen in mice fed the control diet or repleted with 1,25(OH)2D3 (Fig. 4, asterisks). 
Higher magnifications showed that ECaC1 is predominantly localized to the apical 
domain of distal tubular segments. In these immunopositive tubules, calbindin-D28K 
+/- control +/- calcium +/- 1,25(OH)2D3
-/- control -/- calcium -/- 1,25(OH)2D3
Na+/K+-ATPase
Calbindin-D9K
Calbindin-D28K
Na+/K+-ATPase
Calbindin-D9K
Calbindin-D28K
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was observed throughout the cytosol. Intriguingly, the immunofluorescence staining of 
calbindin-D9K appeared to be more compartmentalized and associated with apical and 
basolateral membranes (Fig. 5). 
 
 
FIGURE 4. Localization of the Ca2+ transport proteins in kidney of 1αOHase-/- and 1αOHase+/- mice. Effect of 
normal diet, Ca2+-enriched diet and 1,25(OH)2D3-supplemented diet on the expression pattern of ECaC1 
(green), calbindin-D28K (blue), and calbindin-D9K (red). Bar is 100 µm. 
 
 
 
 
 
 
FIGURE 5.  
Immunofluorescence triple staining of a 
mice kidney cortex section depicting the 
cellular localization of ECaC1 (green), 
calbindin-D28K (blue) and calbindin-D9K 
(red) in distal tubules. A glomerulus is 
depicted in the image (G). Bar is 25 µm. 
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DISCUSSION 
 
The present study demonstrates that the expression of the renal Ca2+ transport proteins 
ECaC1, calbindin-D28K, calbindin-D9K and NCX1 is significantly down-regulated in 
the kidney of 1αOHase-/- mice, which is in line with a diminished Ca2+ reabsorption 
capacity contributing to the development of hypocalcemia. Furthermore, high dietary 
Ca2+ intake restored the decreased expression of Ca2+ transport proteins independent of 
1,25(OH)2D3 and normalized the serum Ca2+ concentration.  
Recently two laboratories independently generated 1αOHase knockout mice strains 
that represent valuable animal models for PDDR since they display undetectable 
1,25(OH)2D3 concentrations, hypocalcemia, secondary hyperparathyroidism, and 
failure to thrive (4, 5). The 1αOHase-/- mice developed distinct histological evidence of 
rickets and osteomalacia. There was a correlative relationship between the expression 
level of these Ca2+ transport proteins and blood Ca2+ levels. Normalization of the serum 
Ca2+ level by 1,25(OH)2D3 or Ca2+ supplementation was associated with an increase in 
the expression level of the renal Ca2+ transport proteins, confirming the essential role 
of these proteins in active hormone-mediated Ca2+ transport and maintaining Ca2+ 
balance. These findings imply that in addition to intestinal Ca2+ absorption, the kidney 
also plays a crucial role in maintaining body Ca2+ homeostasis. This follows from 
experiments performed with VDR knockout mice. In these hypocalcemic mice, urinary 
Ca2+ excretion is inappropriately high, suggesting renal Ca2+ wasting due to disturbed 
Ca2+ reabsorption (11, 16, 17). Taken together, in 1αOHase-/- and VDR-/- mice the 
sustained hypocalcemia is related to defective distal Ca2+ reabsorption. 
The reduced expression level of the Ca2+ transport proteins in the 1αOHase-/- mice was 
restored by high dietary Ca2+ intake and accompanied by normalization of serum Ca2+ 
concentrations. This effect was observed in the absence of 1αOHase-activity. In 
contrast, the Ca2+-enriched diet reduced the expression of Ca2+ transport proteins in 
1αOHase+/- mice, which exhibit normal serum vitamin D and Ca2+ levels. Under 
physiological conditions, Ca2+ acts via a negative feedback mechanism that eventually 
leads to suppression of the 1αOHase-activity, which decreases Ca2+ reabsorption and 
expression of Ca2+ transport proteins (3). 
Our study with 1αOHase-/- mice has revealed that Ca2+ supplementation can up-
regulate gene transcription encoding for Ca2+ transporters in the absence of circulating 
1,25(OH)2D3, but the molecular mechanism of this vitamin D-independent Ca2+-
sensitive pathway remains elusive. It is likely, however, that Ca2+-responsive elements 
are present in the promoter regions of the ECaC1 and calbindin genes in addition to the 
identified vitamin D-responsive ones (15, 18, 19). Several elements have been 
proposed to function as Ca2+-sensitive transcriptional regulators, including the serum-
responsive element and the cAMP/Ca2+-responsive element (20). Of interest is the 
identification by Arnold and Heintz of a Purkinje cell expression specific element 
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(PCE1) in the calbindin-D28K gene that functions as a Ca2+-sensitive transcriptional 
regulatory mechanism (21). This mechanism may play a role in fine-tuning the Ca2+ 
buffer capacity of Purkinje cells. Since these elements could not be found in the 5 
upstream region of the ECaC1 and NCX1 gene, this Ca2+-sensitive transcriptional 
mechanism could only apply to the calbindin-D28K up-regulation reported here. 
 Recovery of expression of Ca2+ transport proteins and normalization of the serum Ca2+ 
concentration by high dietary Ca2+ intake were associated with a dissociation in the 
localization of the calbindins in kidney cortex. In the 1αOHase mutant mice, calbindin-
D28K was up-regulated by Ca2+ and present in more cells than calbindin-D9K, whose 
amount and localization was not altered. Most of the distal tubular segments co-express 
ECaC1 and calbindin-D28K, but a subpopulation of distal tubules was identified that 
expresses calbindin-D28K. Histochemical studies in mouse and rat kidney revealed only 
the highest expression of ECaC1 and calbindin-D28K in most of the distal convoluted 
tubule (DCT2) and connecting tubule; in these segments, both proteins co-localize (15, 
22). Prominent NCX1 and PMCA1b immunostaining was exactly congruent with that 
of ECaC1 immunostaining (22). Staining of the three latter proteins abruptly 
disappeared at the transition to the cortical collecting duct, whereas staining of 
calbindin-D28K continued along the CCD (22). These latter tubules do express 
calbindin-D28K at higher levels after feeding the mice a Ca2+-enriched diet. This raises 
the intriguing question of whether calbindin-D28K can exert additional functions in 
these latter segments besides its known function of Ca2+ diffusion facilitation. 
It is essential that the number of ECaC1 channels at the plasma membrane is matched 
by the cytosolic Ca2+ buffering capacity of these cells since the activity of ECaC1 is 
tightly controlled by the ambient Ca2+ concentration (23, 24). The necessity of 
sufficient Ca2+ buffering is underscored by the conspicuous co-localization of ECaC1, 
the calbindins, NCX1, and PMCA1b in Ca2+ transporting epithelial cells (14, 22). The 
1,25(OH)2D3 responsiveness of ECaC1 and calbindins is in line with previous studies. 
Until now there is only limited data available regarding regulation of the basolateral 
extrusion systems by vitamin D. Similar to ECaC1 and the calbindins, an impressive 
reduction of NCX1 was observed but no significant down-regulation of PMCA1b was 
measured. Van Baal et al. concluded that Na+/Ca2+-exchange is the primary Ca2+ 
extrusion mechanism, whereas only a minor amount of Ca2+ in the distal tubular cells is 
extruded by the plasma Ca2+ pump (25). These findings point to a crucial role of the 
exchanger in vitamin-D-dependent Ca2+ reabsorption. The present observation that 
ECaC1, calbindins, NCX1, and to a lesser extent PMCA1b, are synchronically 
controlled by 1,25(OH)2D3 demonstrates the intimate relation between apical Ca2+ 
influx, cytosolic Ca2+ diffusion, and basolateral Ca2+ extrusion during 1,25(OH)2D3-
stimulated Ca2+ reabsorption. 
Chapter 3 
 64 
Several pathological symptoms in 1αOHase-/- and VDR-/- mice are similar including 
severe hypocalcemia, hyperparathyroidism and rickets, but there are also distinctive 
differences between both mouse models. Renal expression of the Ca2+ transport 
proteins was consistently decreased in 1αOHase-/- mice whereas different effects were 
reported in VDR-/- mice (11, 26). Obviously, 1,25(OH)2D3 levels are exceptionally 
elevated in VDR-/- mice, whereas in 1αOHase-/- mice its synthesis is impaired (4, 5, 11, 
17, 27). In addition to the VDR-mediated genomic pathway, many studies describe the 
existence of another nongenomic pathway regulated by 1,25(OH)2D3. There are 
indications that 1,25(OH)2D3 stimulates passive paracellular Ca2+ transport in VDR-/- 
mice to compensate for the reduction in Ca2+ reabsorption (28). Furthermore, 
1,25(OH)2D3 has been implicated in the stabilization of mRNA (29), regulation of 
voltage-gated and store-operated Ca2+ channels (30, 31), opening of chloride channels 
(32), modulation of protein kinase C activity (33) and activation of mitogen-activated 
protein kinases (34), which eventually lead to the onset of rapid or long-term biological 
responses. Recent studies have indicated that the generation of these rapid responses 
could be mediated via a putative membrane receptor with ligand binding properties 
different from those of the nuclear VDR (35-37). As an alternative to a specific 
membrane receptor for 1,25(OH)2D3, it has been suggested that membrane-associated 
annexin II might serve as a receptor for 1,25(OH)2D3-mediated responses (38, 39). It is 
conceivable that these 1,25(OH)2D3-mediated nongenomic pathways will influence the 
expression and activity of Ca2+ transport proteins in the kidney and, therefore, the 
1αOHase-/- mouse is an ideal mouse model to study the effect of dietary Ca2+ 
independent of the 1,25(OH)2D3 regulation of transcellular Ca2+ transport in kidney. 
Our study provides new insights in the localization of the Ca2+ transport proteins 
resulting in a more comprehensive molecular model for active Ca2+ reabsorption in the 
distal part of the nephron (Fig. 6). ECaC1 is predominantly localized along the apical 
membrane and facilitates the first step in this active transport process. The uniform 
distribution of calbindin-D28K throughout the cytosol is in accordance with the 
postulated physiological role as a cytosolic Ca2+ buffer and as a shuttle mechanism 
between the luminal influx and the basolateral efflux sites (Fig. 6). The efflux of Ca2+ 
is mainly facilitated by Na+/Ca2+-exchange and to a lesser extent by the ATP-
dependent Ca2+ pump (25). The conspicuous localization of calbindin-D9K along the 
basolateral and apical membranes excludes a cytosolic Ca2+ shuttle function. 
Alternatively, calbindin-D9K could distribute Ca2+ quickly along the plane of the 
plasma membrane after influx through a few scattered Ca2+ channels and supply 
sufficient Ca2+ to a small number of extrusion proteins (Fig. 6).  
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FIGURE 6. Model of transcellular Ca2+ transport by cells lining the distal part of the nephron. Entry of Ca2+ is 
facilitated by the apical Ca2+ channel ECaC1. Subsequently, the ion binds to calbindin-D9K (light gray) or 
directly to calbindin-D28K (dark gray) and diffuses through the cytosol to the basolateral membrane. Here, 
Ca2+ ions are extruded, directly or via intermission of calbindin-D9K, by a Na+/Ca2+-exchanger (NCX1) and a 
Ca2+-ATPase (PMCA1b). 
 
 
In conclusion, the present study demonstrate that high dietary Ca2+ intake is an 
important regulator of the renal Ca2+ transport proteins in 1,25(OH)2D3-deficient status 
and thus contributes to the normalization of blood Ca2+ levels. The treatment of choice 
for PDDR patients is long-term replacement therapy with 1,25(OH)2D3. Repletion with 
vitamin D analogues has proved to be beneficial in various clinical situations such as 
the prevention of rickets during infancy. It will therefore be of interest to compare the 
benefits of supplemented dietary Ca2+ to long-term treatment with vitamin D 
analogues. 
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ABSTRACT   
 
The epithelial Ca2+ channels TRPV5 and TRPV6 are localized to the brush border 
membrane of intestinal cells and constitute the postulated rate-limiting entry step of 
active Ca2+ absorption. The aim of the present study was to investigate the hormonal 
regulation of these channels. To this end, the effect of 17β-estradiol (17β-E2), 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) and dietary Ca2+ on the expression of the 
duodenal Ca2+ transport proteins was investigated in vivo and analyzed using real-time 
quantitative PCR. Supplementation with 17β-E2 increased duodenal gene expression of 
TRPV5 and TRPV6 but also calbindin-D9K and plasma membrane Ca2+-ATPase 
(PMCA1b) in ovariectomized rats. 25-Hydroxyvitamin D3-1α-hydroxylase (1αOHase) 
knockout mice are characterized by hyperparathyroidism, rickets, hypocalcaemia, and 
undetectable levels of 1,25(OH)2D3 and were used to study the 1,25(OH)2D3-
dependency of the stimulatory effects of 17β-E2. Treatment with 17β-E2 upregulated 
mRNA levels of duodenal TRPV6 in these 1αOHase knockout mice, which was 
accompanied by increased serum Ca2+ concentrations from 1.69 ± 0.10 to 2.03 ± 0.12 
mM (P<0.05). In addition, high dietary Ca2+ intake normalized serum Ca2+ in these 
mice and upregulated expression of genes encoding the duodenal Ca2+ transport 
proteins except for PMCA1b. Supplementation with 1,25(OH)2D3 resulted in increased 
expression of TRPV6, calbindin-D9K, and PMCA1b and normalization of serum Ca2+. 
Expression levels of duodenal TRPV5 mRNA are below detection limits in these 
1αOHase knockout mice, but supplementation with 1,25(OH)2D3 upregulated the 
expression to significant levels. In conclusion, TRPV5 and TRPV6 are regulated by 
17β-E2 and 1,25(OH)2D3, whereas dietary Ca2+ is positively involved in the regulation 
of TRPV6 only.  
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INTRODUCTION 
 
The maintenance of the extracellular Ca2+ concentration is important for mammalian 
development and function. Intestinal Ca2+ absorption is a crucial control system in the 
regulation of Ca2+ homeostasis, because it facilitates the entry of dietary Ca2+ into the 
extracellular compartment (1). 
The intestinal absorption of Ca2+ follows two pathways: a transcellular and a 
paracellular route (2). Paracellular transport is the passive, nonsaturable way of 
intestinal Ca2+ absorption, which occurs down an electrochemical gradient. 
Transcellular Ca2+ absorption takes place against an electrochemical gradient and, 
therefore, requires energy. This active Ca2+ transport is under the control of hormones 
in a Ca2+-dependent manner (3). 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active 
form of vitamin D, is the primary regulator of active Ca2+ absorption. 1,25(OH)2D3 is 
synthesized from the inactive metabolite 25-hydroxyvitamin D3 by 25-hydroxyvitamin 
D3-1α-hydroylase (1αOHase) in kidney. 1,25(OH)2D3 acts through nuclear vitamin D 
receptors (VDR), which are present within the enterocytes of the intestine (4-6). In 
addition, functional estrogen receptors have also been detected in small intestine (7). 
Arjmandi et al. showed that 17β-estradiol (17β-E2) enhances the uptake of Ca2+ by 
intestinal cells in vitro (8). Furthermore, active intestinal Ca2+ absorption can be 
regulated by dietary Ca2+ intake. Active absorption of Ca2+ is increased after feeding a 
low Ca2+ diet or under conditions of increased Ca2+ needs (3).  
The importance of the hormones involved in Ca2+ homeostasis is reflected by severe 
disorders. For example, mutations in the genes encoding for 1αOHase or VDR result in 
pseudovitamin D-deficiency rickets (VDDR-I) and hereditary hypocalcemic vitamin 
D-resistant rickets (VDDR-II), respectively (9, 10). High oral doses of Ca2+ can 
prevent the concomitant bone pathology (11). Furthermore, estrogen deficiency in 
postmenopausal women results in a negative Ca2+ balance and osteoporosis. This is 
often associated with intestinal malabsorption, which is corrected by estrogen therapy 
(12). On the basis of these data, it is obvious that active Ca2+ absorption in the small 
intestine plays an indispensable role in Ca2+ homeostasis and bone mineralization. 
Active Ca2+ absorption is localized to the duodenum and can be described in three 
sequential cellular steps: entry, intracellular diffusion, and extrusion (2). The Ca2+-
binding protein calbindin-D9K is involved in intracellular diffusion of Ca2+. It binds 
Ca2+ and moves it from the brush border membrane to the basolateral site of the 
duodenal cell. In this respect, calbindin serves as both a Ca2+ carrier and a cytosolic 
Ca2+ buffer (13, 14). The extrusion of Ca2+ across the basolateral membrane from the 
enterocyte is mediated by the plasma membrane Ca2+-ATPase (PMCA1b) (15). The 
molecular nature of the apical Ca2+ entry channel was elusive until the identification of 
the epithelial Ca2+ channels ECaC1 and ECaC2 (16, 17). These two Ca2+ channels 
represent a new family of Ca2+-selective ion channels belonging to the superfamily of 
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transient receptor potential (TRP) channels. The TRP family can be divided by 
sequence homology in several subfamilies (18). ECaC1 and ECaC2 are members of the 
TRP-Vanilloid (TRPV) subfamily and have, therefore, been renamed into TRPV5 and 
TRPV6, respectively (19). Both channels are expressed in several tissues including the 
small intestine, in which they are localized to the brush border membrane of intestinal 
absorptive cells (20, 21). Importantly, it has been postulated that these channels form 
the rate-limiting step in transcellular Ca2+ (re)absorption (22). 
The regulation of TRPV5 and TRPV6 in duodenum may shed new light on hormone-
controlled Ca2+ metabolism. Primary or secondary involvement of one or both 
epithelial Ca2+ channels can be expected in several pathologic situations, such as 
VDDR and osteoporosis. Therefore, the present study was designed to investigate the 
regulation of TRPV5 and TRPV6 as the entry channels of active Ca2+ absorption in 
duodenum. To this end, the effects of 17β-E2, 1,25(OH)2D3, and dietary Ca2+ on the 
expression of these duodenal Ca2+ transport proteins were investigated in vivo and 
analyzed using real-time quantitative PCR. 
 
MATERIALS AND METHODS 
 
Animals 
Twenty-five virgin female Wistar rats (Hsd/Cpd:Wu, SPF-bred by Harlan, CPB, Zeist, 
The Netherlands) were subjected to a bilateral ovariectomy or sham operation. 
Thereafter, rats received daily 17β-E2 (Sigma, St. Louis, MO, USA) or vehicle (gelatin, 
mannitol) added to the pelleted food. Sham-operated animals (Sham, n = 5) served as 
controls. Ovariectomized animals were given either the vehicle alone (OVX, n = 5), or 
2x 32 µg 17β-E2/day (OVX + E2L, n = 5), 2x 125 µg 17β-E2/day (OVX + E2M, n = 5) 
or 2x 500 µg 17β-E2/day (OVX + E2H, n = 5). Treatment was started immediately after 
ovariectomy and lasted for 7 days.  
1αOHase knockout mice were generated by Dardenne and colleagues through 
inactivation of the 1αOHase gene (23). Three different experiments were performed, 
using these homozygous knockout mice as a vitamin D-deficient model, to study the 
effect of: 1) 17β-E2 supplementation: using Alzet osmotic minipumps (model 1007D). 
Eight male 1αOHase knockout mice, 9 wk of age, were randomized in two groups. 
Control mice received vehicle solution alone (15% (vol/vol) ethanol, 50% (vol/vol) 
DMSO) and the supplemented group received an infusion dose of 10 µg 17β-E2/day for 
7 days. 2) Ca2+ supplementation: eight 1αOHase knockout mice were equally divided 
into two groups and were fed either a normal diet (1.1% (wt/wt) Ca2+, 0.8% (wt/wt) 
phosphorus, 0% (wt/wt) lactose) from age 3 to 8 wk or received a Ca2+-enriched diet 
(2% (wt/wt) Ca2+, 1.25% (wt/wt) phosphorus, 20% (wt/wt) lactose; Harlan Tekland, 
Madison, WI). 3) 1,25(OH)2D3 supplementation: eight 1αOHase knockout mice 
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received either 1,25(OH)2D3 or vehicle injections intraperitoneally from ages 3 to 8 
wk. From weeks 3 to 4, mice were daily injected intraperitoneally with 1,25(OH)2D3 
repletions of 500 pg/g body weight and 100 pg/g body weight daily in weeks 5-8.  
At the end of the treatment periods, animals were killed and blood and duodenum 
tissue samples were taken. The animal ethics board of the University Medical Centre 
Nijmegen approved all animal experimental procedures. 
 
Analytical procedures 
Serum Ca2+ concentrations were analyzed using a colorimetric assay kit as described 
previously (24). Serum 17β-E2 was measured by an extraction procedure using diethyl 
ether followed by radioimmunoassay (DPC, Los Angeles, CA, USA) (25). 
 
TABLE 1.  Sequences of primers and Taqman probes for real-time quantitative PCRa 
 
a PCR primers and fluorescent probes (5FAM-3TAMRA) were designed using the computer program 
Primer Express (Applied Biosystems) and purchased from Biolegio (Malden, The Netherlands). Transient 
receptor potential vanilloid, (TRPV)5/TRPV6, epithelial Ca2+ channel 1 and 2; PMCA1b, plasma membrane 
Ca2+-ATPase; HPRT, hypoxanthine-guanine phosphoribosyl transferase. R, rat; M, mouse. 
 
RNA isolation and quantitative PCR 
Total RNA from duodenal mucosa was isolated using Trizol reagent (Gibco BRL, Life 
Technologies, Breda, The Netherlands) according to the manufacturers protocol. RNA 
was treated with DNAse to prevent contamination of genomic DNA and finally 
resuspended in diethylpyrocarbonate-treated milliQ. Total RNA (2 µg) was subjected 
to reverse transcription using Moloney murine leukemia virus reverse transcriptase 
(Gibco BRL) as described previously (20). Expression levels of duodenal TRPV5, 
TRPV6, calbindin-D9K, and PMCA1b mRNA were quantified by real-time quantitative 
PCR, using the ABI Prism 7700 Sequence Detection System (PE Biosystems, 
Rotkreuz, Switzerland). With the use of standard curves, the amount of copy numbers 
of the target genes in each sample was calculated and expressed as a ratio to the 
5-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-35-TTACCAGTGTCAATTATATCTTCAACAATC-35-TTATCAGACTGAAGAGCTACTGTAATGATC-3
HPRT
5-CAGCTGAAAGGCTTCCCGCCAAA-35-CAGCCATTGCTCTATTGAAAGTTC-35-CGCCATCTTCTGCACCATT-3
PMCA1b
5-CAAAAATATGCAGCCAAGGAAGGCGA-35-CTCCATCGCCATTCTTATCCA-35-CCTGCAGAAATGAAGAGCATTTT-3
Calbindin-D9K 
5-TTCCAGCAACAAGATGGCCTCTACTCTGA-35-AGTTTTTCTCCTGAATCTTTTTCCAA-35-ATCCGCCGCTATGCACA-3
TRPV6
5-TGTTTCTCAGATAGCTGCTCTTGTACTTCCTCTTTGT-35-GTTTGGAGAACCACAGAGCCTCTA-35-CGTTGGTTCTTACGGGTTGAAC-3
TRPV5
ProbeReverse primerForward primerGene
R
M
5-TGCTTCTCAGATAGTTGTTCTTGTACTTCCTCCTTGT-35-TTGCAGAACCACAGAGCCTCTA-35-CTTACGGGTTGAACACCACCA-3
R
M
5-TTCCAGCAACAAGATGACCTCTACTCTGA-35-AGTTTTTCTCCTGAGTCTTTTTCCA-35-ATCCGCCGCTATGCACA-3
R
M
5-CAAAAATATGCAGCCAAAGAAGGCGA-35-TTCTCCATCACCGTTCTTATCCA-35-CCCGAAGAAATGAAGAGCATTTT-3
R
M
5-CAGCTGAAAGGCTTCCCGCCAAA-35-CAGCCATTGTTCTATTGAAAGTTC-35-CGCCATCTTCTGCACAATT-3
R
M
5-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-35-TTACCAGTGTCAATTATATCTTCAACAATC-35-TATCAGACTGAAGAGCTACTGTAATGACC-3
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hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene. Primers and probes 
targeting the genes of interest were designed using Primer Express software (Applied 
Biosystems, Foster City, CA) and are listed in Table 1.  
 
Statistical analysis 
Values are expressed as mean ± SE. Statistical significance was determined by 
ANOVA followed by contrast analysis according to Fisher. In case of only two 
experimental groups, statistical significance was determined using the Mann-Whitney 
U-test. Differences in means with P values <0.05 were considered statistically 
significant. All analyses were performed using the Statview Statistical Package (Power 
PC version 4.51, Berkely, California, USA) on a Macintosh computer. 
 
RESULTS   
 
OVX Wistar rats were used as a model of estrogen deficiency. Ovariectomy was 
confirmed by the reduced serum 17β-E2 levels compared with sham-operated animals 
(Table 2). Correction of this deficiency by supplementation with 17β-E2 resulted in a 
dose-responsive increase with significantly higher serum 17β-E2 levels in OVX+E2H 
rats (Table 2). Importantly, 17β-E2 treatment reduced serum Ca2+ levels, resulting in a 
slight but significantly lower serum Ca2+ concentration in the OVX+E2H group (Table 
2).  
 
TABLE 2.  Effects of OVX and 17β-E2 supplementation on serum parameters in female Wistar 
rats 
 
Data are presented as mean ± SE (n = 5). OVX, ovariectomized; 17β-E2, 17β-estradiol; Sham, sham-
operated; E2L, supplemented with 2x 32 µg 17β-E2/day; E2M, supplemented with 2x 125 µg 17β-E2/day; 
E2H, supplemented with 2x 500 µg 17β-E2/day. * P < 0.05 versus OVX.,  P < 0.05 versus all groups. 
 
Subsequently, we investigated whether 17β-E2 treatment altered the expression of 
genes encoding Ca2+ transport proteins involved in duodenal transcellular Ca2+ 
absorption. With the use of real-time quantitative PCR, a more than sevenfold increase 
in TRPV6 mRNA levels was observed in OVX rats supplemented with the highest 
dose of 17β-E2 compared with untreated OVX animals (Fig. 1A). TRPV5 gene 
Ca2+ (mM)
Sham OVX
17β-E2 (pg/ml)
2.38 ± 0.02 2.40 ± 0.03
11 ± 6 5 ± 3
OVX + E2L OVX + E2M OVX + E2H
2.39 ± 0.02 2.36 ± 0.04
5 ± 1 12 ± 2
2.31 ± 0.02*
64 ± 6
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expression was also upregulated by 17β-E2, although detection levels were lower and 
differences between the various groups were less pronounced than for TRPV6 (Fig. 
1B). In addition, upregulation of both Ca2+ channels was accompanied by an increase 
in expression of the other Ca2+ transport proteins, namely calbindin-D9K (9-fold) and 
PMCA1b (2-fold) (Fig. 1C, D).  
 
 
FIGURE 1.  
Effects of ovariectomy (OVX) 
and 17β-estradiol (17β-E2) 
supplementation on mRNA 
expression levels of Ca2+ 
transport proteins in duodenum 
of rats. With the use of real-time 
quantitative PCR, duodenal 
expression of TRPV6 (A), 
TRPV5 (B), calbindin-D9K (C), 
and plasma membrane Ca2+-
ATPase (PMCA1b; D) of the 
different experimental groups 
were measured and presented as 
a ratio to hypoxanthine-guanine 
phosphoribosyl transferase 
(HPRT) expression. Sham, sham-
operated; E2L: supplemented 
with 2x 32 µg 17β-E2/day; E2M, 
supplemented with 2x 125 µg 
17β-E2/day; E2H, supplemented 
with 2x 500 µg 17β-E2/day. Data 
are presented as mean ± SE (n = 5). * P<0.05 versus OVX, OVX+E2L;  P<0.05 versus Sham, OVX, 
OVX+E2L;  P<0.05 versus OVX, OVX+E2L, OVX+E2M; # P<0.05 versus OVX. 
 
 
 
FIGURE 2.  
Effect of 17β-E2 supplementation on the mRNA expression level of 
TRPV6 in duodenum of 25-hydroxyvitamin D3-1α-hydroxylase 
(1αOHase) knockout mice. Duodenal expression of TRPV6 assessed 
by real-time quantitative PCR analysis is presented as a ratio to 
HPRT expression. Control, 1αOHase knockout mice; 17β-E2, 
1αOHase knockout mice supplemented with 10 µg 17β-E2/day. Data 
are presented as mean ± SE (n = 4). * P<0.05 versus control. 
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These observations led us to study the influence of 17β-E2 treatment on duodenal 
TRPV5 and TRPV6 expression in 1αOHase knockout mice to investigate the 
involvement of 1,25(OH)2D3. Serum 17β-E2 levels were not detectable in the male 
mice but rose to 67 pg/ml after treatment with 17β-E2. Interestingly, after treatment 
with 17β-E2, serum Ca2+ levels significantly increased from a hypocalcemic state to 
subnormal concentrations of 2.03 ± 0.12 mM (Table 3). Analysis of gene expression in 
duodenum revealed a 12-fold increase in TRPV6 mRNA after treatment with 17β-E2 
(Fig. 2). 
 
TABLE 3.  The effect of 17β-E2, 1,25(OH)2D3, and high dietary Ca2+ on serum Ca2+ levels in 
1αOHase knockout mice 
 
Data are presented as mean ± SE (n = 4). 1αOHase, 25-hydroxyvitamin D3-1α-hydroxylase; Control, 
1αOHase knockout mice; Treated, 1αOHase knockout mice supplemented with 17β-E2 (10 µg/day for 7 
days), 1,25(OH)2D3 (500 pg/g body weight daily in weeks 3-4 and 500 pg/g body weight daily in weeks 5-8), 
or high dietary Ca2+ (2% (wt/wt) Ca2+-enriched diet from age 3-8 wk). * P<0.05 versus control. 
 
In two following experiments, the 1αOHase knockout mice were used to study the 
influence of 1,25(OH)2D3 itself and dietary Ca2+ on gene expression levels of the Ca2+ 
transport proteins. Inactivation of the 1αOHase gene in the knockout mice resulted in 
severe hypocalcaemia with serum Ca2+ concentrations as low as 1.20 mM. 
Supplementation with 1,25(OH)2D3 or a high dietary Ca2+ intake normalized serum 
Ca2+ concentrations (Table 3). Subsequently, analysis of gene expression showed an 
increase in mRNA levels of TRPV6 after high dietary Ca2+ intake (Fig. 3A). 
1,25(OH)2D3 supplementation also upregulated the expression of this transcript, but to 
a much higher degree (Fig. 4A). In addition, high dietary Ca2+ stimulated the 
expression of calbindin-D9K significantly (Fig. 3B), whereas PMCA1b levels were not 
significantly changed (P >0.1, Fig. 3C). Supplementation with 1,25(OH)2D3 
significantly upregulated the expression of both calbindin-D9K (Fig. 4B) and PMCA1b 
(Fig. 4C). Detection of TRPV5 mRNA in duodenum was below detection limits in the 
1αOHase knockout mice. In addition, after treatment with either 17β-E2 or high dietary 
High dietary Ca2+ 1.20 ± 0.05 2.33 ± 0.10*
1,25(OH)2D3 1.20 ± 0.05 2.59 ± 0.07*
17β-E2 1.69 ± 0.10 2.03 ± 0.12*
Serum Ca2+ concentration (mM)
Control Treated
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Ca2+, expression of TRPV5 mRNA levels could also not be detected. Interestingly, 
supplementation with 1,25(OH)2D3 upregulated the expression of TRPV5 mRNA to 
significant levels. 
 
 
 
FIGURE 3. Effect of dietary Ca2+ on the mRNA expression levels of Ca2+ transport proteins in duodenum of 
1αOHase knockout mice. Duodenal expression of TRPV6 (A), calbindin-D9K (B), and PMCA1b (C) of the 
different experimental groups assessed by real-time quantitative PCR analysis is presented as a ratio to 
HPRT expression. Control, 1αOHase knockout mice; Calcium, 1αOHase knockout mice on a Ca2+-enriched 
diet (2% (wt/wt) Ca2+ from ages 3-8 wk). Data are presented as mean ± SE (n = 4).  * P<0.05 versus control. 
 
 
FIGURE 4. Effect of 1,25(OH)2D3 supplementation on the mRNA expression levels of Ca2+ transport proteins 
in duodenum of 1αOHase knockout mice. Duodenal expression of TRPV6 (A), calbindin-D9K (B), and 
PMCA1b (C) of the different experimental groups assessed by real-time quantitative PCR analysis is 
presented as a ratio to HPRT expression. Control, 1αOHase knockout mice; 1,25(OH)2D3, 1αOHase 
knockout mice supplemented with 1,25(OH)2D3 (500 pg/g body weight daily in weeks 3 and 4 and 500 pg/g 
body weight daily in weeks 5-8). Data are presented as mean ± SE (n = 4).  * P<0.05 versus control. 
 
DISCUSSION 
 
The present study demonstrated that duodenal TRPV5 and TRPV6 mRNA levels are 
both upregulated by 17β-E2 and 1,25(OH)2D3, whereas dietary Ca2+ is positively 
involved in the regulation of TRPV6 mRNA only. Moreover, the expression of genes 
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encoding the other known duodenal Ca2+ transport proteins is upregulated 
concomitantly, which will facilitate Ca2+ absorption optimally.  
OVX rats were used as an animal model of estrogen deficiency in postmenopausal 
women (26). Ovariectomy did not affect mRNA expression levels of the various Ca2+ 
transport proteins in duodenum, which agrees with the measured unchanged serum 
Ca2+ levels 1 week after OVX. Theoretically, the loss of function of 17β-E2 could be 
compensated by other mechanisms, such as 1,25(OH)2D3, within a 7-day period. In 
contrast, a significant upregulation of TRPV5 and TRPV6 mRNA expression was 
observed after estrogen replacement therapy in OVX rats. These increased mRNA 
levels were accompanied by upregulated mRNA levels of both calbindin-D9K and 
PMCA1b. However, upregulation of the genes encoding for the Ca2+ transport proteins 
was accompanied by decreased serum Ca2+ levels after 17β-E2 treatment. Several 
studies in human subjects observed this effect of estrogen treatment on serum Ca2+ 
levels (12, 27). It has been suggested that this fall in Ca2+ is transitory, due to increased 
Ca2+ requirements of the estrogen-deficient animals. Correction of estrogen deficiency 
results in decreased bone resorption and increased formation, causing a slight fall in 
serum Ca2+ concentration (28). 
Because 1,25(OH)2D3 is the primary hormone involved in the regulation of Ca2+ 
absorption, it has been suggested that the effects of estrogen on intestinal absorption of 
Ca2+ are indirectly mediated by 1,25(OH)2D3 (28). In the kidney, production of 
1,25(OH)2D3 by 1αOHase plays a pivotal role in maintaining Ca2+ homeostasis (29). It 
was demonstrated by Stumpf et al. that 17β-E2 was retained in the cell nuclei of 
proximal tubules, where the synthesis of 1,25(OH)2D3 takes place (30). Conflicting 
data are presented concerning the effect of 17β-E2 on 1α-hydroxylase activity and 
1,25(OH)2D3 synthesis (12, 25, 31-34). So far, conclusive in vivo data for a direct 
effect of 17β-E2, independent of 1,25(OH)2D3, on intestinal Ca2+ absorption are 
lacking.  
Dardenne et al. generated 1αOHase knockout mice by targeted inactivation of the 
1αOHase gene (23). These knockout mice express the same clinical phenotype as 
patients with VDDR-I, characterized by hyperparathyroidism, hypocalcemia, rickets 
and undetectable levels of 1,25(OH)2D3. These mice represent an ideal animal model in 
which to study the role of 17β-E2 on intestinal Ca2+ transport independent of 
1,25(OH)2D3. Treatment with 17β-E2 increased serum Ca2+ levels to subnormal 
concentrations. Furthermore, 17β-E2 treatment was associated with an upregulation of 
duodenal TRPV6 mRNA expression. The observations that functional estrogen 
receptors are present within the enterocytes (7) and that 17β-E2 enhances the uptake of 
Ca2+ by intestinal cells in vitro (8) are suggestive of a direct role in Ca2+ absorption. 
Together, these findings provide further evidence that 17β-E2 acts directly on 
duodenum to promote active Ca2+ absorption.  
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In the 1αOHase knockout mice, high dietary Ca2+ intake increased the expression 
levels of the genes encoding Ca2+ transport proteins, which was accompanied by 
normalization of serum Ca2+ levels. Under physiological conditions, Ca2+ acts via a 
negative feedback mechanism that eventually leads to suppression of 1αOHase activity 
and production of 1,25(OH)2D3, which decreases expression of the Ca2+ transporting 
proteins and active Ca2+ absorption (35). However, this study suggests that in the 
absence of 1αOHase activity, and thus circulating 1,25(OH)2D3, Ca2+ supplementation 
can increase the expression level of duodenal Ca2+ transport proteins. The mechanism 
that underlies this vitamin D-independent Ca2+-regulated pathway is not known. 
Previous studies have shown that cAMP- and serum-response elements can function as 
a Ca2+-response element (CaRE) in the control of gene expression (36, 37). Recently, a 
new Ca2+-responsive transcription factor was discovered in neuronal cells that 
contributes to Ca2+-stimulated gene expression of the brain-derived neurotrophic factor 
(BDNF) through a CaRE found in the promoter of the BDNF gene (38). Moreover, in 
the promoter region of calbindin-D28K, a Ca2+-sensitive transcriptional regulatory 
mechanism, named Purkinje cell element, was identified, which may play a key role in 
setting the Ca2+ buffering capacity of Purkinje cells (39). Likewise, Ca2+-response 
elements and/or transcription factors could be involved in the Ca2+-mediated regulation 
of gene expression found in our study. 
Interestingly, high dietary Ca2+ intake, using VDR knockout mice, resulted in a 
decreased expression of both TRPV5 and TRPV6 and a reduction in calbindin-D9K and 
PMCA1b expression (40). The VDR is a nuclear receptor and acts as a ligand-activated 
transcription factor. On activation by 1,25(OH)2D3, the VDR can alter the rate of gene 
expression. However, 1,25(OH)2D3 can also activate second messenger pathways 
mediated by cell surface receptors (41, 42). Furthermore, previous studies have shown 
that this nongenomic effect of 1,25(OH)2D3 can stimulate intestinal Ca2+ transport, a 
process called transcaltachia (42, 43). VDR knockout mice have elevated 1,25(OH)2D3 
levels, which decrease after high dietary Ca2+ intake (40).  It is conceivable that this 
influences the intestinal expression of Ca2+ transport proteins and Ca2+ absorption 
through 1,25(OH)2D3-mediated nongenomic pathways, which could possibly explain 
the differential findings between VDR and 1αOHase knockout mice after high dietary 
Ca2+ intake. 
The genomic response of 1,25(OH)2D3 is demonstrated by the significant increase in 
mRNA levels of TRPV6, calbindin-D9K, and PMCA1b after supplementation with 
1,25(OH)2D3 in the 1αOHase knockout mice. Furthermore, repletion with 1,25(OH)2D3 
normalized serum Ca2+ concentrations. In agreement with our findings, previous 
studies have shown that 1,25(OH)2D3 stimulates the expression level of calbindins and 
affects Ca2+ extrusion at the basolateral membrane of duodenal cells (4, 44, 45). 
1,25(OH)2D3 has also been shown to stimulate transcellular Ca2+ transport in the 
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human intestinal cell line Caco-2 and to increase the expression of calbindin-D9K in 
these cells (46, 47). Recently, Wood et al. demonstrated that expression of TRPV6 in 
Caco-2 cells is upregulated by 1,25(OH)2D3 (48). Besides TRPV6, also TRPV5 is 
expressed as apical Ca2+ channel in duodenum (20, 21). However, mRNA expression 
levels of this latter Ca2+ channel are hundredfolds lower in duodenum. Several other 
studies reported that TRPV5 expression could not be detected in Caco-2 cells and 
human intestinal tissue (48-50).  In our 1αOHase knockout mice, the expression of 
duodenal TRPV5 is also below detection limits. Only after supplementation with 
1,25(OH)2D3, TRPV5 mRNA reaches a detectable level in duodena of these knockout 
mice. Taken together, these findings indicate that 1,25(OH)2D3 is a significant 
regulator of both epithelial Ca2+ channels in duodenum and support the idea that 
1,25(OH)2D3 stimulates active intestinal Ca2+ absorption by increasing the rate of Ca2+ 
influx across the intestinal brush border membrane (2, 51). In addition to TRPV6, 
which is abundantly present in duodenum, TRPV5 can also be strongly upregulated 
and could play an important role in intestinal Ca2+ absorption. The generation of 
TRPV5 and TRPV6 knockout mice will further substantiate the importance of these 
channels in Ca2+ homeostasis in general and, in particular, their role in Ca2+ absorption. 
Similar to TRPV5 and TRPV6, also calbindin-D9K and PMCA1b mRNA levels are 
upregulated after different supplementations in rat and mouse. The activity of the 
epithelial Ca2+ channels is controlled by a Ca2+-dependent feedback mechanism (52, 
53). Therefore, to facilitate Ca2+ transport, it is important to maintain a low 
intracellular Ca2+ environment. By the upregulation of the buffering and extrusion 
mechanisms, this requirement is fulfilled. Moreover, upregulation of expression levels 
of the genes encoding the intestinal Ca2+ transport proteins was accompanied by 
normalization of the serum Ca2+ concentration. Together, these findings underline the 
intimate relationship among apical influx, cytosolic diffusion, and basolateral efflux 
systems in transcellular Ca2+ transport, which could contribute to increased Ca2+ 
absorption and ultimately normalization of serum Ca2+ levels. 
In conclusion, the present study demonstrated that 17β-E2 and 1,25(OH)2D3 are both 
positively involved in the regulation of duodenal TRPV5 and TRPV6, whereas dietary 
Ca2+ has a stimulatory effect on the expression of TRPV6 only. This regulation 
substantiates the possible role of these channels in the pathogenesis of hormone-
regulated Ca2+-disorders, such as osteoporosis or VDDR. Future research should aim to 
further unravel the mechanisms controlling the activity of TRPV5 and TRPV6, which 
may lead to new insights regarding Ca2+ homeostasis-related disorders.  
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ABSTRACT  
 
Background: the kidney is one of the affected organs involved in the clinical symptoms 
of parathyroid hormone (PTH)-related disorders, like primary hyperparathyroidism and 
familial hypocalciuric hypercalcemia. The molecular mechanism(s) underlying 
alterations in renal Ca2+ handling in these disorders is poorly understood. Methods: 
parathyroidectomized and PTH-supplemented rats and mice infused with the 
calcimimetic compound NPS R-467 were used to study the in vivo effect of PTH on 
the expression of renal transcellular Ca2+ transport proteins, including the epithelial 
Ca2+ channel TRPV5, calbindins, and the Na+/Ca2+-exchanger (NCX1). In addition, the 
effect of PTH on transepithelial Ca2+ transport in rabbit connecting tubule/cortical 
collecting duct (CNT/CCD)  primary cultures was determined. Results: decreased PTH 
levels in parathyroidectomized rats or NPS R-467-infused mice, resulted in reduced 
expression of these proteins, which is consistent with diminished Ca2+ reabsorption, 
causing the development of the observed hypocalcemia. PTH supplementation of 
parathyroidectomized rats restored the expression of the renal Ca2+ transport machinery 
and serum Ca2+ levels, independent of serum 1,25-dihydroxyvitamin D3 levels and 
renal vitamin D or Ca2+-sensing receptor mRNA abundance. Inhibition of the PTH-
stimulated transepithelial Ca2+ transport by the TRPV5-specific inhibitor ruthenium red 
reduced the PTH-stimulated expression of calbindin-D28K and NCX1 in rabbit 
CNT/CCD primary cultures. Conclusion: PTH stimulates renal Ca2+ reabsorption 
through the coordinated expression of renal transcellular Ca2+ transport proteins. 
Moreover, the PTH-induced stimulation is enhanced by the magnitude of the Ca2+ 
influx through the gatekeeper TRPV5, which in turn facilitates the expression of the 
downstream Ca2+ transport proteins. Therefore, the renal transcellular Ca2+ transport 
proteins, including TRPV5, could contribute to the pathogenesis of PTH-related 
disorders. 
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INTRODUCTION 
 
Primary hyperparathyroidism is a common endocrine disorder characterized by 
elevated parathyroid hormone (PTH) levels that are inappropriate to the level of serum 
Ca2+ (1). This underlines the importance of PTH as an essential component of Ca2+ 
homeostasis. Secretion of PTH from the parathyroid glands is regulated by the ambient 
Ca2+ concentration, sensed by the parathyroid Ca2+-sensing receptor (CaSR) (2). The 
CaSR is activated by high serum Ca2+ concentrations and couples to the inhibition of 
PTH secretion. Inactivating mutations of the CaSR result in familial hypocalciuric 
hypercalcemia or neonatal severe hyperparathyroidism (3), whereas autosomal 
dominant hypocalcemia is caused by activating mutations (4). These disorders 
demonstrate the predominant role of the CaSR in controlling parathyroid gland 
function and, hence, the role of PTH in regulating systemic Ca2+ balance. From the 
clinical symptoms of these PTH-related disorders, like hypo- or hypercalciuria and 
renal stone formation, it is clear that also renal Ca2+ handling is affected.  
Regulation of Ca2+ reabsorption in the kidney is crucial for the maintenance of normal 
serum Ca2+ levels and occurs via paracellular as well as transcellular routes. 
Transcellular or active Ca2+ reabsorption is the primary target for regulation by 
calciotropic hormones, including 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and PTH. 
Active Ca2+ reabsorption takes place in the distal convoluted tubule (DCT) and 
connecting tubule (CNT) of the kidney. Luminal Ca2+ enters these tubular cells via the 
epithelial Ca2+ channels, TRPV5 and TRPV6, is then transported across the cell in 
association with Ca2+-carrier proteins (i.e. calbindins) and is finally extruded into the 
blood stream via the Na+/Ca2+-exchanger (NCX1) and the plasma membrane Ca2+-
ATPase (PMCA1b) (5-8). PTH receptors have been detected throughout the kidney, as 
well as in the actively Ca2+ transporting tubules DCT and CNT (9, 10). Therefore, the 
contribution of these Ca2+ transport proteins to the altered Ca2+ handling in PTH-
related disorders seems likely. 
Treatment of primary hyperparathyroidism has been limited to surgical ablation 
(parathyroidectomy) of the affected glands. A new approach for treating primary 
hyperparathyroidism is to target the mechanisms that regulate the secretion of PTH. 
The CaSR is the first step in this process. In the last decade synthetic compounds, 
referred to as calcimimetic compounds, have been developed (11, 12). Type I 
calcimimetics are full agonists of the CaSR, whereas type II calcimimetics are small 
organic compounds that, upon binding to the receptor, enhance the sensitivity of the 
CaSR to Ca2+ in an allosteric fashion, thereby altering PTH secretion by the 
parathyroid glands. In this way, the type II calcimimetic compounds may provide a 
novel therapy for treating hyperparathyroidism (11, 12).  
The present study aims to gain insight into the molecular mechanism(s) underlying the 
alterations in renal Ca2+ handling in PTH-related disorders. To this end, the in vivo 
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effect of PTH on the expression of proteins involved in renal transcellular Ca2+ 
reabsorption was examined. Here, we demonstrated that PTH affects renal Ca2+ 
handling through the coordinated regulation of the expression of renal transcellular 
Ca2+ transport proteins. Moreover, the PTH-induced increase in Ca2+ influx through 
TRPV5 facilitates the expression of downstream Ca2+ transport proteins, thereby 
further emphasizing the gatekeeper function of TRPV5. 
 
MATERIALS AND METHODS 
 
Animals 
In experiment 1, male Sabra rats, weighing 250 g, had free access to normal rat chow 
and water. After acclimatization, rats were either sham-operated (Sham, n=4) or 
parathyroidectomized (PTX, n=8) by cauterization. After 7 days, Alzet osmotic 
minipumps were implanted subcutaneously (model 2001, Durect Corporation, 
Cupertino, CA, USA). Sham-operated rats received vehicle solution (2% (wt/vol) 
cysteine HCl) and PTX rats received either vehicle solution or bovine PTH 1-34 
(Sigma, St. Louis, MO, USA) at a rate of 0.25 U PTH 1-34/hour (PTX+PTH) for 7 
days.  
In experiment 2, male C57BL6 mice, 8 weeks of age, were fed standard chow and 
given water ad libitum. After acclimatization, mice were divided in four groups of 5 
animals each. Mice were anesthetized and an Alzet model 1007D osmotic minipump 
(Durect Corporation) was implanted subcutaneously. The pump infused the 
calcimimetic compound NPS R-467 (NPS Pharmaceuticals, Salt Lake City, UT, USA) 
at a dose of 10, 30 or 100 µmol per kg body weight (BW) per day or vehicle solution 
(45% (wt/vol) aqueous solution of 2-hydroxypropyl-β-cyclodextrin). At the end of the 
treatment periods, animals were sacrificed, and blood and kidney samples were taken.  
The animal ethics board of the University Medical Center Nijmegen and Hadassah 
University Hospital Jerusalem approved all animal experimental procedures. 
 
Primary cultures of rabbit kidney CNT/CCD  
Rabbit kidney connecting tubule/cortical collecting duct (CNT/CCD) cells were 
immunodissected from New Zealand white rabbits (5 weeks of age) with monoclonal 
antibody R2G9 and set in primary culture on permeable filter supports (0.33 cm2, 
Corning-Costar, Cambridge, MA, USA) as described previously in detail (13). The 
culture medium was a 1:1 mixture of Dulbeccos modified Eagles/Hams F-12 
medium (Gibco, Paisley, UK) supplemented with 5% (v/v) decomplemented Fetal Calf 
Serum, 10 µg/ml ciproxin, 10 µg/ml non-essential amino acids (Gibco), 5 µg/ml 
insulin, 5 µg/ml transferrin, 50 nM hydrocortisone, 70 ng/ml prostaglandin E1, 50 nM 
Na2SeO3, 5 pM triiodothyronine, and 5 µM indomethacin, equilibrated with 5% CO2-
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95% air at 37°C. Two days after seeding, the cells were incubated for 120 h with and 
without 100 nM bovine PTH 1-34 (Sigma) at the apical (total volume 100 µl) and 
basolateral (total volume 600 µl) compartment, whereas 10 µM ruthenium red was 
added only to the apical side. Transport assays were performed with confluent 
monolayers 7 days after seeding the cells.  
 
Determination of transepithelial Ca2+ transport 
Confluent monolayers of primary cultures were washed and preincubated in a 
physiological salt solution containing (mM) 140 NaCl, 2 KCl, 1 K2HPO4, 1 KH2PO4, 1 
MgCl2, 1 CaCl2, 5 glucose, 5 L-alanine, 10 HEPES/Tris (pH 7.4) and 5 µM 
indomethacin for 15 min at 37°C, adding 10 µM of the TRPV5-mediated Ca2+ influx 
blocker ruthenium red (14) to the apical side. Subsequently, the monolayers were 
incubated with 100 nM PTH and 10 µM ruthenium red for a further 90 min to measure 
transepithelial Ca2+ transport. At the end of the incubation period, 25 µl samples were 
collected in duplo from the apical compartment and assayed for Ca2+ concentration 
using a colorimetric assay kit (Boehringer, Mannheim, Germany). Under the outlined 
experimental conditions, these polarized renal cells exhibit transcellular Ca2+ transport, 
of which the net apical-to-basolateral Ca2+ flux is linear with time for at least 3 hours 
(13, 15). Ca2+ reabsorption is expressed in nmol.h-1.cm-2.    
 
Analytical procedures 
Serum Ca2+ concentrations were analyzed using a colorimetric assay kit as described 
previously (16). Serum phosphorus levels were measured on a Hitachi autoanalyzer 
(Hitachi Corp., Tokyo, Japan). PTH levels were determined using either a rat PTH (1-
34) immunoradiometric assay or a mouse intact PTH enzyme-linked immunosorbent 
assay kit (Immunotopics, San Clemente, CA, USA). 1,25(OH)2D3 was measured by 
immunoextraction followed by quantitation by 125I-radioimmunoassay (IDS, Boldon, 
UK) (17).  
 
RNA isolation and quantitative PCR  
Total RNA from kidney and primary CNT/CCD cells was isolated using Trizol 
Reagent (Gibco BRL, Life Technologies, Breda, The Netherlands) according to the 
manufacturers protocol. Total DNAse-treated RNA (2 µg) was reverse-transcribed 
using Moloney murine leukemia virus reverse transcriptase (Gibco BRL) as described 
previously (18). Expression of TRPV5, TRPV6, calbindin-D28K, calbindin-D9K, NCX1, 
PMCA1b, CaSR, and vitamin D receptor (VDR) mRNA, as well as mRNA levels of 
the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT), as 
an endogenous control, were determined by quantitative real-time PCR on an ABI 
Prism 7700 Sequence Detection System (PE Biosystems, Rotkreuz, Switserland). The 
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primer and probe sequences of CaSR, VDR, TRPV5, calbindin-D28K and NCX1 are 
depicted in Table 1. Other sequences have been described previously (19, 20).  
 
TABLE 1.  Sequences of primers and Taqman probes for real-time quantitative PCRa 
 
a PCR primers and fluorescent probes (5FAM3TAMRA) were designed using the computer program 
Primer Express (Applied Biosystems, Branchburg, New Jersey, USA) and purchased from Biolegio (Malden, 
The Netherlands). CaSR: Ca2+-sensing receptor; VDR: vitamin D receptor; TRPV5: transient receptor 
potential, vanilloid, member 5; NCX1: Na+/Ca2+-exchanger. R = rat, M = mouse, Rb = rabbit. Sequences of 
the other target genes used are as described previously [19, 20].  
 
Immunohistochemistry 
Kidney tissue was cut into pieces, placed in 1% (wt/vol) periodate-lysine-
paraformaldehyde fixative for 2 h at room temperature, and incubated overnight at 4°C 
in phosphate-buffered saline containing 15% (wt/vol) sucrose. Subsequently, kidney 
tissues were frozen in liquid nitrogen and 7 µm sections were cut for the staining 
procedure. For detection of TRPV5 abundance or co-localization of TRPV5 and CaSR, 
kidney sections were stained with guinea pig anti-TRPV5 antiserum (1:50) as 
described previously (19) and rabbit anti-human CaSR antibody (1:500; antiserum 
4641, a gift from NPS Pharmaceuticals). To visualize TRPV5 and CaSR, sections were 
stained with goat anti-guinea Alexa 488-conjugated anti-IgG (1:300, Sigma) and goat 
anti-rabbit Alexa 594-conjugated anti-IgG (1:300, Sigma), respectively. Sections were 
visualized by confocal laser scanning microscopy (MRC-1024, Bio-Rad, Richmond, 
CA, USA). To quantify TRPV5 protein expression, digital images of each kidney 
section were taken with a Zeiss Axioskop microscope (Thornwood, NY, USA) and the 
integrated optical density was measured by computer analysis with the Image-Pro Plus 
version 3.0 software (Media Cybernetics, Silver Spring, MD, USA).  
 
Immunoblotting 
For protein analysis, frozen kidney tissue and the cultured cells were homogenized in 
ice-cold solubilization buffer as previously described (21). Total kidney protein 
NCX1
Calbindin-D28K
TRPV5
5-AGGACAACCGGCGACACTGCCA-35-TGTCCACGCAGCGTTTGA-35-AATGGAGATTGCCGCATCAC-3
VDR
5-CGGAAGTTATACCTGATGCACTCCACAGACTCT-35-GCAAAGATCATGGCTTGTAACCA-35-CTTTCCTATCCATTTTGGAGTAGCA-3
CaSR
ProbeReverse primerForward primerGene
R
M
5-CGGAAGTTATACCTAATGCACTCCACAGACTCT-35-GCGAATATCATGGCTTGTAACCA-35-CTTTCCTATCCATTTTGGAGTAGCA-3
R
M
5-AGGACAACCGGCGACACTGCCA-35-TGTCCACACAGCGTTTGA-35-AATGGAGATTGCCGCATCAC-3
Rb 5-TCCTCTGCGAGTGCTTCGCTATGTGG-35-CCTTGTCTGAGCACTTGAATGC-35-CGGGTTGAGAACCATCATGAC-3
Rb 5-ATGGCCAGGTTACTACCAGTGCAAGAGAATTT-35-CCACACATTTTGATTCCCTGAA-35- GATGGGAAGCTGGAATTAACTGA -3
Rb 5- AGCTGACCAAGCTAGGAAGGCTGTCAGC -35-TTTCCGTGTTGACTTCATGCA-35-GGGCTGGCAACATTTTAAAGAG-3
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fractions (10 µg) or cell protein fractions (4 µl) were separated on 12% or 16.5% 
(wt/vol) SDS-PAGE gels and blotted to PDVF-nitrocellulose membranes (Immobilon-
P, Millipore Corporation, Bedford, MA). Blots were incubated with calbindin-D28K 
antibody (1:10000, Sigma), calbindin-D9K antibody (1:3000, Swant, Bellinzona, 
Switzerland) or Na+/K+-ATPase antibody (1:10000, kindly provided by J.B. 
Koenderink, ref. 22) and thereafter with peroxidase-conjugated goat anti-rabbit 
antibody (1:2000, Sigma). Immunoreactive protein was detected using the enhanced 
chemiluminescence method as described by the manufacturer (Amersham, 
Buckinghamshire, UK). Protein expression was quantified by computer-assisted 
densitometry with the use of the Image-Pro Plus version 3.0 software (Media 
Cybernetics). 
 
Statistical analysis 
Values are expressed as mean ± SE. Statistical significance of differences between 
groups was determined by ANOVA followed by pair-wise comparisons using the 
method of least significant difference. An unpaired t-test was used for comparisons 
between control and 100 µmol/kg BW/day groups. Differences in means with P < 0.05 
were considered statistically significant.  
 
RESULTS 
 
TABLE 2.  Effect of parathyroidectomy and PTH supplementation on serum parameters in Sabra 
ratsa 
 
a Sham, sham-operated; PTX, parathyroidectomized; PTX+PTH, PTX supplemented with 0.25 U PTH 1-
34/hour. Data are presented as mean ± SE (n = 4).  b P<0.05 versus Sham. c P<0.05 versus Sham and 
PTX+PTH. d P<0.05 versus Sham and PTX. 
 
Rescue of PTX-induced hypocalcaemia by PTH supplementation in rats 
Surgical removal of the parathyroid glands resulted in the reduction of serum PTH 
levels, whereas serum PTH levels tended to increase after infusion with 0.25 U PTH 1-
34/hour (Table 2). Moreover, parathyroidectomy caused a severe hypocalcemia and 
PTX + PTHSham PTX
2.89 ± 0.06 1.61 ± 0.07c
43.5 ± 14.7 6.1 ± 2.9b
2.51 ± 0.04d
14.4 ± 4.6
375 ± 9 261 ± 29b
1.59 ± 0.06 2.15 ± 0.04c
234 ± 13b
1.82 ± 0.10d
Ca2+ (mM)
PTH (pg/ml)
1,25(OH)2D3 (pM)
Phosphorus (mM)
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hyperphosphatemia, which were partially restored by PTH supplementation (Table 2). 
In addition, serum 1,25(OH)2D3 levels were decreased in PTX rats, but no changes 
were observed after PTH supplementation (Table 2).  
 
 
FIGURE 1. Effect of PTX and supplementation with PTH 1-34 on mRNA expression levels of genes 
encoding Ca2+ transport proteins in rat kidney. Using real-time quantitative PCR, renal mRNA expression of 
TRPV5 (A), TRPV6 (B), calbindin-D28K (C), NCX1 (D), PMCA1b (E), CaSR (F), and VDR (G) of the 
different experimental groups were measured and presented as a ratio to HPRT expression. White bars: 
sham-operated rats; Gray bars: parathyroidectomized (PTX) rats; Black bars: PTX rats supplemented with 
0.25 U PTH 1-34/hour. Data are presented as mean ± SE (n = 4). * P<0.05 versus All. # P<0.05 versus Sham. 
 
Effect of PTH on renal expression of Ca2+ transporters 
To investigate the effect of PTH on renal Ca2+ handling, the expression of genes 
encoding Ca2+ transport proteins involved in transcellular Ca2+ reabsorption was 
examined using quantitative real-time PCR. Surgical removal of the parathyroid glands 
in rats induced a 70% decrease in TRPV5 mRNA levels, which were completely 
normalized after PTH infusion (Fig. 1A). In contrast, no significant effects were 
detected on the expression of TRPV6 mRNA between Sham, PTX and PTX+PTH rats 
(Fig. 1B). Similar to TRPV5 expression, mRNA transcripts encoding for calbindin-
D28K were down-regulated in PTX rats and partially restored in the PTH-supplemented 
animals (Fig. 1C). The expression of calbindin-D9K was not measured, because it is not 
detectable in rat kidney. In addition, PTX reduced the expression of NCX1 (Fig. 1D), 
whereas PMCA1b mRNA levels were not altered (Fig. 1E). No differences were 
observed in CaSR or VDR mRNA levels after PTX or subsequent infusion of PTH 
(Fig. 1F, G). 
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FIGURE 2. Effect of PTX and supplementation with PTH 1-34 on protein expression levels of TRPV5 in rat 
kidney. Immunofluorescence staining of kidney cortex sections of Sham, PTX and PTX+PTH rats showing 
the abundance of TRPV5 (A), which was quantified by computer analysis of the integrated optical density 
and expressed in relative percentages (B). Glomeruli (G) are depicted in the images. Immunoblots of samples 
(10 µg protein each) from homogenates of kidney tissue were labeled with antibodies against calbindin-D28K 
(D). Expression of calbindin-D28K protein was quantified by computer-assisted densitometry analysis and 
expressed in relative percentages (C). Sham (white bars), sham-operated rats; PTX (gray bars), para-
thyroidectomized rats; PTX+PTH (black bars), PTX rats supplemented with 0.25 U PTH 1-34/hour. Data are 
presented as mean ± SE (n = 4). * P<0.05 versus Sham. # P<0.05 versus All. 
 
Subsequently, examination of the expression of renal Ca2+ transport proteins by 
immunohistochemistry revealed a marked decrease in TRPV5 protein abundance in 
response to PTX, as indicated by the reduced immunopositive staining (Fig. 2A). As 
observed for TRPV5 mRNA expression, PTH supplementation increased the protein 
abundance in the PTX animals. The corresponding integrated optical density analysis 
confirmed the significant decline in TRPV5 protein abundance after PTX (Fig. 2B). 
Furthermore, Western blot analysis of calbindin-D28K consistently demonstrated a 
down-regulation in the protein abundance in PTX rats and a subsequent normalization 
after PTH infusion (Fig. 2D). Densitometric analysis of the intensity of the immuno-
complexes confirmed this decrease in calbindin-D28K protein expression after PTX 
(Fig. 2C).  
 
NPS R-467 treatment reduced serum PTH and Ca2+ levels in mice 
Infusion of the calcimimetic compound NPS R-467 for 7 days reduced serum PTH 
levels. Furthermore, this reduction was associated with a fall in serum Ca2+ 
concentrations and an increase in serum phosphorus levels. Measurements of 
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circulating 1,25(OH)2D3 levels revealed no effect of NPS R-467 treatment compared 
with vehicle (Table 3).  
 
TABLE 3.  Effect of treatment with NPS R-467 on serum parameters in male C57BL6 micea 
 
a Control, treated with vehicle; 10 µmol/kg, treated with NPS R-467 at 10 µmol/kg BW/day; 30 µmol/kg, 
treated with NPS R-467 at 30 µmol/kg BW/day; 100 µmol/kg, treated with NPS R-467 at 100 µmol/kg 
BW/day. Data are presented as mean ± SE (n = 5). b P<0.05 versus Control. c P<0.05 versus 10 µmol/kg. 
 
Reduction in renal Ca2+ transport proteins after NPS R-467 treatment 
To address the molecular mechanism responsible for the decreased serum Ca2+ levels 
upon NPS R-467 infusion, the expression of genes encoding Ca2+ transport proteins 
involved in renal transcellular Ca2+ reabsorption was examined. TRPV5 mRNA 
expression was consistently lower in kidneys of NPS R-467-treated mice compared 
with controls (Fig. 3A), whereas no differences in the expression of TRPV6 were 
detected (Fig. 3B). Similar to TRPV5 expression, mRNA levels of both calbindin-D28K 
and -D9K were down-regulated in response to calcimimetic treatment (Fig. 3C, D). In 
addition, NPS R-467 treatment inhibited the expression of NCX1 (Fig. 3E), whereas 
PMCA1b mRNA levels were only down-regulated at 100 µmol/kg BW/day compared 
with control animals (Fig. 3F). Infusion with NPS R-467 induced a reduction in the 
expression of CaSR mRNA compared with control mice (Fig. 3G), while no 
differences were detected in the mRNA expression of VDR (Fig. 3H).   
Subsequently, the reduced mRNA levels of TRPV5 after NPS R-467 treatment were 
confirmed by immunohistochemical analysis. As shown in figure 4A, the staining 
intensity of the TRPV5 protein was remarkably reduced in kidney cortex sections of 
NPS R-467-treated mice. Figure 4B depicts the corresponding integrated optical 
density analysis and demonstrated that TRPV5 protein expression is significantly 
down-regulated. In addition, the immunoblots shown in figure 4C and 4E demonstrated 
a down-regulation of both calbindin-D28K and -D9K proteins in the NPS R-467-treated 
mice compared with controls, which was confirmed by densitometry (Fig. 4D, F).  
 
Ca2+ (mM)
Control 10 µmol/kg
PTH (pg/ml)
2.42 ± 0.02 2.34 ± 0.02
20.8 ± 2.5 14.6 ± 1.2b
30 µmol/kg
2.26 ± 0.02b
13.0 ± 0.6b
1,25(OH)2D3 (pM)
Phosphorus (mM)
309 ± 59 326 ± 14
2.07 ± 0.19 2.72 ± 0.09b
304 ± 10
2.72 ± 0.12b
100 µmol/kg
2.18 ± 0.06b,c
10.8 ± 1.2b
227 ± 27
2.71 ± 0.06b
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FIGURE 3. Effect of NPS R-467 on mRNA expression levels of genes encoding Ca2+ transport proteins in the 
kidney. Using real-time quantitative PCR, renal mRNA expression of TRPV5 (A), TRPV6 (B), calbindin-
D28K (C), calbindin-D9K (D), NCX1 (E), PMCA1b (F), CaSR (G), and VDR (H) of the different 
experimental groups were measured and presented as a ratio to HPRT expression. White bars: control mice 
treated with vehicle; Light gray bars: mice treated with NPS R-467 at 10 µmol/kg BW/day; Dark gray bars: 
mice treated with NPS R-467 at 30 µmol/kg BW/day; Black bars: mice treated with NPS R-467 at 100 
µmol/kg BW/day. Data are presented as mean ± SE (n = 5). * P<0.05 versus Control. # P<0.05 versus All. 
 
Localization of the CaSR in mouse kidney cortex 
In addition to the presence in the parathyroid glands, the CaSR is also expressed in 
kidney. In figure 5, the distribution of CaSR immunopositive staining in kidney cortex 
was compared to the TRPV5 localization. The distribution of CaSR was most abundant 
in the basolateral region of the thick ascending limb (Fig. 5A, arrowheads). 
Importantly, immunopositive staining for CaSR (Fig. 5A, asterisks and 5C) was also 
observed in TRPV5-expressing DCT and CNT (Fig. 5B, asterisks and 5D). TRPV5 
was predominantly localized along the apical domain of these segments, whereas 
CaSR-specific staining revealed a more diffuse pattern. 
 
Inhibition of PTH-stimulated transepithelial Ca2+ transport decreased calbindin-D28K 
and NCX1 expression 
To determine the molecular mechanism responsible for the regulation of the Ca2+ 
transport proteins, primary cultures of the rabbit CNT/CCD grown to confluence on 
permeable supports were employed. Figure 6A shows that in the absence of any 
stimulus, these monolayers exhibit a net apical-to-basolateral Ca2+ flux of 43 ± 2 
nmol.h-1.cm-2. Treatment with PTH (100 nM) had a stimulatory effect on 
transepithelial Ca2+ reabsorption (Fig. 6A). Apical addition of the Ca2+ channel blocker 
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ruthenium red (10 µM) completely inhibited basal transepithelial Ca2+ reabsorption and 
PTH-stimulated Ca2+ transport (Fig. 6A). Furthermore, the stimulatory effect of PTH 
on Ca2+ transport was accompanied by increased mRNA expression of TRPV5, 
calbindin-D28K and NCX1 (Fig. 6B-D). Importantly, this PTH-induced increase in 
calbindin-D28K and NCX1 mRNA expression was significantly reduced in monolayers 
cultured in the presence of ruthenium red, while the mRNA expression of TRPV5 was 
unaltered after ruthenium red treatment. Immunoblot and densitometric analysis of the 
intensity of the immunocomplexes of calbindin-D28K confirmed this decrease in 
calbindin-D28K protein expression after ruthenium red treatment using the Na+/K+-
ATPase as an internal control for equal loading (Fig. 6E, F).  
 
 
 
FIGURE 4.  
Effect of NPS R-467 on 
protein expression levels of 
TRPV5 in the kidney. 
Immunofluorescence staining 
of kidney cortex sections of 
control and treated mice 
showing the abundance of 
TRPV5 (A), which was 
quantified by computer 
analysis of the integrated 
optical density and expressed 
in relative percentages (B). 
Glomeruli (G) are depicted in 
the images. Immunoblots of 
samples (10 µg protein each) 
from homogenates of kidney 
tissue were labeled with 
antibodies against calbindin-
D28K (C) and calbindin-D9K 
(E). Expression of calbindin-
D28K and -D9K protein was 
quantified by computer-
assisted densitometry 
analysis and expressed in 
relative percentages (D and 
F). Control (open bars), mice treated with vehicle; Treated (filled bars), mice treated with NPS R-467 at 100 
µmol/kg BW/day. Data are presented as mean ± SE (n = 5). * P<0.05 versus Control. 
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FIGURE 5.  
Immunofluorescence localization of the CaSR and 
TRPV5. Double staining of a mice kidney cortex 
section showing staining for CaSR (A) and TRPV5 
(B). The asterisks indicate the tubular segments, 
where CaSR and TRPV5 co-localize. The tubules 
depicted by the arrowheads stained intensely for 
CaSR, but were negative for TRPV5. G is 
glomerulus. Colocalization of CaSR (C) and TRPV5 
(D) in DCT and CNT of kidney cortex section.  
 
 
 
FIGURE 6. Effect of PTH and ruthenium red on Ca2+ transport and expression levels of genes encoding Ca2+ 
transport proteins in primary cultures of rabbit kidney CNT/CCD. (A) Transepithelial Ca2+ transport across 
confluent monolayers was measured in the absence or presence of PTH and ruthenium red. At the end of the 
incubation period apical medium was collected to determine the amount of Ca2+ transported across the 
monolayer. Using real-time quantitative PCR, mRNA expression of TRPV5 (B), calbindin-D28K (C), and 
NCX1 (D) of the different experimental groups were measured and presented as a ratio to HPRT expression. 
(E) Western blot analysis of homogenates from rabbit CNT/CCD cultured in the absence or presence of PTH 
and ruthenium red (RR), labeled with antibodies against calbindin-D28K and Na+/K+-ATPase, as an internal 
control for equal loading. (F) Densitometric analysis of the corresponding blots. Calbindin-D28K expression 
is presented as a ratio to Na+/K+-ATPase expression in relative percentages. Control, unstimulated cells; 
PTH, cells stimulated with 100 nM PTH for 120 h; cultured in the absence (open bars) or presence (filled 
bars) of 10 µM ruthenium red. Data are presented as mean ± SE (n = 9). # P<0.05 versus All. * P<0.05 
versus Control in the presence and absence of ruthenium red.  P<0.05 versus Control in the absence of 
ruthenium red. 
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DISCUSSION 
 
The present study demonstrated that PTH stimulates renal Ca2+ reabsorption through 
the coordinated expression of transcellular Ca2+ transport proteins. Moreover, our 
results indicated that by upregulating the expression of TRPV5, the Ca2+ influx is 
increased, which in turn facilitates the regulation of the downstream Ca2+ transport 
proteins. These findings further emphasize the gatekeeper function of TRPV5. 
The available therapy for treating primary hyperparathyroidism, a disease that so far 
has resisted pharmacologic intervention, has been limited to surgical removal of the 
affected glands. Here, we showed that parathyroidectomy in rats results in marked 
reduction of serum PTH levels and hyperphosphatemia, a well-known symptom in 
hypoparathyroidism (23-25). In addition, PTX induced the concomitant decrease of 
renal mRNA and protein abundance of TRPV5, calbindin-D28K, and NCX1. As 
demonstrated by the hypercalciuria present in TRPV5 knockout mice, the decline in 
renal expression of transcellular Ca2+ transport proteins in the present experiment is 
indicative for a decreased capacity of active Ca2+ reabsorption (26) and relates to the 
development of the observed hypocalcaemia. Serum PTH levels tended to increase 
after PTH supplementation, which was apparently sufficient to restore the expression 
of the renal Ca2+ transport proteins and increase serum Ca2+ concentrations. Moreover, 
these findings imply that PTH, in concert with its well established effect on Ca2+ 
resorption from bone (27), increases renal Ca2+ reabsorption by upregulating the 
expression of TRPV5 and other Ca2+ transport proteins, thereby maintaining the Ca2+ 
balance. In agreement with this finding, PTH receptors have been detected throughout 
the kidney, as well as in the actively Ca2+ transporting tubules DCT and CNT (9). 
Thus, PTH is capable of stimulating active Ca2+ transport in kidney through receptor-
mediated actions.  
Calcimimetic compounds provide a novel non-surgical therapy for hyper-
parathyroidism by enhancing the sensitivity of the CaSR to extracellular Ca2+, thereby 
suppressing the secretion of PTH and normalizing serum Ca2+ levels (11). Studies of 
inherited disorders caused by mutations in CaSR clearly suggested that this receptor is 
the mechanism for Ca2+-mediated regulation of PTH secretion (28). To determine 
whether NPS R-467 could indeed effectively lower PTH levels and affect renal Ca2+ 
handling, mice were treated for 7 days with the calcimimetic compound NPS R-467. In 
agreement with previous findings, NPS R-467 successfully decreased serum PTH 
levels (12, 29). In addition to the suppression of PTH, serum Ca2+ concentrations were 
reduced after NPS R-467 treatment, whereas serum phosphate levels were increased. 
Interestingly, a similar concurrent down-regulation of the expression of the renal Ca2+ 
transport proteins (i.e. TRPV5, calbindin-D28K and -D9K, NCX1, and PMCA1b) was 
observed in kidneys of NPS R-467-treated mice as for the PTX rats, and indicative for 
a decreased capacity of active Ca2+ reabsorption. This finding is consistent with 
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complementary findings in other studies. A short-term use of the type II calcimimetic 
compound NPS R-568 was previously associated with an increase in urinary Ca2+ 
excretion in hypercalcaemic patients with primary hyperparathyroidism (30). Recently, 
Fox et al. showed that injections with NPS R-467 in rats increased the fractional 
excretion of Ca2+ (31).  Taken together, our findings suggested that PTH stimulates the 
coordinated expression of transcellular Ca2+ transport proteins in kidney, which could 
contribute to increased Ca2+ reabsorption and positively affect Ca2+ balance. 
Active Ca2+ reabsorption is a primary target for the regulation by calciotropic 
hormones. We have previously shown that the expression of TRPV5, as well as the 
other proteins involved in active Ca2+ transport, is positively regulated by 1,25(OH)2D3 
and other hormones, like estrogens (19, 32, 33). 1,25(OH)2D3 is synthesized primarily 
as a result of the conversion of 25-hydroxyvitamin D3 by the renal enzyme 25-
hydroxyvitamin D3-1α-hydroxylase (1αOHase). PTH is the major regulator of renal 
1αOHase (34). In turn, 1,25(OH)2D3 controls parathyroid gland growth and suppresses 
the synthesis and secretion of PTH. Moreover, 1,25(OH)2D3 and its analogues are 
frequently used as treatment for secondary hyperparathyroidism (35, 36). Therefore, 
1,25(OH)2D3 could be responsible for the observed effect on the expression of Ca2+ 
transport proteins. However, the decline in TRPV5, calbindin-D28K and -D9K and 
NCX1 expression after NPS R-467 treatment was not due to decreased levels of 
1,25(OH)2D3. In contrast, the decrease in serum PTH levels in the PTX rats did result 
in reduced 1,25(OH)2D3 levels. However, PTH supplementation did not alter serum 
1,25(OH)2D3 levels, but was sufficient to concomitantly elevate the expression of 
TRPV5, calbindin-D28K and NCX1. This supports a regulatory mechanism primarily 
controlled by PTH. However, a possible mechanism by which PTH could affect 
expression is an increased sensitivity for 1,25(OH)2D3 via elevated vitamin D receptor 
(VDR) expression. 1,25(OH)2D3 exerts its biological actions by binding to the VDR 
and the response in the target tissues to 1,25(OH)2D3 is directly related to the VDR 
abundance (34). Parathyroidectomy, PTH supplementation or NPS R-467 infusions 
did, however, not change VDR mRNA levels, suggesting that the alterations in renal 
Ca2+ transport protein expression were not associated with changes in renal VDR 
expression. Together, these findings imply that PTH stimulates renal Ca2+ reabsorption 
by upregulation of the expression of TRPV5 and other Ca2+ transport proteins, 
independently of 1,25(OH)2D3. 
In addition to the presence in parathyroid glands, the CaSR is also expressed in other 
cells involved in systemic Ca2+ homeostasis. Notable among these are certain epithelial 
cells in kidney cortex, particularly those in the cortical thick ascending limb (TAL) and 
DCT (37). Therefore, the observed effect on serum Ca2+ levels after NPS R-467 
infusion could also be explained by a direct action of the CaSR on the Ca2+ transport 
mechanisms in kidney. Immunohistochemical analysis of kidney cortex sections 
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confirmed the intense basolateral expression of CaSR in TAL. Moreover, we 
demonstrated that the CaSR is present in DCT and CNT, confirming previous 
observations (10, 37). However, the acute hypocalcaemic response to the type II 
calcimimetic compound NPS R-568 was abolished in (thyro)PTX rats infused with 
Ca2+ or PTH, suggesting that the effects of the calcimimetic compounds are totally 
dependent on the parathyroid CaSR-mediated inhibition of PTH secretion (29, 38). In 
addition, pharmacologic evidence from a study using NPS R-467 in rats suggested that 
renal CaSR contributes to the regulation of Ca2+ reabsorption by modulating the 
response to PTH rather than by affecting transport mechanisms directly (31). 
Nevertheless, in the present study, the calcimimetic compound NPS R-467 could 
directly affect serum Ca2+ levels via inhibitory actions on the renal CaSR. Remarkably, 
after NPS R-467 treatment CaSR mRNA levels were down-regulated, which could 
indeed mediate the decreased expression of Ca2+ transport proteins by directly affecting 
expression or by modulating the effect of PTH (39, 40). However, parathyroidectomy 
in rats did not change the CaSR mRNA levels, suggesting that differences in CaSR 
expression are not entirely responsible for the observed effect on renal Ca2+ transport 
proteins. In addition to abundance, the activity of the CaSR could play a role in directly 
affecting Ca2+ transporter expression. It is unlikely that CaSRs on parathyroid cells and 
kidney cells are exposed to different levels of NPS R-467. However, the cellular 
environment in which the receptor is expressed could profoundly influence its response 
to ligands. This has already been established for G protein-coupled receptors as well as 
for the different effects of calcimimetics on PTH and calcitonin secretion (38, 41). 
Studies of inherited disorders caused by mutations in CaSR clearly suggest that this 
receptor is the mechanism for Ca2+-mediated regulation of both PTH secretion and 
Ca2+ excretion by the kidney (28). However, no data are present about the physiologic 
function of the CaSR in DCT/CNT and its possible effect on Ca2+ reabsorption. Our 
findings suggest that there are additional or alternative mechanisms to account for the 
altered renal Ca2+ handling, involving PTH-mediated regulation of the expression of 
renal Ca2+ transport proteins. 
In various studies exploring the regulatory role of 1,25(OH)2D3, estrogens, PTH and 
dietary Ca2+, we observed the concomitant upregulation of Ca2+ transport proteins in 
kidney (19, 33).  Likewise, genetic ablation of TRPV5 in mouse resulted in a decreased 
expression of calbindin-D28K and NCX1. As transcellular Ca2+ reabsorption in 
DCT/CNT was abolished in these TRPV5 knockout mice, the concomitant decrease in 
Ca2+ transport proteins, even in the presence of elevated 1,25(OH)2D3 levels, suggested 
a regulatory mechanism controlled primarily by TRPV5 (26). We, therefore, 
hypothesized that the Ca2+ influx through TRPV5 predominantly controls the 
expression of the downstream Ca2+ transport proteins. To further substantiate the effect 
of PTH on Ca2+ influx, rabbit primary cell cultures were used.  These cultures retain 
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many characteristics of the original epithelium, including a net apical-to-basolateral 
Ca2+ transport and hormone responsiveness (13). In rabbit, the CNT and CCD have 
been implicated in active Ca2+ reabsorption and it has been shown that the transcellular 
Ca2+ transport proteins are all present in these cells. (5, 18, 21, 42). Using polarized 
monolayers of the rabbit CNT/CCD, we demonstrated that PTH stimulates 
transepithelial Ca2+ transport, which was accompanied by an increased expression of 
TRPV5, calbindin-D28K, and NCX1. Subsequently, the entry of Ca2+ through TRPV5 
was blocked with ruthenium red, which is a potent inhibitor of TRPV5 with an IC50 of 
around 110 nM (14). Blockage of TRPV5 by ruthenium red eliminated PTH-stimulated 
transepithelial Ca2+ transport and simultaneously decreased the expression of 
calbindin-D28K and NCX1, whereas TRPV5 expression remained unaffected. 
Apparently, there are two mechanisms that are responsible for the effect on calbindin-
D28K and NCX1 expression in the primary CNT/CCD cell monolayers. The magnitude 
of the Ca2+ influx through TRPV5 predominantly controls the expression of calbindin-
D28K and NCX1. In addition, direct stimulation by PTH results in increased expression 
of TRPV5, calbindin-D28K, and NCX1.  
Taken together, our findings imply that the magnitude of the Ca2+ influx through 
TRPV5 controls the expression of the Ca2+ transport proteins. In addition, these results 
confirm the direct effect of PTH on the expression of these renal proteins. Moreover, 
they explain the coordinated regulation of the renal Ca2+ transport proteins and further 
emphasize the gatekeeper function of TRPV5. 
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ABSTRACT 
 
Aging is associated with alterations in Ca2+ homeostasis, which predisposes elder 
people to hyperparathyroidism and osteoporosis. To examine age-related changes in 
the expression of the renal and intestinal epithelial Ca2+ channels, control (TRPV5+/+) 
and TRPV5 knockout (TRPV5-/-) mice with the age of 10, 30 and 52 weeks were 
studied. Aging of TRPV5+/+ mice increased renal Ca2+ excretion and decreased 
intestinal Ca2+ absorption, which was accompanied by reduced expression of TRPV5 
and TRPV6, respectively, despite increased serum 1,25(OH)2D3 levels. Similarly, in 
TRPV5-/- mice the existing renal Ca2+ loss was more pronounced in elder animals, 
whereas the compensatory intestinal Ca2+ absorption and TRPV6 expression declined 
with aging. In both mice strains, aging resulted in a resistance to 1,25(OH)2D3 and 
diminished renal vitamin D receptor mRNA levels, while serum Ca2+ levels remained 
constant. Furthermore, 52-weeks old TRPV5-/- mice showed severe 
hyperparathyroidism, whereas PTH levels in elder TRPV5+/+ mice remained normal. In 
52-weeks old TRPV5-/- mice, serum osteocalcin levels were increased in accordance 
with the elevated PTH levels, suggesting an increased bone turnover in these mice. In 
conclusion, down-regulation of TRPV5 and TRPV6 can explain the impaired Ca2+ 
(re)absorption during aging. Moreover, TRPV5-/- mice likely develop age-related 
hyperparathyroidism and osteoporotic characteristics prior to TRPV5+/+ mice, 
demonstrating the importance of the epithelial Ca2+ channels in Ca2+ homeostasis. 
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INTRODUCTION 
 
Regulation of the Ca2+ absorptive activity of the intestine and kidney is crucial for the 
maintenance of normal extracellular Ca2+ levels. Intestinal Ca2+ absorption and renal 
tubular reabsorption of filtered Ca2+ are modulated on the basis of the bodys overall 
need for Ca2+ gain or loss. Part of the Ca2+ (re)absorption occurs through the active 
transcellular pathway, in which luminal Ca2+ enters the epithelial cell via the apical 
(luminal) Ca2+ channels TRPV5 and TRPV6, then Ca2+ is transported across the cell in 
association with Ca2+-buffering proteins calbindin-D9K and calbindin-D28K, and finally 
Ca2+ extruded across the basolateral membrane into the bloodstream via the Na+/Ca2+-
exchanger (NCX1) and the plasma membrane Ca2+-ATPase (PMCA1b) (1-4). This 
active transport occurs in the distal convoluted tubule (DCT) and connecting tubule 
(CNT) cells of the kidney and in the enterocytes of the duodenum. Moreover, these 
active Ca2+ absorptive cells are the primary targets for regulation by calciotropic 
hormones, including 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite 
of vitamin D3, and parathyroid hormone (PTH). 
It is well known that aging is accompanied by alterations in Ca2+ homeostasis, which 
predisposes older patients to certain Ca2+-related disorders, including hyper-
parathyroidism and osteoporosis. For instance, intestinal Ca2+ absorption decreases 
with aging and in particular active transport of Ca2+ by the duodenum (5, 6). 
Furthermore, there are age-related changes in renal Ca2+ handling (7-10). Renal and 
intestinal calbindins play an important role in active Ca2+ transport, and their 
expression decreases with age in parallel with the age-related decline in Ca2+ 
(re)absorption (6, 11, 12). In addition, the capacity of 1,25(OH)2D3 to stimulate Ca2+ 
absorption reduces with age, whereas circulating levels of PTH rise in rat and man (13, 
14). Moreover, age-related increases in PTH levels may play an important role in bone 
remodeling. Bone loss occurs with aging, leading to reduced bone strength and, 
therefore, of osteoporotic fracture risk in the elderly (9, 15, 16). 
Interestingly, TRPV5 knockout (TRPV5-/-) mice display several alterations in Ca2+ 
homeostasis. For instance, they are impaired in active Ca2+ reabsorption, despite 
enhanced vitamin D levels, causing severe hypercalciuria (17). In contrast to the 
excessive renal Ca2+ wasting, intestinal TRPV6 and calbindin-D9K expression and Ca2+ 
absorption are increased, which could function as a compensatory mechanism to 
maintain a normal serum Ca2+ concentration. Furthermore, TRPV5-/- mice exhibited 
significant disturbances in bone structure, including reduced trabecular and cortical 
bone thickness (17). These findings suggest an essential role for both TRPV5 and 
TRPV6 in Ca2+ homeostasis. Moreover, dysfunction of these channels may contribute 
to disturbances in Ca2+ homeostasis and have implications for age-related changes in 
Ca2+ metabolism.  
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The present study investigated the physiological role of TRPV5 and TRPV6 in the 
aging kidney and intestine. Our results suggest that down-regulation of the renal and 
duodenal proteins involved in transcellular Ca2+ transport, including TRPV5 and 
TRPV6, are responsible for the impaired renal Ca2+ reabsorption and duodenal Ca2+ 
absorption in aging. Moreover, TRPV5-/- mice develop age-related hyper-
parathyroidism and osteoporotic characteristics earlier compared with control mice, 
demonstrating the importance of these epithelial Ca2+ channels in Ca2+ homeostasis. 
 
MATERIALS AND METHODS 
 
Animals 
TRPV5-/- mice were generated and genotyped as described previously (17). TRPV5-/- 
and wild-type mice (TRPV5+/+) were fed standard chow and given water ad libitum. 
Seven to nine littermates of both genotypes of different ages were used. At the age of 
10, 30 and 52 weeks, mice were placed in metabolic cages (Techniplast, Buguggiate, 
Italy) for 48 hours. Mice were allowed to adapt to these cages for 1 day, and then 24-
hours urine samples were collected. Mice were sacrificed and blood, kidney and 
duodenum samples were collected. The animal ethics board of the Radboud University 
Nijmegen approved all animal experimental procedures. 
 
Analytical procedures 
Serum and urine Ca2+ concentrations were analyzed using a colorimetric assay kit as 
described previously (18). Serum PTH levels were measured using mouse intact PTH 
ELISA kit (Immunotopics, San Clemente, CA, USA). Serum osteocalcin and 
1,25(OH)2D3 concentrations were determined by a radioimmunoassay (RIA) (19) and 
immunoextraction followed by quantitation by 125I-RIA (IDS, Boldon, UK) (20), 
respectively.  
 
In vivo 45Ca2+ absorption assay 
Ca2+ absorption was assessed by measuring serum 45Ca2+ at early time points after oral 
gavage. Mice were fasted overnight (12 hours) before the test. Animals were 
hemodynamically stable under anesthesia (urethane, 1.4 mg/g body weight) during the 
experiment. The solution used to measure Ca2+ absorption contained 0.1 mM CaCl2, 
125 mM NaCl, 17 mM Tris, and 1.8 g/l fructose and was enriched with 20 µCi 
45CaCl2/ml (18 Ci/g; New England Nuclear, Newton, Massachusetts, USA). For the 
oral tests, 15 µl/g body weight of this solution was administrated by gavage as 
described previously (21). Blood samples were obtained at 2, 4, 8 and 12 minutes after 
oral gavage and serum (10 µl) was analyzed by liquid scintillation counting. The 
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change in serum Ca2+ concentration (∆µM) was calculated from the 45Ca2+ content of 
the serum samples and the specific activity of the administrated 45Ca2+. 
 
RNA isolation and quantitative PCR  
Total RNA from kidney and duodenal mucosa was isolated using Trizol Reagent 
(Gibco BRL, Life Technologies, Breda, The Netherlands) according to the 
manufacturers protocol. Total DNAse-treated RNA (2 µg) was reverse-transcribed 
using Moloney murine leukemia virus reverse transcriptase (Gibco BRL) as described 
previously (22). Expression of TRPV5, TRPV6, calbindin-D28K, calbindin-D9K, NCX1, 
PMCA1b, and the vitamin D receptor (VDR) as well as mRNA levels of the 
housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT), as an 
endogenous control, were determined by quantitative real-time PCR on an ABI Prism 
7700 Sequence Detection System (PE Biosystems, Rotkreuz, Switserland). The 
following sequences for mouse VDR primers and probe were used: forward, 5-
AATGGAGATTGCCGCATCAC-3; reverse, 5-TGTCCACGCAGCGTTTGA-3; 
probe, 5-AGGACAACCGGCGACACTGCCA-3. The sequences of other target 
genes used are as described previously (23, 24). 
 
Immunohistochemistry 
Kidney tissue was cut into pieces, placed in 1% (wt/vol) periodate-lysine-
paraformaldehyde fixative for 2 h at room temperature, and incubated overnight at 4°C 
in phosphate-buffered saline containing 15% (wt/vol) sucrose. Subsequently, kidney 
tissue was frozen in liquid nitrogen and 7 µm sections were cut for the staining 
procedure. For detection of TRPV5 abundance, kidney sections were stained with 
guinea pig anti-TRPV5 antiserum (1:50) (22). To visualize TRPV5, sections were 
stained with goat anti-guinea pig Alexa 488-conjugated anti-IgG (1:300, Sigma). To 
quantify TRPV5 protein expression, digital images of the kidney sections were taken 
with a Zeiss Axioskop microscope (Thornwood, NY, USA) and the integrated optical 
density was measured by computer analysis with the Image-Pro Plus version 3.0 
software (Media Cybernetics, Silver Spring, MD, USA).  
 
Immunoblotting 
For protein analysis, frozen kidney tissue was homogenized in ice-cold solubilization 
buffer as previously described (25). Total protein fractions (10 µg) were separated on 
12% or 16.5% (wt/vol) SDS-PAGE gels and blotted to PDVF-nitrocellulose 
membranes (Immobilon-P, Millipore Corporation, Bedford, MA). Blots were incubated 
with rabbit anti-calbindin-D28K (1:10,000; (26)) and thereafter with peroxidase-
conjugated goat anti-rabbit antibody (1:2,000; Sigma). Immunoreactive protein was 
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detected using the enhanced chemiluminescence method as described by the 
manufacturer (Amersham, Buckinghamshire, UK). Protein expression was quantified 
by computer-assisted densitometry with the use of the Image-Pro Plus version 3.0 
software (Media Cybernetics). 
 
Statistical analysis 
Values are expressed as mean ± SE. Statistical significance of differences between 
groups was determined by ANOVA followed by pair-wise comparisons using the 
method of least significant difference. Differences in means with P < 0.05 were 
considered statistically significant.  
 
RESULTS 
 
TABLE 1.  Effect of age on serum parameters in TRPV5+/+ and TRPV5-/- micea 
 
a TRPV5+/+, wild-type mice; TRPV5-/-, homozygous knockout mice. Data are presented as mean ± SE (n = 7-
9). b P<0.05 versus All; c P<0.05 versus TRPV5+/+, 10-weeks old and TRPV5-/-, 10-weeks old; d P<0.05 
versus TRPV5-/- all ages; e P<0.05 versus TRPV5+/+, 30- and 52-weeks old; f P<0.05 versus TRPV5+/+ all 
ages; g P<0.05 versus TRPV5-/-, 30-weeks old.  
 
Serum parameters  
No significant differences were observed in body weight between TRPV5-/- and 
TRPV5+/+ mice. With advancing age, body weight increased significantly (Table 1).  
Serum Ca2+ concentrations were slightly elevated in TRPV5-/- mice compared with 
TRPV5+/+ mice, but did not significantly change with increasing age in both strains. In 
addition, serum PTH levels were not different between TRPV5-/- and TRPV5+/+ mice, 
except for a substantial increase in 52-weeks old TRPV5-/- mice. Circulating levels of 
1,25(OH)2D3 were significantly elevated in TRPV5-/- mice compared with TRPV5+/+ 
mice at 10 weeks of age. Interestingly, in TRPV5+/+ mice, serum 1,25(OH)2D3 
7.9 ± 1.4 23.3 ± 3.5
Osteocalcin (µg/l)
2.76 ± 0.02 2.84 ± 0.02f
25.0 ± 1.3 23.2 ± 1.1
10-weeks old
Body weight (g)
Ca2+ (mM)
PTH (pg/ml)
1,25(OH)2D3 (pM)
117 ± 4e 164 ± 10f, g
121 ± 13b 539 ± 81
+ / + - / -
24.1 ± 8.0 23.2 ± 5.6
2.70 ± 0.03d 2.82 ± 0.03
27.9 ± 1.5 27.5 ± 1.2
53 ± 3 105 ± 11e
295 ± 65d 448 ± 39
26.9 ± 5.3
2.71 ± 0.04d
36.0 ± 2.8b
51 ± 8
433 ± 76
67.1 ± 16.2b
2.79 ± 0.04
30.5 ± 1.7c
140 ± 12e, g
562 ± 50
30-weeks old 52-weeks old
+ / + - / - + / + - / -
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concentrations increased with aging, whereas in TRPV5-/- mice, levels remained 
constantly elevated (Table 1). Serum concentrations of the bone turnover marker 
osteocalcin were significantly higher in TRPV5-/- mice compared with TRPV5+/+ mice 
and decreased in both mice strains with age. Moreover, osteocalcin levels rose again in 
52-weeks old TRPV5-/- mice (Table 1).  
 
 
FIGURE 1. Effect of aging on renal Ca2+ excretion and mRNA expression levels of genes encoding renal Ca2+ 
transport proteins. (A) Total excretion of Ca2+ in 24-hours urine samples of TRPV5+/+ (filled bars) and 
TRPV5-/- (open bars) mice 10-, 30- and 52-weeks old (n = 9 mice, 3 mice per cage). Using real-time 
quantitative PCR, renal mRNA expression of TRPV5 (B), TRPV6 (C), calbindin-D28K (D), NCX1 (E), and 
VDR (F) of the different experimental groups were measured and presented as a ratio to HPRT expression (n 
= 7-9). Data are presented as mean ± SE. * P<0.05 versus All; # P<0.05 versus TRPV5+/+;  P<0.05 versus 
TRPV5-/-;  P<0.05 versus TRPV5+/+, 10-weeks old. 
 
Aging results in increased renal Ca2+ excretion and decreased expression of Ca2+ 
transport proteins 
To investigate the effect of aging on renal Ca2+ handling, mice were placed in 
metabolic cages and 24-hours urine samples were collected to determine the amount of 
Ca2+ excretion. Urinary Ca2+ loss in TRPV5-/- mice was significantly higher compared 
with TRPV5+/+ mice. Moreover, Ca2+ excretion increased during aging. Likewise, in 
TRPV5+/+ mice there was a tendency of elevated Ca2+ excretion with increasing age 
(Fig. 1A). Furthermore, the expression of genes encoding the Ca2+ transport proteins 
involved in transcellular Ca2+ reabsorption was examined using quantitative real-time 
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PCR. In TRPV5+/+ mice, a decline in TRPV5 mRNA expression was observed with 
increasing age (Fig. 1B). In addition, a similar reduction in calbindin-D28K expression 
was detected in TRPV5+/+ mice during aging, whereas the expression was significantly 
decreased in TRPV5-/- mice independent of age (Fig. 1D). Expression of the extrusion 
protein NCX1 was also lower in TRPV5-/- mice, but no changes were measured in 
either TRPV5-/- or TRPV5+/+ mice with increasing age (Fig. 1E). No differences in 
TRPV6 mRNA expression were observed between TRPV5-/- and TRPV5+/+ or with 
aging, except for a remarkable upregulation in 52-weeks old TRPV5-/- mice (Fig. 1C).  
Furthermore, VDR mRNA levels were significantly lower in TRPV5-/- mice compared 
with TRPV5+/+ mice. During aging, expression of VDR was decreased in both groups 
of mice (Fig. 1F).  
 
 
 
FIGURE 2. Effect of aging on protein expression levels of TRPV5 and calbindin-D28K in kidney. 
Immunofluorescence staining of kidney cortex sections of TRPV5+/+ mice of different ages showing the 
abundance of TRPV5 (A), which was quantified by computer analysis of the integrated optical density and 
expressed in relative percentages (B). Immunoblots of samples (10 µg protein each) from homogenates of 
kidney tissue were labeled with antibodies against calbindin-D28K (C). Abundance of calbindin-D28K protein 
was quantified by computer-assisted densitometry analysis and expressed in relative percentages (D). Filled 
bars: TRPV5+/+; Open bars: TRPV5-/- mice. Data are presented as mean ± SE (n = 7-9). * P<0.05 versus All; 
 P<0.05 versus TRPV5-/-. 
 
Subsequently, examination of renal Ca2+ transport protein expression by 
immunohistochemistry revealed a marked decrease of TRPV5 protein abundance with 
increasing age, as indicated by the reduced immunopositive staining (Fig. 2A). The 
corresponding integrated optical density analysis confirmed a significant decline in 
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TRPV5 protein abundance (Fig. 2B). Furthermore, Western blot analysis of calbindin-
D28K demonstrated decreased protein abundance in TRPV5-/- mice compared with 
TRPV5+/+ mice. In addition, a down-regulation of the calbindin-D28K abundance in 52-
weeks old TRPV5+/+ mice was observed compared with younger wild-type animals 
(Fig. 2C). Densitometric analysis of the intensity of the immunocomplexes confirmed 
this decrease in calbindin-D28K protein expression with age in TRPV5+/+ mice (Fig. 
2D).  
 
 
 
FIGURE 3. Effect of aging on intestinal Ca2+ absorption and mRNA expression levels of genes encoding 
duodenal Ca2+ transport proteins. (A) Changes in serum Ca2+ within 12 min after 45Ca2+ administration by 
oral gavage in TRPV5+/+ (gray line) and TRPV5-/- (black line) mice 10-weeks old. ∆µM is obtained by the 
equation: (cpm 10 µl serum/cpm 10 µl stock solution) × 102 µM. (B) Comparison of the change in serum 
Ca2+ (∆µM) at 4 min after 45Ca2+ administration by oral gavage between TRPV5+/+ (filled bars) and TRPV5-/- 
(open bars) mice 10-, 30- and 52-weeks old. Using real-time quantitative PCR, duodenal mRNA expression 
of TRPV6 (C), calbindin-D9K (D), PMCA1b (E), and VDR (F) of the different experimental groups were 
measured and presented as a ratio to HPRT expression. Data are presented as mean ± SE (n = 7-9). * P<0.05 
versus All; # P<0.05 versus TRPV5+/+;  P<0.05 versus TRPV5+/+, 30-weeks old;  P<0.05 versus TRPV5+/+, 
52-weeks old; ╫ P<0.05 versus TRPV5-/-, 10- and 30- weeks old. 
 
Aging results in reduced Ca2+ absorption and duodenal expression of Ca2+ transport 
proteins 
Following renal analysis, the effect of aging on intestinal Ca2+ absorption was 
examined. Although the 45Ca2+ absorption rate in TRPV5-/- mice was significantly 
higher compared with TRPV5+/+ littermates (Fig. 3A), aging reduced the amount of 
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45Ca2+ absorbed in both mice strains as shown by the peak 45Ca2+ absorption values at 4 
minutes after oral gavage of mice from different ages (Fig. 3B). To address the 
molecular mechanism responsible for the decreased absorption, the expression of genes 
encoding proteins involved in intestinal Ca2+ absorption was examined. The expression 
of TRPV6 and calbindin-D9K mRNA was significantly upregulated in TRPV5-/- mice 
(Fig. 3C, D). Moreover, aging resulted in a decline of TRPV6 levels in both mice 
strains (Fig. 3C), whereas no changes were observed in the expression of calbindin-D9K 
(Fig. 3D). PMCA1b mRNA levels decreased with age in TRPV5+/+ mice, whereas no 
significant changes were present in the expression of PMCA1b in TRPV5-/- mice with 
increasing age (Fig. 3E). In addition, no significant changes in the expression of 
duodenal VDR were observed during aging in TRPV5+/+ or TRPV5-/- mice (Fig. 3F).  
 
DISCUSSION 
 
The present study demonstrated that an age-related decrease in the expression of the 
key-players responsible for active Ca2+ transport, including TRPV5 and TRPV6, 
contributes to the decline in intestinal and renal Ca2+ (re)absorption with aging. 
Furthermore, our results indicated that mice lacking TRPV5 develop severe hyper-
parathyroidism with aging, suggesting that these mice are more susceptible to age-
related osteoporosis.   
A significant increase in the rate of Ca2+ absorption was observed in TRPV5-/- mice 
compared with their wild-type littermates, which was accompanied by an upregulation 
of duodenal TRPV6 and calbindin-D9K expression. Importantly, despite the renal Ca2+ 
wasting in TRPV5-/- mice, serum Ca2+ levels remained normal and were even slightly 
increased compared with TRPV5+/+ mice. As suggested previously, the increased 
duodenal expression of TRPV6 and calbindin-D9K, thereby increasing Ca2+ absorption, 
could act as a compensatory mechanism triggered by the elevated 1,25(OH)2D3 levels 
in TRPV5-/- mice (17). The slightly elevated serum Ca2+ levels in these knockout mice 
could be due to an overcompensation by 1,25(OH)2D3 and intestinal Ca2+ absorption to 
correct renal Ca2+ loss (27, 28). Moreover, aging was associated with a decline in 
duodenal Ca2+ absorption in both mice strains. In addition, the expression of duodenal 
TRPV6 in TRPV5-/- and TRPV5+/+ mice as well as PMCA1b in TRPV5+/+ mice was 
significantly reduced with age. Previous studies in rats and humans also showed a 
reduction in intestinal Ca2+ absorption as well as a decline in the expression of the Ca2+ 
transporting proteins (29-31). Our results imply that TRPV6 is crucial for duodenal 
Ca2+ absorption and that the decline in expression of this protein is the main cause of 
the decrease in duodenal Ca2+ absorption with aging. 
In kidney of TRPV5+/+ mice, expression of TRPV5 and calbindin-D28K mRNA 
decreased during aging. Previous studies demonstrated a reduction in renal calbindin-
D28K expression with increasing age (11, 12). Decreased expression of TRPV5 and 
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calbindin-D28K could lead to a reduced Ca2+ reabsorption ability resulting in 
hypercalciuria, as shown in the TRPV5-/- mice and described previously (17, 32). 
These results suggest that TRPV5 is a key component in renal Ca2+ reabsorption. In 
accordance with the decreased expression of TRPV5, a tendency towards increased 
urinary Ca2+ excretion was observed in the aging TRPV5+/+ mice. Although the 
hypercalciuria is even more pronounced in elder TRPV5-/- mice, no further decline in 
the expression of the Ca2+ transporting proteins is observed with increasing age.  
Aging in TRPV5+/+ mice was accompanied by increasing serum 1,25(OH)2D3 levels, 
while no differences were observed in aging TRPV5-/- mice. This latter finding could 
be explained by the fact that 1,25(OH)2D3 in these knockout mice is already maximally 
elevated. 1,25(OH)2D3 is a known stimulator of intestinal and renal Ca2+ (re)absorption 
and upregulates the expression of proteins involved in active Ca2+ transport, including 
TRPV5 and TRPV6 (24, 33, 34). Therefore, the decline in the expression of the Ca2+ 
transporting proteins shown in our study suggests that there is a decrease in vitamin D 
sensitivity. Indeed, VDR mRNA levels in kidney of both TRPV5+/+ and TRPV5-/- mice 
gradually decrease with age, suggesting that the kidney develops a refractoriness to 
1,25(OH)2D3 levels. Evidently, Li et al. showed that VDR knockout mice have 
impaired Ca2+ conservation capability in the kidney, despite increased serum 
1,25(OH)2D3 levels (35). Furthermore, intestinal Ca2+ absorption as well as expression 
of duodenal TRPV6 is decreased in VDR knockout mice (21). However, no significant 
differences were found in duodenal VDR mRNA levels during aging in both TRPV5+/+ 
and TRPV5-/- mice. Although several reports described a decrease in intestinal VDR 
expression (36, 37), other studies showed that receptor occupancy was reduced in elder 
rats (38). Our findings indicate an age-related intestinal resistance to the action of 
1,25(OH)2D3, which is apparently not due to a reduction in duodenal VDR mRNA 
levels, thereby resulting in the decline of TRPV6 expression and Ca2+ absorption with 
aging.  
Interestingly, aging of TRPV5+/+ was not associated with a change in serum PTH 
levels, whereas 52-weeks old TRPV5-/- mice show severe hyperparathyroidism. In 
addition to 1,25(OH)2D3, PTH is involved in renal and intestinal Ca2+ reabsorption (39-
41). Moreover, recent findings by our group show that PTH stimulates the expression 
of renal TRPV5, calbindin-D28K and NCX1 (32). Although serum PTH levels remained 
constant or increased, renal Ca2+ reabsorption and intestinal Ca2+ absorption declined 
with age. This would be compatible with a mechanism of desensitization as has been 
described in previous reports, which demonstrated the blunting of PTH-mediated 
signal transduction pathways as well as loss of renal and intestinal PTH receptors (42-
45). Moreover, the elevated PTH levels in elder TRPV5-/- mice have also been found in 
humans and may play an important role in age-related bone loss or senile osteoporosis 
(9, 15, 46). Indeed, the relatively constant levels of serum Ca2+ and the decline in renal 
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and intestinal Ca2+ (re)absorption in aged animals observed in the present study, may 
suggest that bone resorption increases with aging. Osteocalcin levels in TRPV5-/- mice 
are significantly elevated compared to TRPV5+/+ mice, suggestive for increased bone 
turnover, which could be the result of the reduced bone thickness in TRPV5-/- mice 
described previously (17). After the decline in osteocalcin levels in both mice strains, 
which is probably due to the lower need of bone formation and turnover to build the 
skeleton in adult animals, serum osteocalcin levels increased in 52-weeks old TRPV5-/- 
mice in accordance with the elevation of serum PTH. PTH indirectly activates 
osteoclasts and modifies the phenotype of the osteoblast from a cell involved in bone 
formation to a cell directing bone resorption (47, 48). Thus, the age-associated 
hyperparathyroidism in TRPV5-/- could lead to increased bone turnover, thereby 
resulting in net bone loss and aggravating the existing reduction in bone volume. 
In summary, the present findings demonstrated a decline in renal and intestinal Ca2+ 
(re)absorption through TRPV5 and TRPV6 during aging, which is of physiological 
significance in understanding the imbalance in mineral metabolism associated with 
aging. Moreover, TRPV5-/- mice likely develop age-related hyperparathyroidism and 
osteoporotic characteristics earlier compared with TRPV5+/+ mice, corroborating the 
importance of the epithelial Ca2+ channels in Ca2+ homeostasis. 
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INTRODUCTION 
 
Ca2+ play a fundamental role in many cellular processes and its extracellular 
concentration is kept under strict control by the concerted actions of kidney, intestine 
and bone to allow proper physiological functions. The first step in active, transcellular 
Ca2+ transport is the influx of Ca2+ across the apical plasma membrane. Inside the cell, 
Ca2+ is bound to specialized proteins, called calbindins, to maintain low intracellular 
Ca2+ concentrations. Bound Ca2+ subsequently diffuses to the basolateral side of the 
cell, where it is extruded into the bloodstream via the Na+/Ca2+-exchanger (NCX1) 
and/or Ca2+-ATPase (PMCA1b). The epithelial Ca2+ channels TRPV5 and TRPV6 
represent a new family of Ca2+ channels, which belong to the superfamily of transient 
receptor potential channels, and constitute the apical Ca2+ entry mechanism in active 
Ca2+ transport in kidney and intestine. The central role of TRPV5 and TRPV6 in active 
Ca2+ (re)absorption makes it a prime target for regulation to maintain Ca2+ balance.  
  
REGULATION OF TRPV5 AND TRPV6 
 
A tight control of the amount of active Ca2+ transport is of utmost importance to 
maintain the extracellular Ca2+ balance. Various calciotropic hormones are known to 
be involved in the regulation of Ca2+ homeostasis. The effect of several of these 
hormones on the renal and intestinal TRPV5 and TRPV6 expression have been 
investigated as described in this thesis (see Table 1).  
 
Estrogen 
In chapter 2 and 4, estrogen was identified as one of the hormones regulating TRPV5 
and TRPV6 expression. In ovariectomized rats, 17β-estradiol replacement therapy 
resulted in upregulation of renal TRPV5 mRNA and protein levels (chapter 2). In 
addition, in duodenum of estrogen treated rats, both TRPV5 and TRPV6 mRNA levels 
were increased (chapter 4). Similarly, in 25-hydroxyvitamin D3-1α-hydroxylase 
(1αOHase) knockout mice, which are unable to synthesize the active metabolite of 
vitamin D, estrogen supplementation resulted in increased expression of  renal TRPV5 
(chapter 2) and duodenal TRPV6 (chapter 4) and partially restored serum Ca2+ 
concentrations. Thus, TRPV5 and TRPV6 expression is transcriptionally controlled by 
estrogen in a vitamin D-independent manner. A study by Van Cromphaut et al. 
substantiated the role of estrogen in the regulation of TRPV5 and TRPV6 (1). Here, 
renal TRPV5 and duodenal TRPV6 expression were reduced in estrogen receptor α 
(ERα) knockout mice and upregulated by estrogen treatment. In contrast, no 
differences in the expression of TRPV5 or TRPV6 were observed in ERβ knockout 
mice and, therefore, the estrogen effects seem to be solely mediated by ERα (1). 
Interestingly, Weber et al. (2) described an estrogen response element in the promoter 
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sequence of the mouse TRPV6 gene, which was absent in the mouse TRPV5 gene. 
Alternatively, transcriptional activation by the estrogen-liganded ER can be mediated 
through other elements, like activator protein 1 (AP-1) or GC-rich stimulatory protein 
(Sp1) binding sites (3, 4). Several of these AP-1 and Sp1 sites are present in the human 
and mouse TRPV5 promoter and could be involved in the positive effect of estrogen on 
TRPV5 expression (5). Taken together, these data suggest that the function of estrogen 
in the maintenance of Ca2+ balance is at least in part fulfilled by controlling 
(re)absorption of the amount of Ca2+ through the regulation of TRPV5 and TRPV6. 
 
TABLE 1.   Hormonal regulation of TRPV5 and TRPV6  
 
OVX, ovariectomized; 1αOHase-/-, 1α-hydroxylase knockout mice; PTX, parathyroidectomized; PTH, 
parathyroid hormone; CaSR, Ca2+-sensing receptor; ↑, up-regulation; ↓, down-regulation; ND, not detectable; 
?, not determined; =, not changed 
 
Vitamin D 
The first evidence for a vitamin D-sensitivity of the epithelial Ca2+ channels TRPV5 
and TRPV6 was obtained from in vivo studies in which rats were depleted for vitamin 
D3. The reduced renal TRPV5 expression and accompanied hypocalcemia were 
completely restored after 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) supplementation 
(6). Subsequently, a correlation between the 1,25(OH)2D3-induced expression of 
TRPV6, calbindin-D9K, and PMCA1b and transcellular Ca2+ transport was established 
in Caco-2 cells, which are used as a human intestinal cell model (7, 8). In addition, 
several genetically modified mouse models, in which the vitamin D system has been 
inactivated, were created to further elucidate the vitamin D-dependent regulation of 
these Ca2+ transport proteins and their functional consequence on transcellular Ca2+ 
transport. St-Arnaud and co-workers (9) generated the 1αOHase knockout mice that 
represent a unique animal model for vitamin D-deficiency rickets type I (VDDR-I), 
Chapter 5??=↓CaSR agonist, NPS R-467
Chapter 5??=↑PTX rats + PTH
Chapter 5??=↓PTX rats
Chapter 3 and 4↑ND?↑1αOHase-/- + dietary Ca2+
Chapter 3 and 4↑↑?↑1αOHase-/- + vitamin D
Chapter 2 and 4↑ND?↑1αOHase-/- + estrogen
Chapter 3 and 4 ↓ND?↓1αOHase-/-
Chapter 2 and 4↑↑?↑OVX rats + estrogen
TRPV6TRPV5TRPV6TRPV5
ReferenceDuodenumKidney
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since these mice display undetectable 1,25(OH)2D3 concentrations, hypocalcemia, 
secondary hyperparathyroidism, osteomalacia and rickets. In chapter 3 and 4 these 
mice were used to investigate the regulation of Ca2+ transport proteins in kidney and 
intestine, respectively, and their role in maintaining the Ca2+ balance. The 
hypocalcemia in these mice was accompanied by reduced expression of TRPV5, 
calbindin-D28K and -D9K, and NCX1 in kidney and down-regulation of duodenal 
TRPV6, calbindin-D9K and PMCA1b. Repletion with 1,25(OH)2D3 was associated with 
restoration of expression levels of renal (chapter 3) and duodenal (chapter 4) Ca2+ 
transporters and normalization of serum Ca2+ concentrations, confirming the essential 
role of these proteins in active 1,25(OH)2D3-mediated Ca2+ (re)absorption. Similar 
observations were made from experiments performed with vitamin D receptor (VDR) 
knockout mice (2, 10). In these hypocalcemic mice, renal TRPV5 as well as duodenal 
TRPV6 expression levels are reduced. Analysis of putative promoter regions of human 
and murine TRPV5/6 genes revealed potential vitamin D response elements in line 
with the previously observed functional data (2, 5, 6). Together these findings indicate 
that the expression of TRPV5 and TRPV6 is indeed controlled by 1,25(OH)2D3.  
 
Dietary Ca2+ 
Several aforementioned studies provide evidence that the TRPV5 and TRPV6 channels 
are regulated by 1,25(OH)2D3, however, it is difficult to distinguish the effects of 
hypocalcemia from those of vitamin D-deficiency. Moreover, high dietary Ca2+ has 
been implicated in reducing the risk of osteoporosis and as treatment for patients with 
VDDR to prevent rickets and hyperparathyroidism. As described in chapter 3 and 4, 
high dietary Ca2+ indeed resulted in the rescue of several phenotypes of the 1αOHase 
knockout mice, including the hypocalcemia. Interestingly, dietary Ca2+ enrichment, 
which down-regulated renal TRPV5 expression in wild-type mice, resulted in an up-
regulation of renal TRPV5 and other Ca2+ transport proteins participating in active Ca2+ 
reabsorption in the knockout mice (chapter 3). Likewise, expression of the intestinal 
Ca2+ transport proteins, TRPV6, calbindin-D9K, and PMCA1b were increased upon 
high dietary Ca2+ treatment in the 1αOHase knockout mice (chapter 4).  In addition, 
high dietary Ca2+ intake in VDR knockout mice normalized serum Ca2+ concentrations. 
However, this was accompanied by reduced expression of duodenal TRPV5 and 
TRPV6 and decreased serum 1,25(OH)2D3 levels (10). VDR-independent effect of 
1,25(OH)2D3 has been described previously in both kidney and intestine (11-13). It is 
conceivable that the 1,25(OH)2D3-mediated nongenomic pathways influence the 
expression of TRPV5 and TRPV6 and Ca2+ (re)absorption, thereby explaining the 
differences between 1αOHase and VDR knockout mice after high dietary Ca2+ (chapter 
3 and 4). Together, these findings demonstrate the vitamin D-independent regulation of 
Ca2+ transport proteins, including TRPV5 and TRPV6, by dietary Ca2+. However, the 
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molecular mechanism of this vitamin D-independent Ca2+-sensitive pathway remains 
elusive. 
 
Parathyroid hormone  
Chapter 5 demonstrates the regulation of the epithelial Ca2+ channels by parathyroid 
hormone (PTH). Here, parathyroidectomy in rats resulted in decreased serum PTH 
levels and hypocalcemia, which was accompanied by decreased levels of renal TRPV5, 
calbindin-D28K, and NCX1. Supplementation with PTH restored serum Ca2+ 
concentrations and abundance of these Ca2+ transporters in kidney, without affecting 
serum 1,25(OH)2D3 levels or renal VDR mRNA levels (chapter 5). In addition, PTH 
stimulated transepithelial Ca2+ transport and increased the expression of TRPV5, 
calbindin-D28K, and NCX1 in polarized monolayers of a rabbit primary connecting 
tubule/cortical collecting duct (CNT/CCD) cell culture, confirming the direct effect of 
PTH on the expression of these renal proteins (chapter 5). Furthermore, PTH secretion 
by the parathyroid glands is regulated by the Ca2+-sensing receptor (CaSR), which 
forms a unique molecular target for drugs or compounds that can directly alter the 
activity of the receptor, thereby manipulating PTH secretion and extracellular Ca2+ 
balance (14, 15). As described in chapter 5, treatment of mice with the calcimimetic 
compound NPS R-467 reduced serum PTH levels in a dose-dependent manner, which 
was accompanied by a significant decrease in serum Ca2+ concentration. Moreover, 
analysis of renal samples demonstrated an overall downregulation of mRNA 
expression levels and proteins involved in active transcellular Ca2+ reabsorption, 
including TRPV5 (chapter 5). TRPV5 and CaSR are present in the same cells along the 
distal convoluted tubule and connecting tubule (DCT/CNT) and, therefore, the effects 
of NPS R-467 on the expression of Ca2+ transporters could involve a direct action of 
CaSRs in kidney. However, at present no data is available about the physiological 
function of the CaSR in DCT/CNT and its possible effect on Ca2+ reabsorption. 
Moreover, previous studies have indicated that the effect of calcimimetic compounds 
results from the inhibition of PTH secretion or by modulating the response to PTH 
rather than by affecting transport mechanisms directly (16, 17). Overall, these data 
suggest that PTH is positively involved in renal Ca2+ reabsorption by upregulation of 
the expression of TRPV5 and other Ca2+ transport proteins.  
 
COORDINATED REGULATION OF CA2+ TRANSPORT PROTEINS 
 
In the various studies described in this thesis, exploring the regulatory role of estrogens 
(chapter 2 and 4) 1,25(OH)2D3 and dietary Ca2+ (chapter 3 and 4), and PTH (chapter 
5), the expression of the proteins involved in active Ca2+ (re)absorption was regulated 
in a coordinated fashion. Likewise, genetic ablation of TRPV5 in mice resulted in a 
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decreased expression of calbindin-D28K and NCX1, even in the presence of elevated 
1,25(OH)2D3 levels (18). These findings suggest a regulatory mechanism controlled by 
the Ca2+-influx channels. Evidence for a coordinated regulation of the Ca2+ transport 
proteins mediated by TRPV5 is provided in chapter 5. In polarized monolayers of 
rabbit CNT/CCD, blockage of Ca2+ influx through TRPV5 by ruthenium red 
eliminated PTH-stimulated transepithelial Ca2+ transport and simultaneously decreased 
the expression of calbindin-D28K and NCX1, whereas TRPV5 expression remained 
unaffected. Thus, the Ca2+ influx through TRPV5 controls the expression of the 
downstream Ca2+ transport proteins, which further emphasizes the gatekeeper function 
of TRPV5 (chapter 5). Moreover, the activity of the epithelial Ca2+ channels TRPV5 
and TRPV6 is tightly controlled by the intracellular Ca2+ concentration (19, 20). By the 
concomitant upregulation of the buffering and extrusion mechanisms, intracellular Ca2+ 
levels remain low, thereby controlling the Ca2+-dependent feedback inhibition of 
TRPV5 and TRPV6 channel activity. In this way, the concerted regulation of TRPV5/6 
and the other Ca2+-transporting proteins facilitates Ca2+ (re)absorption and guarantees 
sufficient capacity during high transport rates. 
 
REGULATION OF TRPV5 AND TRPV6 BY ASSOCIATED PROTEINS 
 
TRPV5 and TRPV6 are constitutively active, unlike many other TRP channels that are 
activated by binding of ligands (21). This implies that in order to regulate TRPV5/6 
activity, short-term acting mechanisms must exist to control the activity of these 
channels located on the plasma membrane. A number of regulatory proteins have been 
identified that modify the biophysical, pharmacological, and expression properties of 
TRPV5 and TRPV6 by direct interactions (see Table 2). 
 
S100A10-annexin 2 complex 
The S100A10-annexin 2 complex plays an important role in biological processes 
including endocytosis, exocytosis and membrane-cytoskeletal interactions (22). 
Recently, we demonstrated a regulatory role for the S100A10-annexin 2 complex in 
the trafficking of TRPV5 and TRPV6 (23). S100A10 and annexin 2 were present along 
the apical membrane of TRPV5-expressing tubules and along the brush-border 
membrane of duodenum, which is in agreement with the TRPV6 localization. 
Moreover, disruption of the S100A10-binding motif in TRPV5 or TRPV6 (Table 2) 
prevented the facilitation of Ca2+ inward currents, which was accompanied by a major 
disturbance in their subcellular localization (23). Importantly, down-regulation of 
annexin 2 using annexin 2-specific siRNAs significantly inhibited the currents through 
TRPV5, indicating that annexin 2 in conjunction with S100A10 is crucial for TRPV5 
activity (23). Interestingly, S100A10 and annexin 2 are co-regulated by 1,25(OH)2D3 
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in a similar fashion as TRPV5 (23). These results clearly show that the S100A10-
annexin 2 complex is a significant component for the trafficking of the epithelial Ca2+ 
channels towards the plasma membrane and, therefore, the functionality of these 
channels. 
 
TABLE 2.  Binding domains in TRPV5 and TRPV6 of various interacting proteins 
 
Several regulatory proteins have been identified that modify the activity and expression of TRPV5 and 
TRPV6 by direct interactions. Presented are amino acid sequences and motifs of binding domains in TRPV5 
and TRPV6 of these associated proteins.  
 
NHERF2 
The Na+/H+-exchanger regulating factors, NHERF1 or NHERF2, are PDZ domain 
containing proteins. PDZ motifs, which are also present in TRPV5 and TRPV6, are 
recognized by PDZ domains, which are modular protein interaction domains that play 
a role in protein targeting and protein complex assembly (24).  NHERF1 and NHERF2 
have been shown to modulate the targeting and trafficking of several renal proteins, 
like the epithelial Na+/H+-exchanger NHE3 and epithelial K+ channel ROMK1, as well 
as members of the TRP superfamily (25-27). Recently, a study by Embark et al. 
showed that co-expression of TRPV5 with NHERF2 and the serum and glucocorticoid 
inducible kinases SGK1 and SGK3 in Xenopus laevis oocytes increased cell surface 
TRPV5 abundance and activity (28). Furthermore, it was demonstrated that NHERF2 
binds to the C-terminal end of TRPV5 (Table 2) and its second PDZ domain is 
required for the stimulating effect of SGK1/NHERF2 on TRPV5 activity and 
abundance at the plasma membrane (29).   
35MLERK 
mouse, 596-601
80K-H
331-8-14 motif 
mouse, 649-667
TM-domain 
mouse, 327-577
1-5-10 motif 
mouse, 93-103
rabbit, 578-730rabbit, 1-327
31C-tail motif 
human, 694-725
Calmodulin
29YHF
rabbit, 728-730
NHERF2
23VATTV 
rabbit, 597-601
VATTV 
rabbit, 598-602
S100A10
C-tailTransmembraneN-tailC-tailN-tail
Ref.TRPV6TRPV5
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Calmodulin 
Calmodulin (CaM) is a ubiquitous protein, which is known to play a pivotal role in the 
Ca2+-dependent feedback regulation of several ion channels, acting as a Ca2+ sensor 
(30). Niemeyer et al. showed for the first time that CaM binds to the C-terminus of 
human TRPV6 in a Ca2+-dependent manner (Table 2) (31). Binding of CaM was 
prevented by PKC-mediated phosphorylation of a threonine residue within the CaM 
binding-site. However, the described mechanism of competitive regulation of TRPV6 
activity by PKC and CaM is restricted to human TRPV6, since the PKC site in the 
CaM binding-site is not conserved in other species (32).  The regulation of TRPV6 
activity by CaM was recently confirmed by Lambers and coworkers (33). In their 
study, CaM was shown to bind to the C- and N- tails of both TRPV5 and TRPV6 as 
well as the transmembrane domain of TRPV6 in a Ca2+-dependent fashion (Table 2) 
(33). Furthermore, electrophysiological measurements of HEK293 cells heterologously 
co-expressing Ca2+-insensitive CaM mutants and TRPV6 revealed a significantly 
reduced inward Ca2+ current. Moreover, the high affinity EF-hand Ca2+-binding sites of 
CaM were demonstrated to contribute primarily to the observed CaM effect upon 
TRPV6 activity (33). Remarkable is the finding that CaM mutants had no effect on 
currents of TRPV5-expressing cells, despite the high homology between TRPV5 and 
TRPV6, similar Ca2+-dependent regulation of channel activity and binding of CaM to 
both channels. Taken together, these results suggest that CaM positively affects 
TRPV6 activity. 
 
80K-H 
80K-H was initially identified as a PKC substrate and subsequently associated with 
intracellular signaling (34). A study by Gkika et al. demonstrated a functional role for 
80K-H in the Ca2+-dependent regulation of TRPV5 channel activity (35). 80K-H and 
TRPV5 co-localized in 1,25(OH)2D3-responsive epithelia and showed a similar 
transcriptional regulation by 1,25(OH)2D3 and dietary Ca2+.  The specific interaction of 
80K-H with TRPV5 resides in the C-terminal tail of TRPV5, corresponding to the 
amino acid sequence MLERK (Table 2). Furthermore, inactivation of the two EF-hand 
Ca2+-binding structures in 80K-H reduced the TRPV5-mediated Ca2+ current and 
increased TRPV5 sensitivity to intracellular Ca2+, accelerating the feedback inhibition 
of channel activity. The membrane localization of 80K-H and TRPV5 was not altered, 
suggesting that 80K-H has a direct effect on TRPV5 activity (35). Therefore, it was 
hypothesized that 80K-H acts as a novel Ca2+ sensor, facilitating the Ca2+ influx 
through TRPV5.  
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TRPV5 AND TRPV6 IN DISEASE 
 
Recently, a study by Hoenderop et al. demonstrated that ablation of the TRPV5 gene in 
mice seriously disturbed renal Ca2+ handling, which was localized primarily to the 
DCT/CNT, causing increased serum 1,25(OH)2D3 levels, intestinal Ca2+ 
hyperabsorption and bone abnormalities (18). In addition, preliminary results of studies 
using TRPV6 knockout mice showed a defect in intestinal Ca2+ absorption, despite 
increased serum 1,25(OH)2D3 levels, deficient renal reabsorption and decreased bone 
mineral density (36). These animal models clearly show that alterations in TRPV5 and 
TRPV6 have severe implications for proper renal and intestinal Ca2+ (re)absorption and 
bone development. A role for TRPV5 and TRPV6 has, therefore, been considered in 
diverse Ca2+-related disorders, including variation in the urinary Ca2+ excretion during 
treatment with pharmaceutical agents. 
 
Aging 
Aging has important negative effects on Ca2+ balance. Age-related changes in renal 
Ca2+ handling, intestinal Ca2+ malabsorption and resistance to 1,25(OH)2D3 result in 
the development of hyperparathyroidism and ultimately senile osteoporosis (37). In 
chapter 6, the effect of aging on the expression of renal and intestinal TRPV5 and 
TRPV6 was investigated. Aging of wild-type mice resulted in decreased expression of 
renal TRPV5 and calbindin-D28K, in accordance with reduced Ca2+ reabsorption 
capability. Despite increased serum 1,25(OH)2D3 levels, aging caused a decline in 
duodenal TRPV6 and PMCA1b expression, which was associated with reduced 
intestinal Ca2+ absorption. Similar results were obtained in aging TRPV5 knockout 
mice, in which the existing renal Ca2+ loss was more pronounced in elder animals and 
the compensatory intestinal Ca2+ absorption and duodenal TRPV6 expression declined 
with aging (chapter 6). Different from the wild-type mice, aging TRPV5 knockout 
mice developed a severe hyperparathyroidism, indicating that these TRPV5-deficient 
mice are more susceptible to age-related osteoporosis, thereby demonstrating the 
importance of the epithelial Ca2+ channels in Ca2+ homeostasis (chapter 6). Taken 
together, these findings suggest that down-regulation of the key players responsible for 
active Ca2+ transport, including TRPV5 and TRPV6, contributes to the impaired 
intestinal and renal Ca2+ (re)absorption associated with aging. 
 
Estrogens and postmenopausal osteoporosis 
The deleterious effects of estrogen deficiency after menopause lead to a negative Ca2+ 
balance associated with renal Ca2+ loss, intestinal Ca2+ malabsorption and post-
menopausal osteoporosis, which can be corrected by estrogen replacement therapy (38-
41). In addition, estrogen has been implicated in the protection against Ca2+ 
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nephrolithiasis via an increased reabsorption of Ca2+. In premenopausal women, kidney 
stone formation is less common than in age-matched men, which is associated with a 
lower urinary Ca2+ excretion (42, 43). As shown in chapter 2 and 4, estrogen has a 
stimulatory effect on the expression of active Ca2+ transport proteins in both kidney 
and duodenum, including TRPV5 and TRPV6. Thus, the presence of estrogen may 
protect premenopausal women against Ca2+ nephrolithiasis by increasing TRPV5 
expression and stimulating Ca2+ reabsorption. Conversely, decreased active Ca2+ 
transport through TRPV5 and TRPV6 as a result of estrogen deficiency would be in 
line with increased Ca2+ wasting and Ca2+ malabsorption in postmenopausal women. 
 
Vitamin D-deficiency rickets 
Vitamin D-deficiency rickets type I (VDDR-I) is an autosomal recessive disease 
characterized by low or undetectable levels of 1,25(OH)2D3 resulting in hypocalcemia, 
rickets, osteomalacia and growth retardation. The disease is caused by mutations in the 
1αOHase gene (9, 44). In clinical practice, patients are treated with vitamin D 
analogues and/or an enriched Ca2+ diet to prevent rickets, which correct the major 
perturbations in Ca2+ homeostasis. As previously mentioned, in 1αOHase knockout 
mice a down-regulation of renal TRPV5 as well as intestinal TRPV6 expression was 
demonstrated, whereas supplementation with 1,25(OH)2D3 or an enriched Ca2+ diet 
restored expression levels of these Ca2+ transporters and serum Ca2+ concentrations 
(chapter 3 and 4). These data suggest that decreased channel abundance contributes to 
defective renal and intestinal Ca2+ absorption and, thereby, the sustained hypocalcemia 
in VDDR-I. In addition, patients with hereditary hypocalcemic vitamin D-deficiency 
rickets type II (VDDR-II), an autosomal recessive disorder caused by defects in the 
gene encoding the nuclear vitamin D receptor (VDR), display a similar phenotype 
except for the elevated serum 1,25(OH)2D3 levels (45). Experiments performed with 
VDR knockout mice revealed disturbed Ca2+ absorption and inappropriately high renal 
Ca2+ excretion, which was accompanied by a down-regulation of TRPV5 and TRPV6 
in kidney and duodenum (2, 10). Together, these data suggest that TRPV5 and TRPV6 
play a central role in the pathophysiology of vitamin D-deficiency rickets and 
determine, at least in part, the clinical phenotype of VDDR-I and VDDR-II.  
 
Idiopathic hypercalciuria and renal stone disease 
Normocalcemic hypercalciuria in the absence of any known underlying cause is termed 
idiopathic hypercalciuria (IH). The pathogenesis of this autosomal dominant disorder is 
either excessive intestinal Ca2+ absorption (absorptive IH) or defective renal tubular 
Ca2+ reabsorption (46). Furthermore, an increased urinary excretion of Ca2+ is a 
considerable risk factor and hypercalciuria is implicated in 40-50% of kidney stone 
formers, which represents an important clinical problem with considerable socio-
Chapter 7 
 134 
economic impact (46). Several potential candidate genes, which could be associated 
with idiopathic nephrolithiasis, have been analyzed using familial clustering. However, 
promising genes like the VDR, 1αOHase and the CaSR gene were shown not to be 
associated with IH (47-49). In addition, the TRPV5 gene was screened in nine families 
with a high-penetrance autosomal dominant inheritance and a phenotype suggesting a 
primary renal defect. However, no mutations were identified in the open reading frame 
containing 15 exons and 3 kb of the 5-flanking region of the TRPV5 gene (50). Since 
the IH population is a heterogenous group, TRPV5 cannot be completely excluded as a 
candidate gene. Moreover, activating or silencing mutations in TRPV5 and TRPV6 can 
hypothetically lead to primary renal as well as absorptive IH. Single nucleotide 
polymorphisms (SNPs) in the Ca2+-sensing receptor have been shown to significantly 
increase the relative risk of hypercalciuria (51). The same may be applicable to SNPs 
in the genes encoding the epithelial Ca2+ channels or genes involved in the regulation 
of TRPV5 and TRPV6 activity and, therefore, may be involved in the complex genetic 
background of IH. 
 
PTH-related disorders 
There are several disorders with disturbed Ca2+ homeostasis, characterized by hypo- or 
hyperparathyriodism. Primary and secondary hyperparathyroidism are common 
disorders characterized by elevated PTH levels. Others involve inactivating mutations 
in the CaSR gene, resulting in familial hypocalciuric hypercalcemia or neonatal severe 
hyperparathyroidism (52), whereas autosomal dominant hypocalcemia is caused by 
activating mutations, resulting in hypoparathyroidism (53). These PTH-related 
disorders are associated with hypo- or hypercalciuria, renal stone formation and bone 
abnormalities. Data presented in chapter 5 clearly showed that PTH is positively 
involved in Ca2+ reabsorption through the upregulation of renal TRPV5, suggesting a 
possible role for the epithelial Ca2+ channels in the pathogenesis of PTH-related 
disorders. Furthermore, to minimize the effect of elevated PTH on bone and other 
tissues (54), vitamin D compounds have been widely used in the treatment of 
hyperparathyroidism. However, use of compounds such as 1,25(OH)2D3 has frequently 
been accompanied by the undesired side-effects of hypercalcemia and 
hyperphosphatemia, which increase the risk of soft tissue and vascular calcification 
(55). To avoid these negative effects, vitamin D analogues have been developed with 
the aim of suppressing PTH secretion with minimal calcemic action (56). In addition to 
the effects of 1,25(OH)2D3 on Ca2+ (re)absorption (chapter 3 and 4), Hoenderop et al. 
showed that various vitamin D analogues all increased serum Ca2+ levels, although at 
different levels and time-scales, reflecting their individual pharmacokinetics (57). 
Moreover, these vitamin D compounds differentially up-regulated the expression of 
TRPV5 and TRPV6 expression in kidney and intestine, by means of variation in 
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magnitude and duration of induction, which could explain the differences in calcemic 
activity of the vitamin D compounds (57). Recently, calcimimetic compounds have 
been developed, which may provide a novel therapy for treating hyperparathyroidism. 
Calcimimetics are small organic compounds that, upon binding to the CaSR, enhance 
the sensitivity of the CaSR for Ca2+ in an allosteric fashion, thereby inhibiting PTH 
secretion by the parathyroid glands (14, 15). As described in chapter 5, infusion of the 
calcimimetic compound NPS R-467 in mice, indeed, reduced serum PTH levels and 
was accompanied by decreased serum Ca2+ levels, which could in part be the results of 
a decline in Ca2+ reabsorption through down-regulation of renal TRPV5 expression.  
 
Prostate Cancer 
First evidence that TRP channels could be involved in the progression of certain types 
of cancer came from analysis of TRPM1, which gene expression is inversely correlated 
with the aggressiveness of malignant melanoma cells (58). In addition, TRPM8 has 
originally been cloned from prostate cancer tissue (59). Moreover, TRPV6 was shown 
to be strongly upregulated in carcinomas of various tissues, including prostate (60-63). 
TRPV6 is highly expressed in prostate cancer cells compared with healthy prostate 
epithelia and TRPV6 transcripts are abundantly expressed in lymph node metastasis of 
prostate origin (61, 64). The appearance of TRPV6 correlates positively with the tumor 
grade and TRPV6 might, therefore, be a promising new marker for tumor progression 
and target for the development of drugs against prostate cancer. Interestingly, prostate 
carcinoma is a hormone-sensitive malignancy and anti-androgens are frequently used 
in prostate cancer treatment. Peng et al. showed that in a human prostate 
adenocacinoma cell line TRPV6 mRNA expression was decreased upon 
dihydrotestosteron treatment, whereas an androgen receptor antagonist significantly 
increased TRPV6 mRNA levels (60). Furthermore, estrogens, which are also used 
therapeutically in prostate cancer, positively regulate TRPV6 (chapter 4).  In addition, 
vitamin D has received considerable interest as a possible anticancer drug, particularly 
in prostate cancer (65). VDR presence was demonstrated in prostate epithelial cells and 
vitamin D analogues were shown to inhibit the growth of primary cultures of human 
prostate tissue and cancer cell lines (66-68). As discussed previously, the positive 
regulation of TRPV6 by 1,25(OH)2D3 (chapter 4) and several analogues (57) has been 
clearly established. Apoptosis is induced by either depleting the cell or by overloading 
the cell with Ca2+ (69-71). Therefore, an increased Ca2+ influx through TRPV6 could 
be involved in the apoptotic anti-cancer effects of vitamin D and other compounds on 
prostate carcinoma and TRPV6 might be a possible target in the development of novel 
anticancer therapy in prostate carcinoma.  
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Thiazide diuretics 
Thiazide diuretics, widely used in hypertension therapy, have the unique characteristic 
of increasing renal Na+ excretion by inhibiting the apical NaCl-cotransporter (NCC) in 
DCT, resulting in an increased salt and water loss and, thereby, decrease the 
extracellular volume (ECV) (72). Moreover, these drugs concomitantly increase Ca2+ 
reabsorption (73). This hypocalciuric effect provides therapeutic opportunities in for 
instance idiopathic hypercalciuria and nephrolithiasis. Furthermore, thiazides have 
been shown to increase bone mineral density and decrease fracture risk, spiking 
interest in the favorable long-term effects of these diuretics in counteracting 
osteoporosis (74). The decreased Ca2+ excretion during chronic thiazide administration 
has been explained by ECV contraction enhancing the paracellular Ca2+ reabsorption in 
proximal tubules as well as a direct stimulation of active Ca2+ reabsorption in the DCT 
(73, 75-79). Interestingly, in Gitelmans syndrome, a recessive disorder caused by 
mutations in the gene encoding NCC, hypocalciuria is invariably present (80, 81). 
Some hypotheses concerning the mechanism responsible for this hypocalciuria also 
center on stimulation of active Ca2+ transport (77). However, Nijenhuis et al. showed 
that chronic hydrochlorothiazides (HCTZ) treatment consistently decreased the mRNA 
expression and protein abundance of the transporters responsible for active Ca2+ 
reabsorption, including TRPV5, while prevention of ECV contraction during HCTZ 
treatment prohibited the development of hypocalciuria (79). Furthermore, HCTZ 
administration still induced hypocalciuria in TRPV5 knockout mice (82). In addition, 
Loffing et al. showed recently in a mouse model for Gitelmans syndrome that 
mutation in NCC did not lead to increased abundance of renal TRPV5 and NCX1 (83). 
Moreover, in vivo micropuncture experiments indicated that the hypocalciuria in these 
NCC-deficient mice or in HCTZ-treated mice is not related to increased Ca2+ transport 
rates in DCT and CNT, but rather through stimulation of passive Ca2+ transport in the 
proximal tubule (82, 83).  
 
Tacrolimus 
Immunosuppressant drugs, like tacrolimus, are prescribed in various disorders and to 
organ transplant recipients. Besides the immunosuppressive actions, tacrolimus also 
affects mineral homeostasis. Treatment with tacrolimus has been associated with 
increased bone turnover, negative Ca2+ balance and hypercalciuria. This hypercalciuric 
effect has been attributed to increased bone resorption and decreased renal Ca2+ 
reabsorption (84-86). Recently, it has been demonstrated that treatment with tacrolimus 
in rats enhanced renal Ca2+ wasting, which was accompanied by a decreased 
expression of the active Ca2+ transport proteins TRPV5 and calbindin-D28K. (87). Thus, 
down-regulation of the renal Ca2+ transport proteins could contribute to the 
pathogenesis of tacrolimus-induced hypercalciuria.  
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FUTURE DIRECTIONS 
 
TRPV5 and TRPV6 comprise a unique pair of Ca2+ channels among the TRP 
superfamily. Distinctive physiological functions important for body Ca2+ homeostasis 
have now been established for these channels, but many areas remain open for further 
investigations. Dysregulation or dysfunction of these epithelial Ca2+ channels may 
contribute to disturbances in Ca2+ homeostasis and be associated with several diseases. 
In this respect, further examination of the underlying mechanism of the stimulatory 
effect of the calciotropic hormones, identification of regulatory domains and additional 
binding partners of TRPV5/6, that participate in the channel complex and the signaling 
pathways controlling channel activity, will disclose more detailed information 
concerning the molecular regulation of the Ca2+ channel activity. Future investigations, 
particularly performed in (tissue-specific) TRPV5 and TRPV6 knockout models, will 
certainly help to further delineate the key functions of these Ca2+-transporting proteins. 
  
 
REFERENCES 
 
1. Van Cromphaut SJ, Rummens K, Stockmans I, van Herck E, Dijcks FA, Ederveen AGH, 
Carmeliet P, Verhaeghe J, Bouillon R, Carmeliet G: Intestinal calcium transporter genes are 
upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent 
mechanisms. J Bone Miner Res 18: 1725-1736, 2003 
2. Weber K, Erben RG, Rump A, Adamski J: Gene Structure and Regulation of the Murine 
Epithelial Calcium Channels ECaC1 and 2. Biochem Biophys Res Commun 289: 1287-1294, 2001 
3. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor 
pathways to AP-1. J Steroid Biochem Mol Biol 74: 311-317, 2000 
4. Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 
interactions. Vitam Horm 62: 231-252, 2001 
5. Muller D, Hoenderop JG, Merkx GF, van Os CH, Bindels RJ: Gene structure and chromosomal 
mapping of human epithelial calcium channel. Biochem Biophys Res Commun 275: 47-52, 2000 
6. Hoenderop JG, Muller D, van der Kemp AW, Hartog A, Suzuki M, Ishibashi K, Imai M, Sweep 
F, Willems PH, van Os CH, Bindels RJ: Calcitriol controls the epithelial calcium channel in 
kidney. J Am Soc Nephrol 12: 1342-1349, 2001 
7. Wood RJ, Tchack L, Taparia S: 1,25-Dihydroxyvitamin D3 increases the expression of the CaT1 
epithelial calcium channel in the Caco-2 human intestinal cell line. BMC Physiol 1: 11, 2001 
8. Fleet JC, Eksir F, Hance KW, Wood RJ: Vitamin D-inducible calcium transport and gene 
expression in three Caco-2 cell lines. Am J Physiol Gastrointest Liver Physiol 283: G618-625, 
2002 
9. Dardenne O, Prud'homme J, Arabian A, Glorieux FH, St-Arnaud R: Targeted inactivation of the 
25-hydroxyvitamin D3-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of 
pseudovitamin D-deficiency rickets. Endocrinology 142: 3135-3141, 2001 
10. van Cromphaut S, Dewerchin M, Hoenderop JG, Stockmans I, van Herck E, Kato S, Bindels RJ, 
Collen D, Carmeliet P, Bouillon R, Carmeliet G: Duodenal calcium absorption in vitamin D 
receptor-knock out mice: functional and molecular aspects. Proc Natl Acad Sci U S A 98: 13324-
13329, 2001 
Chapter 7 
 138 
11. Nemere I, Yoshimoto Y, Norman AW: Calcium transport in perfused duodena from normal 
chicks: enhancement within fourteen minutes of exposure to 1,25-hydroxyvitamin D3. 
Endocrinology 115: 1476-1483, 1984 
12. Suzuki M, Kurihara S, Kawaguchi Y, Sakai O: Vitamin D3 metabolites increase [Ca2+]i in rabbit 
renal proximal straight tubule cells. Am J Physiol 260: F757-F763, 1991 
13. Nemere I, Schwartz Z, Pedrozo H, Sylvia VL, Dean DD, Boyan BD: Identification of a 
membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein 
kinase C. J Bone Miner Res 13: 1353-1359, 1998 
14. Nemeth EF: Calcium receptors as novel drug targets. San Diego, Academic Press Inc., 1996, 
1019-1035 
15. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin 
MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc 
Natl Acad Sci U S A 95: 4040-4045, 1998 
16. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF: Calcimimetic compound NPS R-568 
stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats. J 
Pharmacol Exp Ther 290: 480-486, 1999 
17. Fox J, Scott KR, Lowe SH, Nemeth EF: Renal Ca2+ receptors regulate calcium excretion by 
modulating the response to PTH. J Am Soc Nephrol abstract: SA-FC179, 2003 
18. Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat 
AM, Waarsing JH, Rossier BC, Vallon V, Hummler E, Bindels RJ: Renal Ca2+ wasting, 
hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112: 1906-
1914, 2003 
19. Vennekens R, Hoenderop JG, Prenen J, Stuiver M, Willems PH, Droogmans G, Nilius B, Bindels 
RJ: Permeation and gating properties of the novel epithelial Ca2+ channel. J Biol Chem 275: 3963-
3969, 2000 
20. Nilius B, Prenen J, Vennekens R, Hoenderop JG, Bindels RJ, Droogmans G: Modulation of the 
epithelial calcium channel, ECaC, by intracellular Ca2+. Cell Calcium 29: 417-428, 2001 
21. Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA, Caterina MJ, Clapham DE, 
Harteneck C, Heller S, Julius D, Kojima I, Mori Y, Penner R, Prawitt D, Scharenberg AM, 
Schultz G, Shimizu N, Zhu MX: A Unified Nomenclature for the Superfamily of TRP Cation 
Channels. Mol Cell 9: 229-231, 2002 
22. Gerke V, Moss SE: Annexins: from structure to function. Physiol Rev 82: 331-371, 2002 
23. van de Graaf SF, Hoenderop JG, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, 
Nilius B, Bindels RJ: Functional expression of the epithelial Ca2+ channels (TRPV5 and TRPV6) 
requires association of the S100A10-annexin 2 complex. Embo J 22: 1478-1487, 2003 
24. Hung AY, Sheng M: PDZ domains: structural modules for protein complex assembly. J Biol 
Chem 277: 5699-5702, 2002 
25. Shenolikar S, Weinman EJ: NHERF: targeting and trafficking membrane proteins. Am J Physiol 
Renal Physiol 280: F389-395, 2001 
26. Mery L, Strauss B, Dufour JF, Krause KH, Hoth M: The PDZ-interacting domain of TRPC4 
controls its localization and surface expression in HEK293 cells. J Cell Sci 115: 3497-3508, 2002 
27. Yun CC, Palmada M, Embark HM, Fedorenko O, Feng Y, Henke G, Setiawan I, Boehmer C, 
Weinman EJ, Sandrasagra S, Korbmacher C, Cohen P, Pearce D, Lang F: The Serum and 
Glucocorticoid-Inducible Kinase SGK1 and the Na+/H+ Exchange Regulating Factor NHERF2 
Synergize to Stimulate the Renal Outer Medullary K+ Channel ROMK1. J Am Soc Nephrol 13: 
2823-2830, 2002 
28. Embark H, Setiawan I, Poppendieck S, van de Graaf S, Boehmer C, Palmada M, Wieder T, 
Gerstberger R, Cohen P, Yun C, Bindels R, Lang F: Regulation of the Epithelial Ca2+ Channel 
TRPV5 by the NHE Regulating Factor NHERF2 and the Serum and Glucocorticoid Inducible 
General Discussion and Summary  
 139 
Kinase Isoforms SGK1 and SGK3 Expressed in Xenopus oocytes. Cell Physiol Biochem 14: 203-
212, 2004 
29. Palmada M, Poppendieck S, Embark HM, van de Graaf SFJ, Boehmer C, Bindels RJM, Lang F: 
Requirement of PDZ domains for the stimulation of the epithelial Ca2+ channel TRPV5 by the 
NHE regulating factor NHERF2 and the serum and glucocorticoid inducible kinase SGK1. Cell 
Physiol Biochem 15: 175-182, 2005 
30. Saimi Y, Kung C: Calmodulin as an ion channels subunit. Annu Rev Physiol 64: 289-311, 2002 
31. Niemeyer BA, Bergs C, Wissenbach U, Flockerzi V, Trost C: Competitive regulation of CaT-
like-mediated Ca2+ entry by protein kinase C and calmodulin. Proc Natl Acad Sci U S A 98: 3600-
3605, 2001 
32. Hirnet D, Olausson J, Fecher-Trost C, Bodding M, Nastainczyk W, Wissenbach U, Flockerzi V, 
Freichel M: The TRPV6 gene, cDNA and protein. Cell Calcium 33: 509-518, 2003 
33. Lambers TT, Weidema AF, Nilius B, Hoenderop JG, Bindels RJ: Regulation of the mouse 
epithelial Ca2+ channel TRPV6 by the Ca2+-sensor calmodulin. J Biol Chem 279: 28855-28861, 
2004 
34. Hirai M, Shimizu N: Purification of two distinct proteins of approximate Mr 80,000 from human 
epithelial cells and identification as proper substrates for protein kinase C. Biochem J 270: 583-
589, 1990 
35. Gkika D, Mahieu F, Nilius B, Hoenderop JG, Bindels RJ: 80K-H as a new Ca2+ sensor regulating 
the activity of the epithelial Ca2+ channel transient receptor potential cation channel V5 (TRPV5). 
J Biol Chem 279: 26351-26357, 2004 
36. Bianco S, Peng JB, Takanaga H, Kos CH, Crescenzi A, Brown EM, Hediger MA: Mice lacking 
the epithelial calcium channel CaT1 (TRPV6) show a deficiency in intestinal calcium absorption 
depite high plasma levels of 1,25-dihydroxy vitamin D (Abstract). FASEB J 18: A706, 2004 
37. Bouillon R, Carmeliet G, Boonen S: Ageing and calcium metabolism. Baillieres Clin Endocrinol 
Metab 11: 341-365, 1997 
38. Young MM, Nordin BE: The effect of the natural and artificial menopause on bone density and 
fracture. Proc R Soc Med 62: 242, 1969 
39. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM: Prevention of 
postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and 
hormone-replacement therapy. N Engl J Med 325: 1189-1195, 1991 
40. Nordin BE, Need AG, Morris HA, Horowitz M, Robertson WG: Evidence for a renal calcium 
leak in postmenopausal women. J Clin Endocrinol Metab 72: 401-407, 1991 
41. Colin EM, van den Bemd GJ, van Aken M, Christakos S, de Jonge HR, Deluca HF, Prahl JM, 
Birkenhager JC, Buurman CJ, Pols HA, van Leeuwen JP: Evidence for involvement of 17beta-
estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the 
rat. J Bone Miner Res 14: 57-64, 1999 
42. Soucie JM, Thun MJ, Coates RJ, McClellan W, Austin H: Demographic and geographic 
variability of kidney stones in the United States. Kidney Int 46: 893-899, 1994 
43. Heller HJ, Sakhaee K, Moe OW, Pak CY: Etiological role of estrogen status in renal stone 
formation. J Urol 168: 1923-1927, 2002 
44. Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, 
Yanagisawa J, Tanaka T, Kato S: Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-
hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 338: 653-
661, 1998 
45. Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D: Hereditary 
vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in 
decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest 99: 297-304, 1997 
Chapter 7 
 140 
46. Asplin JR, Favus MJ, Coe FL: Nephrolithiasis, in The kidney (vol 5th ed), edited by Rector Ba, 
Philadelphia, Pennsylvania, WD Saunders, 1996, pp 1893-1935 
47. Zerwekh JE, Hughes MR, Reed BY, Breslau NA, Heller HJ, Lemke M, Nasonkin I, Pak CY: 
Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive 
hypercalciuria. J Clin Endocrinol Metab 80: 2960-2965, 1995 
48. Scott P, Ouimet D, Proulx Y, Trouve ML, Guay G, Gagnon B, Valiquette L, Bonnardeaux A: The 
1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in 
French-Canadian families. J Am Soc Nephrol 9: 425-432, 1998 
49. Lerolle N, Coulet F, Lantz B, Paillard F, Houillier P, Soubrier F, Gattegno B, Jeunemaitre X, 
Ronco P, Rondeau E: No evidence for point mutations of the calcium-sensing receptor in familial 
idiopathic hypercalciuria. Nephrol Dial Transplant 16: 2317-2322, 2001 
50. Muller D, Hoenderop JG, Vennekens R, Eggert P, Harangi F, Mehes K, Garcia-Nieto V, 
Claverie-Martin F, van Os C, Nilius B, Bindels RJ: Epithelial Ca2+ channel (ECaC) in autosomal 
dominant idiopathic hypercalciuria. Nephrol Dial Transplant 17: 1614-1620, 2002 
51. Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, Porfirio 
B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML: Influence of calcium-
sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 
13: 2517-2523, 2002 
52. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinman B, Levi T, Seidman SE, 
Seidman JG: Mutations in the human Ca2+ sensing receptor gene cause familial hypocalciuric 
hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993 
53. Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, 
Seidman JG: Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene 
mutation. Nat Genet 8: 303-307, 1994 
54. Bro S, Olgaard K: Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30: 606-
620, 1997 
55. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, 
Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage 
renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000 
56. Slatopolsky E, Finch J, Brown A: New vitamin D analogs. Kidney Int Suppl: 83-87, 2003 
57. Hoenderop JG, van der Kemp AW, Urben CM, Strugnell SA, Bindels RJ: Effects of vitamin D 
compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1α-
hydroxylase knockout mice. Kidney Int 66: 1082-1089, 2004 
58. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW: 
Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. 
Cancer Res 58: 1515-1520, 1998 
59. Tsavaler L, Shapero MH, Morkowski S, Laus R: Trp-p8, a novel prostate-specific gene, is up-
regulated in prostate cancer and other malignancies and shares high homology with transient 
receptor potential calcium channel proteins. Cancer Res 61: 3760-3769, 2001 
60. Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, Freeman 
MR: CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res 
Commun 282: 729-734, 2001 
61. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese 
E, Bonkhoff H, Flockerzi V: Expression of CaT-like, a novel calcium-selective channel, 
correlates with the malignancy of prostate cancer. J Biol Chem 276: 19461-19468, 2001 
62. Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR: Calcium-
Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and Is 
Aberrantly Expressed in Human Malignancies. Lab Invest 82: 1755-1764, 2002 
General Discussion and Summary  
 141 
63. Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, Flockerzi V: TRPV6 and 
prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel 
expression. Biochem Biophys Res Commun 322: 1359-1363, 2004 
64. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H: Expression of the Ca2+-selective cation 
channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. 
Oncogene 22: 7858-7861, 2003 
65. Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Marnocha R, 
Bruskewitz R, Mazess R, Bishop C, Bhattacharya A, Bailey H, Wilding G: Phase I trial of 
1alpha-hydroxyvitamin D2 in patients with hormone refractory prostate cancer. Clin Cancer Res 
8: 2820-2827, 2002 
66. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P: The human 
prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 
alpha,25-dihydroxyvitamin D3. Cancer Res 52: 515-520, 1992 
67. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D: Antiproliferative 
effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54: 
805-810, 1994 
68. Zhao XY, Peehl DM, Navone NM, Feldman D: 1alpha,25-dihydroxyvitamin D3 inhibits prostate 
cancer cell growth by androgen-dependent and androgen-independent mechanisms. 
Endocrinology 141: 2548-2556, 2000 
69. Haverstick DM, Heady TN, Macdonald TL, Gray LS: Inhibition of human prostate cancer 
proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry. 
Cancer Res 60: 1002-1008, 2000 
70. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S: Expression of calbindin-
D28K in a pancreatic islet beta-cell line protects against cytokine-induced apoptosis and necrosis. 
Endocrinology 142: 3649-3655, 2001 
71. Nicotera P, Orrenius S: The role of calcium in apoptosis. Cell Calcium 23: 173-180, 1998 
72. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na+-Cl- 
cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol 279: 
F161-169, 2000 
73. Costanzo LS, Windhager EE: Calcium and sodium transport by the distal convoluted tubule of the 
rat. Am J Physiol Renal Physiol 235: F492-506, 1978 
74. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil 
AR, Gamble GD: Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal 
women: A randomized controlled trial. Am J Med 109: 362-370, 2000 
75. Friedman PA: Codependence of renal calcium and sodium transport. Annu Rev Physiol 60: 179-
197, 1998 
76. Friedman PA, Bushinsky DA: Diuretic effects on calcium metabolism. Semin Nephrol 19: 551-
556, 1999 
77. Ellison DH: Divalent cation transport by the distal nephron: insights from Bartter's and 
Gitelman's syndromes. Am J Physiol Renal Physiol 279: F616-625, 2000 
78. Loffing J, Loffing-Cueni D, Valderrabano V, Klausli L, Hebert SC, Rossier BC, Hoenderop JG, 
Bindels RJ, Kaissling B: Organization of the mouse distal nephron: distributions of transcellular 
calcium and sodium transport pathways. Am J Physiol Renal Physiol 281: F1021-1027, 2001 
79. Nijenhuis T, Hoenderop JG, Loffing J, van der Kemp AW, van Os CH, Bindels RJ: Thiazide-
induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in 
kidney. Kidney Int 64: 555-564, 2003 
80. Lemmink HH, van den Heuvel LP, van Dijk HA, Merkx GF, Smilde TJ, Taschner PE, Monnens 
LA, Hebert SC, Knoers NV: Linkage of Gitelman syndrome to the thiazide-sensitive sodium-
Chapter 7 
 142 
chloride cotransporter gene with identification of mutations in Dutch families. Pediatr Nephrol 
10: 403-407, 1996 
81. Schultheis PJ, Lorenz JN, Meneton P, Nieman ML, Riddle TM, Flagella M, Duffy JJ, 
Doetschman T, Miller ML, Shull GE: Phenotype resembling Gitelman's syndrome in mice 
lacking the apical Na+-Cl- cotransporter of the distal convoluted tubule. J Biol Chem 273: 29150-
29155, 1998 
82. Nijenhuis T, Vallon V, van der Kemp AWCM, Loffing J, Hoenderop JGJ, Bindels RJM: 
Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-
induced hypocalciuria and hypomagnesemia. J Clin Invest 115: 1651-1658, 2005 
83. Loffing J, Vallon V, Loffing-Cueni D, Aregger F, Richter K, Pietri L, Bloch-Faure M, Hoenderop 
JG, Shull GE, Meneton P, Kaissling B: Altered renal distal tubule structure and renal Na+ and 
Ca2+ handling in a mouse model for Gitelman's syndrome. J Am Soc Nephrol 15: 2276-2288, 
2004 
84. Reid IR, Ibbertson HK: Evidence for decreased tubular reabsorption of calcium in glucocorticoid-
treated asthmatics. Horm Res 27: 200-204, 1987 
85. Reid IR: Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol 137: 209-
217, 1997 
86. Aicher L, Meier G, Norcross AJ, Jakubowski J, Varela MC, Cordier A, Steiner S: Decrease in 
kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-
induced calciuria and tubular mineralization. Biochem Pharmacol 53: 723-731, 1997 
87. Nijenhuis T, Hoenderop JG, Bindels RJ: Downregulation of Ca2+ and Mg2+ transport proteins in 
the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc 
Nephrol 15: 549-557, 2004 
 
 8 Chapter    
 
 
 
Nederlandse Samenvatting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nederlandse Samenvatting 
 145 
INLEIDING 
 
Calcium speelt een onmisbare rol in veel fysiologische processen, zoals 
spiercontracties en bloedstolling. Het handhaven van de calciumbalans is dan ook van 
cruciaal belang voor de normale ontwikkeling en werking van het lichaam. Ongeveer 
99% van de totale hoeveelheid calcium in het lichaam is opgeslagen in het skelet en de 
overgebleven 1% bevindt zich in de extracellulaire vloeistof, waaronder het bloed. 
Deze extracellulaire calciumconcentratie wordt strikt gereguleerd door de 
samenwerking van calciumopname in de darm, uitwisseling van calcium met bot en de 
uitscheiding van calcium in de nieren. De nauwkeurige afstemming van deze processen 
wordt gereguleerd door calciotropische hormonen, waaronder het paraathormoon 
(PTH) en vitamine D. Deze hormonen grijpen onder andere aan op gespecialiseerde 
epitheelcellen in de nieren en de twaalfvingerige darm, waar calcium vanuit het lumen 
(zijde van voeding of voorurine) naar de bloedzijde van de cel wordt getransporteerd. 
Dit wordt actief of transcellulair calciumtransport genoemd.  
  
ACTIEF CALCIUMTRANSPORT 
 
Het actieve transport van calcium vindt plaats in drie discrete stappen. Allereerst komt 
calcium de cel binnen via de epitheliale calciumkanalen TRPV5 en TRPV6. Eenmaal 
in de cel wordt calcium gebonden door gespecialiseerde calciumbindende eiwitten, 
calbindines genaamd (calbindine-D28K en calbindine-D9K), zodat de vrije intracellulaire 
calciumconcentratie laag blijft. Dit complex diffundeert vervolgens naar de bloedzijde 
van de cel. Hier wordt calcium tenslotte door twee energieverbruikende 
uitscheidingsmechanismen, een natrium/calcium-uitwisselaar (NCX1) en een ATP-
afhankelijke calciumpomp (PMCA1b), naar buiten gepompt het bloedcompartiment in 
(Fig. 1, hoofdstuk 1). In de distale niercellen wordt op deze manier calcium vanuit de 
urine terug opgenomen in het bloed (reabsorptie) en in de darm vanuit de voeding 
(absorptie). 
 
REGULATIE VAN TRPV5 EN TRPV6 
 
De activiteit van TRPV5 en TRPV6 bepaalt in belangrijke mate de hoeveelheid 
calcium dat getransporteerd wordt door de cel. Daarom worden deze kanalen ook wel 
de poortwachters van het actieve calciumtransport genoemd. In de distale niercellen 
wordt deze functie voornamelijk vervuld door TRPV5 (Fig. 5, hoofdstuk 1). 
Daarentegen vormt TRPV6 het belangrijkste calciuminfluxkanaal in de darm. De 
centrale rol van TRPV5 en TRPV6 in het actieve calciumtransport veronderstelt dat 
deze kanalen een belangrijk aangrijpingspunt voor regulatie vormen. Het vergaren van 
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kennis omtrent de regulatie van deze kanalen zal dan ook meer inzicht geven in de 
manier waarop de calciumbalans in het lichaam wordt gehandhaafd. Het is bekend dat 
calciotropische hormonen betrokken zijn bij de regulatie van de calciumbalans en de 
invloed van enkele van deze hormonen op TRPV5 en TRPV6 is onderzocht in de 
studies bescheven in dit proefschrift.       
 
Oestrogenen 
Door het wegvallen van oestrogenen na de menopauze ontstaat er een negatieve 
calciumbalans, hetgeen kan resulteren in postmenopauzale osteoporose 
(botontkalking). Deze negatieve effecten van oestrogeendeficiëntie, zoals het verlies 
van calcium via de nieren en de verminderde opname van calcium in de darm, kunnen 
verholpen worden met oestrogeentherapie. In hoofdstuk 2 en 4 worden de effecten van 
oestrogenen op TRPV5 en TRPV6 beschreven. In deze studies werden de eierstokken 
verwijderd bij ratten om een situatie van oestrogeendeficiëntie na te bootsen. 
Vervolgens werden deze ratten gesupplementeerd met oestrogenen. Deze behandeling 
met oestrogenen resulteerde in een verhoging van de hoeveelheid TRPV5 in de nieren. 
Ook in de darm werd de expressie van zowel TRPV5 als TRPV6 verhoogd. Om uit te 
sluiten dat dit effect veroorzaakt zou worden door eventuele veranderingen in de 
vitamine D huishouding, werd het effect van oestrogenen ook bekeken in een genetisch 
gemodificeerd muismodel, waarin de aanmaak van vitamine D verstoord is. 
Behandeling van deze vitamine D-deficiënte muizen met oestrogenen resulteerde ook 
hier in een toename van TRPV5 in de nieren en van TRPV6 in de darm. Tevens werd 
de verlaagde calciumbloedwaarde in deze muizen gedeeltelijk gecorrigeerd door de 
oestrogeenbehandeling. Deze bevindingen suggereren dat oestrogenen een rol spelen in 
het behoud van de calciumbalans door de hoeveelheid calcium dat in de nieren en darm 
wordt ge(re)absorbeerd te controleren via de regulatie van TRPV5 en TRPV6.  
 
Vitamine D 
Het belang van vitamine D voor de calciumbalans wordt geïllustreerd door  
verscheidene ziekten veroorzaakt door het disfunctioneren van vitamine D. Mutaties in 
het enzym dat voor de aanmaak van vitamine D zorgt, leiden tot de ziekte bekend als 
vitamin D-deficiency rickets type I (VDDR-I), waarbij de vitamine D-deficiëntie 
onder meer leidt tot een zeer lage calciumbloedwaarde en botafwijkingen. In hoofdstuk 
3 en 4 werd een genetisch gemodificeerde muis bestudeerd, welke representatief is 
voor de ziekte VDDR-I, om de regulatie van TRPV5 en TRPV6 door vitamine D te 
onderzoeken. De lage calciumbloedwaarde in deze muizen ging gepaard met een 
afname van de hoeveelheid TRPV5 en TRPV6 in de nieren en darm. Daarentegen 
resulteerde het supplementeren van deze muizen met vitamine D in een toename van 
het aantal calciumkanalen, wat tevens gepaard ging met het normalizeren van de 
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calciumbloedwaarde. Dit bevestigt de essentiële rol van deze kanalen in actief 
calciumtransport in nieren en darm en daardoor het behoud van de calciumbalans. 
Tezamen wijzen deze resultaten erop dat beide calciumkanalen, TRPV5 en TRPV6, 
gereguleerd worden door vitamine D en wellicht bijdragen aan het klinische fenotype 
van vitamine D-geassocieerde ziekten als VDDR-I.     
 
Calciumrijk dieet 
Bij patiënten met aandoeningen, zoals VDDR, wordt vaak een calciumrijk dieet 
voorgeschreven om verstoringen in de calciumbalans te corrigeren en het risico op 
botafwijkingen te verminderen. Deze behandeling werd ook toegepast op het VDDR-
muismodel, zoals beschreven in hoofdstuk 3 en 4. Een calciumrijk dieet corrigeerde 
inderdaad het fenotype van deze muis, waaronder de verlaagde calciumbloedwaarde. 
Daarnaast zorgde dit dieet voor een verhoging van TRPV5 in de nieren. Ook in de 
darm werd een toename van TRPV6 gezien in deze vitamine D-deficiënte muizen, 
wijzend op een verhoogde absorptie van calcium. Deze bevindingen demonstreren een 
vitamine D-onafhankelijke regulatie van TRPV5 en TRPV6 door calcium in de 
voeding.     
 
PTH  
Hoofdstuk 5 beschrijft een studie naar de effecten van PTH op epitheliale 
calciumkanalen in de nieren. Door het verwijderen van de PTH-klieren in de rat daalde 
zowel de PTH- als de calciumbloedwaarde. Dit ging gepaard met een afname van de 
hoeveelheid TRPV5 in de nieren. Door deze ratten weer te supplementeren met PTH 
normalizeerde de calciumbloedwaarde en ook de hoeveelheid TRPV5 in de nieren 
werd verhoogd, zonder enig effect op de vitamine D huishouding. Dit PTH-
stimulerende effect werd bevestigd in een celkweek van distale niercellen, waarin de 
hoeveelheid TRPV5 toenam alsmede het transport van calcium door deze cellen. 
Recent zijn er nieuwe farmaca ontwikkeld voor het behandelen van patiënten met 
hyperparathyroidie (verhoogde PTH-bloedwaarde). Deze farmaca, zoals NPS R-467, 
versterken de gevoeligheid van de calciumreceptor voor calcium in de PTH-klieren, 
waardoor de secretie van PTH in het bloed geremd wordt. Toediening van deze stof 
aan muizen resulteerde naast een verlaging van de PTH-bloedwaarde ook in een daling 
van de calciumwaarde, welke deels veklaard kon worden door de verlaging in 
calciumreabsorptie door de afname van TRPV5 in de nieren (hoofdstuk 5). Tezamen 
suggereren deze resultaten dat PTH positief betrokken is bij de reabsorptie van calcium 
in de nieren door de regulatie van TRPV5. 
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GECOÖRDINEERDE REGULATIE VAN CALCIUMTRANSPORT EIWITTEN 
 
Uit de verscheidende studies beschreven in dit proefschrift blijkt dat naast TRPV5 en 
TRPV6 ook de andere eiwitten betrokken bij het actieve calciumtransport, waaronder 
calbindines en de uitscheidingsmechanismen NCX1 en PMCA1b, gereguleerd worden 
op een gecoördineerde manier. In hoofdstuk 5 wordt bewijs geleverd dat TRPV5 
hierbij een sleutelrol speelt. Zoals hierboven beschreven, veroorzaakte PTH een 
verhoging in het actieve calciumtransport in een celkweek van distale niercellen, 
waarbij tevens de hoeveelheid TRPV5 als ook calbindin-D28K en NCX1 toenam. 
Echter, door het blokkeren van de calciuminstroom door TRPV5, met behulp van de 
stof ruthenium red, werd ook het PTH-gestimuleerde actieve calciumtransport geremd. 
Dit ging gepaard met een daling in de hoeveelheid calbindin-D28K en NCX1, terwijl de 
expressie van TRPV5 niet veranderde. Deze resultaten laten zien dat de gecoördineerde 
regulatie van de verschillende eiwitten betrokken bij actief calciumtransport deels 
bepaald wordt door de hoeveelheid calcium dat door TRPV5 de cel instroomt. Dit 
illustreert nog eens de poortwachter-functie van deze epitheliale calciumkanalen. 
 
DE ROL VAN TRPV5 EN TRPV6 BIJ VEROUDERING 
 
Veroudering gaat gepaard met negatieve effecten op de calciumbalans, welke zich 
uiteindelijk kunnen uiten in botontkalking ofwel ouderdoms-osteoporose. In hoofdstuk 
6 wordt een studie beschreven naar de effecten van veroudering op TRPV5 en TRPV6. 
Tijdens veroudering van normale muizen daalde de capaciteit van de 
calciumreabsorptie in de nieren tezamen met de hoeveelheid TRPV5. Ongeacht de 
verhoging in de vitamine D-bloedwaarde, was er ook een verlaging in TRPV6 en 
verslechterde de calciumopname in de darm tijdens veroudering. Soortgelijke 
resultaten werden verkregen in TRPV5 knockout muizen, waarin het TRPV5 
calciumkanaal niet meer aanwezig is. In tegenstelling tot normale muizen, 
ontwikkelden deze TRPV5 knockout muizen ernstige hyperparathyroidie (sterk 
verhoogde PTH-bloedwaarde), wijzend op een grotere kans op botontkalking in deze 
muizen. Deze bevindingen suggereren dat een afname van de hoeveelheid TRPV5 en 
TRPV6 in de nieren en de darm bijdraagt aan de verstoringen in de (re)absorptie van 
calcium die samengaan met veroudering.     
 
TOEKOMST PERSPECTIEF 
 
De in dit proefschrift beschreven studies leverden nieuwe inzichten op in de hormonale 
regulatie van TRPV5 en TRPV6. Disregulatie of disfunctioneren van deze kanalen kan 
bijdragen aan verstoringen in de calciumbalans en geassocieerd worden met diverse 
ziekten. Gedetailleerde kennis omtrent de achterliggende mechanismen in de 
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hormonale regulatie van TRPV5 en TRPV6 en de identificatie van additionele 
regulatoire domeinen en eiwitten zal meer inzicht geven in de moleculaire regulatie 
van deze kanalen. Toekomstig onderzoek in TRPV5 en TRPV6 knockout modellen zal 
zeker bijdragen aan de opheldering van de sleutelfuncties en het fysiologisch belang 
van deze kanalen voor de calciumbalans. 
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LIST OF ABBREVIATIONS 
 
1,25(OH)2D3 1,25-dihydroxyvitamin D3 
17β-E2 17β-estradiol 
1αOHase 25-hydroxyvitamin D3-1α-hydroxylase 
25(OH)D3 25-hydroxyvitamin D3 
Å angstrom 
ANOVA analysis of variance 
AP-1 activator protein 1 
ATL ascending thin limb of Henles loop 
ATP adenosine 5-triphosphate 
 [Ca2+]i intracellular calcium concentration 
45Ca2+ radioactive calcium isotope 
CaBP calbindin 
CaM calmodulin 
cAMP adenosine 3,5-cyclic monophosphate 
CaRE calcium-response element 
CaSR calcium-sensing receptor 
CaT calcium transporter 
CCD cortical collecting duct 
CD  collecting duct 
cGMP guanine 3,5-cyclic monophosphate 
CNT connecting tubule 
cTAL cortical thick ascending limb of Henles loop 
DCT distal convoluted tubule 
DEPC diethylpyrocarbonate 
DME Dulbeccos modified Eagles medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DTL descending thin limb of Henles loop 
EC50 half maximal effective concentration 
ECaC epithelial calcium channel 
ECV extracellular volume 
ER estrogen receptor 
ERE estrogen response element 
F12 Hams F12 medium 
FCS fetal calf serum 
HCTZ hydrochlorothiazide 
HEPES N-2-hydroxyethyl-piperazine-N-2-ethanesulfonic acid 
List of Abbreviations 
 154 
HHS hypomagnesemia hypercalciuria syndrome 
HPRT hypoxanthine-guanine phosphoribosyl transferase 
IH idiopathic hypercalciuria 
IMCD inner medullary collecting duct 
Mab monoclonal antibody 
mRNA messenger ribonucleic acid 
mTAL medullary thick ascending limb of Henles loop 
NCC NaCl-cotransporter 
NCX Na+/Ca2+-exchanger 
NHERF Na+/H+-exchanger regulating factor 
NKCC2 Na+-K+-2Cl--cotransporter 
OMCD outer medullary collecting duct 
OVX ovariectomized 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PCT proximal convoluted tubule 
PDDR pseudovitamin D-deficiency rickets = VDDR-I 
PDZ postsynaptic density-95/Discs large/zona occludens-1 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
PLP periodate-lysine-paraformaldehyde 
PMCA plasma membrane Ca2+-ATPase 
PSS physiological salt solution 
PST proximal straight tubule 
PT proximal tubule 
PTH parathyroid hormone 
PTHrP PTH-related protein 
PTX parathyroidectomized 
RIA radioimmunoassay 
ROMK ATP-regulated K+ channel 
RT reverse trancriptase 
RNA ribonucleic acid 
RXR retinoid X receptor 
SDS sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel elctrophoresis 
SE standard error 
siRNA small interference RNA 
SNP single nucleotide polymorphism 
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Sp1 stimulatory protein 1 
SPF specific pathogen-free 
TAL thick ascending limb of Henles loop 
Tris tris(hydroxy-methyl)aminomethane 
TRP transient receptor potential 
TRPV TRP-vanilloid 
VDR vitamin D receptor 
VDDR-I vitamin D-deficiency rickets, type I = PDDR 
VDDR-II hereditary hypocalcemic vitamin D-resistant rickets, type II 
VDRE vitamin D-responsive element 
wk week 
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afdeling. Daarnaast mijn co-promotor dr. Joost Hoenderop. Beste Joost, bedankt voor 
je betrokkenheid bij het onderzoek, leren de puntjes op de i te zetten bij het schrijven 
en voor je enorme (soms te enorme) enthousiasme.  
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maar wat dan uitliep op wat eten en heel veel kletsen, zodat de winkels allang weer 
gesloten waren. Ik vind het erg leuk dat jij mij wilt bijstaan als paranimf. 
 
And, of course, thanks to all my colleagues of the department of Physiology. In the 
recent years the department has grown into a super-sized, international group of 
enthusiastic researchers. It is hard to believe that four and a half years have passed 
since I started and thanks to all of you ... the helping hands, encouragements, 
Dankwoord 
 159 
support, professional and personal interest, laughs, drinks, dinners, BBQs, movies, 
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 those years were great. It is hard to imagine a more caring, kind and 
helpful group of colleagues. I really enjoyed working with all of you. Thanks a lot!  
 
Stan wil ik hier met name bedanken voor zijn interesse en gezelligheid, maar zeker 
voor het fungeren als vraagbaak, niet alleen over experimenten en technieken, maar 
ook over het AIO zijn, promoveren en het maken van een proefschrift. En mijn 
naamgenoot Monique, bedankt voor je steun, zowel op als buiten het lab, en je 
gezelligheid. Samen als M&M, geef ons maar een 7-upje, blijven eten en als nodig 
staat jouw slaapbankje klaar. Bedankt! 
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hebben al die jaren voor de muizen gezorgd, waardoor mijn experimenten goed zijn 
verlopen. Met name Henk en Gerry, zonder jullie verzorging, hulp, kennis, interesse en 
gezelligheid tijdens de experimenten was dit proefschrift er niet geweest. Bedankt! 
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duidelijk is. Bedankt voor jullie betrokkenheid en interesse. Ook wil ik Leonie 
bedanken voor haar hulp en creativiteit bij het maken van de voorkant van dit boekje. 
 
Mijn ouders en zussen. Hier ligt ie dan. Dit is wat ik al die jaren heb geprobeerd uit te 
leggen. Gelukkig hebben jullie ervoor gezorgd dat ik de afgelopen maanden (jaren) 
ook eens achter de computer vandaan kwam. Effe bellen (jullie naar mij dan), oppassen 
op de ondeugende Stein en lachende Anne, winkelen, filmpje kijken, kaartje leggen of 
gewoon even gezellig op visite. Bedankt voor jullie steun, begrip, interesse en liefde al 
die jaren! 
 
Dankwoord 
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En tenslotte, op deze laatste pagina van mijn proefschrift, de meest belangrijke 
persoon. Lieve Jeroen. Eindelijk ben ik uitgetypt en is het klaar. Jij hebt misschien wel 
de grootste bijdrage geleverd de afgelopen jaren, kreeg het op je dak als iets niet goed 
was, stond met het eten te wachten als ik weer eens te laat thuis kwam, of moest alleen 
voor de hondjes zorgen als ik op congres of werkbezoek was. Bedankt dat je er voor 
me bent!! 
